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ABSTRACT 
Tethered IL-15 to augment the therapeutic potential of T cells expressing chimeric 
antigen receptor: Maintaining memory potential, persistence, and antitumor activity 
Adoptive immunotherapy can retarget T cells to CD19, a tumor-associated antigen (TAA) 
expressed on B-cell malignancies, by the expression of a chimeric antigen receptor (CAR). 
Infusion of CAR-modified T cells for the treatment B-cell malignancies has demonstrated 
promise in preclinical and clinical trials. These data highlight the ability of infused CD19-
specific T cells to be synchronously activated by large burdens of CD19+ leukemia and 
lymphoma. This can lead to dramatic antitumor effects, but also exposes the recipient to 
toxicity associated with tumor-cell lysis and cytokine storm. Clinical trials will now be 
addressing the targeting of minimal burdens of CD19+ malignancy as patients are enrolled 
earlier in their disease course and receive concomitant chemotherapy. It is likely that the 
existing populations of CAR T cells generated ex vivo to address relapsed disease may not 
be able to address minimal residual disease (MRD). Therefore, we have developed a 
clinically appealing approach to sustaining the persistence of CAR T cells independent of 
TAA by providing signaling through the common gamma chain receptor (γc).  Administration 
of exogenous soluble recombinant cytokines that signal through the γc, such as interleukin 
(IL)-2, have been used clinically to sustain the persistence of adoptively transferred T cells.  
However, systemic high-dose administration has resulted in dose-limiting toxicities. Unlike 
IL-2, IL-15 possesses numerous attributes desirable for adoptive therapy and has been 
ranked among the most valuable immunotherapeutic agent for cancer treatment. It is a pro-
survival cytokine that promotes the survival of long-lived T-cell memory subsets and in vivo 
antitumor activity. Unlike other γc family cytokines, IL-15 is transpresented to responding T 
cells in the context of IL-15 receptor alpha (IL-15Rα).  Therefore, we hypothesized that a 
membrane-bound IL-15 fusion protein (mIL15) tethered to the cell surface would enhance 
T-cell costimulation to support persistence independent of CAR activation by preserving T-
cell memory potential and maintain antitumor activity in the presence of low TAA. Using 
clinically compliant methods, the generated mIL15-CAR T cells mimicked the physiologic 
mechanism of transpresentation to sustain costimulation via phosphorylation of signal 
transducer and activator of transcription (pSTAT5).  In contrast to conventional CD19-
specific CAR T cells, mIL15-CAR T cells persisted in mice independent of the presence of 
TAA and mediated potent rejection of a systemically distributed CD19+ leukemia. The 
potential for sustained immunity against B-cell malignancies was shown as, in the absence 
vii 
 
of antigen, mIL15-CAR T cells were long-lived and adopted a desirable CD45ROnegCCR7+ 
“low-differentiation” state with a memory-like molecular profile and phenotype. These 
results have direct implications for the design of an adoptive immunotherapy clinical trial 
evaluating mIL15-CAR T cells in the setting of MRD and warrants further investigation of 
mIL15 to engineer T cells targeting other tumor cells that have sequestered or low levels of 
TAA.    
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CHAPTER 1 
Background 
 
1.1 B-cell Acute Lymphoblastic Leukemia 
B-lineage acute lymphoblastic leukemia (ALL) occurs in both pediatric and adult 
populations where approximately 60% of B-ALL cases are in individuals younger than 20 
years old (1, 2).  This tumor cell type typically initiates at the pro-B cell stage where 
development is halted and the cells retain progenitor characteristics without further 
differentiation to a mature state (3).  Initial induction therapy with chemotherapeutics is 
aggressive, toxic, and long-term (4).  Chemotherapeutic treatment of adult and pediatric 
ALL have disease relapse rates of 65% and 20%, respectively, due to drug-resistant 
residual disease (5, 6).  Adults have poor prognosis, where greater than 60% will succumb 
to their disease, but about 80% of pediatric patients have long-term survival (7).  However, 
children who relapse have a cure rate of 25-40% (8).  As leukemia is the most frequently 
occurring childhood malignancy at 34% (9), though, the absolute number of relapses is 
substantial and makes it one of the most common pediatric malignancies (10, 11).  
Especially concerning for pediatric patients are the late treatment effects that may have to 
be fought years after treatment.  The aggressive induction treatments, and even some of 
the less toxic therapies introduced more recently, increase the risks of other chronic and 
serious health conditions of childhood cancer survivors and can include organ impairment 
and secondary cancers (12).   The high incidence of ALL relapse, especially in poor 
prognostic groups such as those with very early relapse or CR3+ (13, 14), coupled with the 
associated long-term health effects of aggressive chemotherapeutic treatment has 
prompted the use of immune-based therapies.   
 
 
1.2 CD8 T Cell Differentiation During Immune Response 
Cytotoxic T lymphocytes (CTLs) are a component of the adaptive immune system that 
participates in the elimination of cells that have been infected by virus or intracellular 
bacteria.  Quiescent naïve T cells residing in secondary lymphoid organs can be described 
as CD45RA+CCR7+CD62L-CD27+CD28+ (15).  Upon being alerted to pathogen, antigen 
presenting cells (APC) interact with naïve CD8 T cells in secondary lymphoid organs and 
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initiate the expansion phase of antigen-specific T cells that will go on to address clearance 
of the viral or intracellular bacteria (16).  In a progressive T cell differentiation model, 
priming of the naïve T cells (TN) results in activation, proliferation, and phenotypic changes 
ultimately endowing them with effector function (Fig. 1) (17).  CD45RO expression when 
paired with CD62L and CCR7 signifies central memory T cells (TCM), which traffic amongst 
lymphoid organs and have the hallmark capability of producing IL-2 (18, 19).  As, 
differentiation continues, CD62L and CCR7 are lost, signifying effector memory cells (TEM), 
which are relegated to trafficking in peripheral tissues and are capable of producing copious 
levels of IFNγ (18, 20).  The further along the differentiation path the cell is, the greater the 
acquisition of effector function, but it is concomitant with a loss of longevity.  Progression 
through the stages of differentiation is characterized by stepwise changes in phenotype and 
loss of function that ultimately impacts efficacy in clearing pathogen or, as in the topic of 
this dissertation, clearance of tumor (21, 22).  The contraction phase follows pathogen 
clearance where CD8 T cells quickly become apoptotic and die, leaving only 5-10% to 
remain in the memory T cell pool (16).    
The road travelled between the initial naïve state of a T cell and the final terminally 
differentiated T cell that dies, is under considerable debate.  Several models have been 
proposed to explain T cell differentiation and diversification: separate-precursor model, 
decreasing–potential model, signal–strength model, asymmetric cell fate model (reviewed 
in (16, 23)).  They aim to explain how heterogeneous populations of short-lived effector and 
long-lived memory CD8 T cells are formed during an immune response, but no consensus 
has been reached in making a model determination since numerous experiments support 
each of the models.  Moreover, these conflicting studies have been done in models of viral 
or bacterial infection and thus studying the determination of T cell lineage in tumor models 
may contribute to this debate and it has remained relatively unexplored. 
What there is more agreement about is that intrinsic factors are modulated throughout T cell 
progression from naive to long-lived memory precursors to short-lived terminally 
differentiated effector cells (reviewed in (16, 17, 24).  Alteration of transcription factor levels 
is not necessarily an on-off switch, but can take the form of a reciprocal gradient of 
transcriptional programs controlling effector and memory differentiation.  
Well-known axes are: eomesdermin (EOMES) opposing T-bet and B cell lymphoma 6 
(BCL-6) opposing B lymphocyte maturation-induced protein 1 (BLIMP-1), where EOMES 
and BCL-6 institute memory programs (16).  The frequency and intensity of T cell receptor 
(TCR) induction  from  antigen  encounter,  signals  from  costimulatory molecules such as   
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Figure 1.  Progressive T cell differentiation model.  Naive T (TN) cells are primed by 
antigen-presenting cells (APCs) at the initiation of an immune response. The strength and 
quality of stimulatory signals influences T cell progression along a differentiation pathway 
that ends in the generation of terminally differentiated short-lived effector T (TEFF) cells. 
Upon pathogen clearance, antigenic and inflammatory stimuli diminish enabling primed T 
cells to become quiescent and enter into various memory subsets depending on the 
intensity of extrinsic signals received.  T cell differentiation increasingly progresses from 
memory stem cell (TSCM), central memory (TCM) cell, to effector memory (TEM). The 
phenotypic characteristics are illustrated as: not expressed (–), low expression (+), 
intermediate expression (++), and high expression (+++).  
 
Adapted from: Gattinoni L, Klebanoff C, Restifo NP. 2012.  Paths to stemness: building the 
ultimate antitumour T cell.  Nature Reviews Cancer 12(10).   Adapted by permission from 
Macmillan Publishers Ltd. 
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CD28, and inflammatory cytokines are extrinsic factors that merge with intrinsic elements to 
mold T cell differentiation (Fig. 2).  The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is 
a central node to which these signals coalesce.  Akt integrates these converging signals 
leading to downstream regulation of the Wnt/β-catenin pathway, forkhead box O (FOXO), 
glycogen synthase kinase 3 (GSK3), and mammalian target of rapamycin complex 1 
(mTORC1) in a rheostat-like manner (25-27).  Strong induction of Akt activation institutes a 
transcription program that drives T cell differentiation and results in enhanced effector 
function with concomitant decline in differentiation to a memory state and loss of survival 
potential (26).  Gaining further understanding of the modulation of external conditions and 
manipulation of intrinsic elements is ultimately the key to modulating T cell responses in 
adoptive cell therapy (ACT).  Work in this dissertation aims to evaluate the intrinsic state of 
genetically-modified T cells.  
 
1.3 Harnessing the Immune System to Target ALL Minimal Residual Disease 
CD8 T cells, and other elements of the immune system, are not limited to responding 
to viral or intracellular bacterial pathogens, but they have also emerged as crucial players in 
holding back cancer development.  This concept has come to be known as cancer 
immunosurveillance.  The immune system can recognize cells that have undergone 
changes predisposing them to cancer, or that have transformed to malignancy, and 
eliminate these abnormal cells (28, 29).  This process may fail and cancer may then arise 
but, with intervention and appropriate assistance, the immune system can be reenergized 
to enable it to return to what it was specifically made to do.   
The high incidence of ALL relapse, especially in poor prognostic groups, has prompted 
the use of immune-based therapies using allogeneic-hematopoietic stem cell 
transplantation (Allo-HSCT) (30).  This therapy is dependent on alloreactive cells present in 
the donor graft for the eradication of remaining leukemic cells to achieve a graft-versus-
leukemia (GVL)-effect to improve disease-free survival (31).  Donor lymphocyte infusions 
have been used to enhance the ability of engrafted T cells to target residual ALL after allo-
HSCT, but this treatment approach for patients with ALL achieves less than a 10% 
remission rate and is associated with a high degree of morbidity and mortality from the 
frequency and severity of graft-versus-host disease (32, 33).   High risk of relapse for   
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Figure 2.  Activation of PI3K/Akt signaling in the CD8 T cell.  In CD8 T cells, PI3K 
activation is initiated by engagement of the TCR with peptide/MHC I complex, signals from 
costimulation, cytokines, and/or chemokines.  Functioning at the plasma membrane, 
activated PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) yielding 
phosphatidylinositol-3,4,5-triphosphate (PIP3), which recruits PH domain-containing 
proteins such as Akt.  Phosphoinositide-dependent protein kinase (PDK1) and mammalian 
target of rapamycin complex 2 (mTORC2) are required for full activation (phosphorylation) 
of the Ser/Thr kinase Akt.  Upon activation, Akt localizes to and functions in the cytosol.  It 
phosphorylates and inhibits tuberous sclerosis complex 1/2 (TSC1/2), which is part of a 
negative regulatory complex of mTORC1.  Resultant mTORC1 activity initiates protein 
synthesis and cell growth via S6K and 4E-BP.  Akt also inhibits GSK3 which regulates  the 
canonical Wnt/β-Catenin pathway.  Additionally, Akt translocates to the nucleus to 
phosphorylate FOXO transcription factors resulting in their nuclear export that plays a role 
in cell quiescence, apoptosis, and memory.   
Reprinted from:  Kim EH, Suresh M. 2013.  Role of PI3K/Akt signaling in memory CD8 T 
cell differentiation.  Frontiers in Immunology 4(20):1-11.  With permission from the Creative 
Commons Attribution License.  
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particular malignancies has been observed in pediatric transplants with high risk ALL and 
Ph+ALL  transplants  achieving 58% and 37%  disease free survival  (34, 35).   With relapse 
still a common and lethal problem in these refractory malignancies, adoptive therapy using 
T cells after HSCT may be used to target residual leukemic cells.  Increasing the GVL-effect 
toward the minimal residual disease (MRD) can be accomplished by redirecting the 
specificity of donor T cells. 
1.4 Adoptive Immunotherapy: Redirecting T Cell Specificity 
In the absence of a tumor-associated antigen and/or a T cell expressing an 
endogenous αβ TCR with specificity for a tumor, T-cell therapy hinges on the ability to 
genetically engineer cells with redirected antigen specificity.  Manipulating T cell specificity 
toward a tumor antigen is possible by the introduction and the expression of a chimeric 
antigen receptor (CAR).  Infusion of such antigen redirected T cells is developing into a 
targeted treatment for the elimination of malignant cells and prevention of disease relapse.  
Numerous formulations of CARs that are specific for several target antigens have been 
developed with some of these approaches progressing into phase I clinical trials (36). 
A CAR is typically composed of an extracellular antibody-derived single-chain variable 
domain (scFv) for antigen recognition and is joined by a flexible linker connected to a 
transmembrane domain and an intracellular signaling domain(s) that includes CD3ζ for T-
cell activation (Fig. 3) (37, 38).  In this way, CAR T-cell recognition of tumor targets occurs 
independently of the major histocompatibility complex enabling their application to be 
universal (37).  Clinical trials using these 1st generation CARs demonstrated the feasibility 
of adoptive transfers, however while some patients did show evidence of tumor responses 
others did not respond with lasting effects (BB-IND11411, LJNC) (39, 40).  In the study by 
Park et al. (40), the persistence of CAR-modified T cells was found to be short and ranged 
from one to seven days in patients with bulky disease.  Numerous studies have now 
demonstrated that T cell persistence correlates with therapeutic efficacy (41-43) and this 
dissertation aims to address the issue of poor or inconsistent persistence of CAR-modified 
T cells.  
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Figure 3.  Schematics of prototypical CARs used to redirect T cell specificity.  CARs 
exist in a dimerized form and are expressed as a fusion protein that links the extracellular 
scFv (VH linked to VL) region, a flexible hinge, an Fc region such as IgG4, a transmembrane 
domain, and intracellular signaling motifs.  The endodomain of the 1st generation CAR 
induces T cell activation solely through CD3-ζ signaling.  The second generation CAR 
provides activation signaling through CD3-ζ and CD28, or other endodomains such as 4-
1BB or OX40.  The 3rd generation CAR activates T cells via a CD3-ζ-containing 
combination of three signaling motifs such as CD28, 4-1BB, or OX40. 
 
Adapted from:  Kebriaei P et al. 2012.  CARs: Driving T-cell specificity to enhance anti-
tumor immunity.  Frontiers in Bioscience 4:520-31.  With permission from Frontiers in 
Bioscience.  
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1.5 Improving Adoptively Transferred T Cell Persistence 
Despite the design of the 1st generation CARs to mimic T cell receptor (TCR) induction by 
signaling via a CD3ζ endodomain to activate modified-T cells, this did not provide the fully 
competent signal that T cells receive in the physiological context. It has been revealed that 
1st generation CARs could induce proliferation for a few cycles but T cell death quickly 
ensued (44).  Normally when T cells are activated in vivo they receive a primary antigen-
induced TCR signal with secondary costimulatory signaling from CD28 that induces the 
production of cytokines (i.e., IL-2 and IL-21), which then feed back into the signaling loop in 
an autocrine/paracrine fashion (45-47).  With this in mind, 2nd generation CARs were 
constructed to include CD28 cytoplasmic signaling domain (41) or other costimulatory 
molecule signaling domains such as 4-1BB (48)(Fig. 3).  Chimeric CD28 co-stimulation 
improves T-cell persistence over the 1st generation CAR by up-regulation of anti-apoptotic 
molecules and production of IL-2, as well as expanding T cells derived from peripheral 
blood mononuclear cells  (PBMC) (41).   Though T cell survival is enhanced,  murine 
experiments demonstrated a significant decline in 2nd generation CAR T cell persistence 
within the first seven days after adoptive transfer (41), indicating key supportive factors are 
still missing.   
Efforts are still underway to identify the optimal combination of signaling endodomains 
and to develop new strategies to further enhance in vivo survival of CAR T cells.  The 
continued development in CAR technology has led to the construction of 3rd generation 
CARs that create triple endodomain fusion receptors and appear to improve in vitro function 
in comparison to the 2nd generation CAR (49) (Fig. 3).  Other reported approaches that 
demonstrated enhanced T cell persistence in adoptive transfers are: (i) the infusion of 
effector CD8+ T cells derived from central memory (TCM), naïve (TN), and memory stem cell 
(TSCM), which demonstrated progressively increasing therapeutic potential (50-52); (ii) 
generation of bi-specific T cells with tumor antigen recognition via an introduced CAR and 
viral antigen specificity via the endogenous TCR that provided a more competent activation 
signal (39); ex vivo propagating CAR T cells in specific cytokine cocktails (53, 54); and (iv) 
the expression of the costimulatory molecules CD80 and 4-1BBL on T cells that provide 
auto- and trans-costimulatory signals (42). 
 While each of these approaches have significant implications for the generation of cells for 
adoptive immunotherapy, continued development of new strategies to enhance modified T 
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cell persistence is still necessary as the described advances that have been made either: 
have not yet demonstrated robust long-term persistence in humans (50-52), may not be 
appropriate across clinical platforms of immunotherapy (39), or persisted only in a tumor 
associated antigen (TAA)-dependent manner (42).  Thus, alternate means for improving T-
cell persistence is warranted and the specific aims of this dissertation address this. 
 
1.6 Cytokines Support Adoptively Transferred T Cell Persistence 
Cytokines in the common gamma chain receptor (γc) family collectively share a four α-
helical bundle structure which signal through hetero-dimeric and trimeric receptor 
complexes that share the γc sub-unit (reviewed in reference (55)). Interleukin (IL)-2, IL-7, 
IL-15, and IL-21 are members of this family and signal through Janus family tyrosine kinase 
(JAK)1 and JAK3. IL-2, IL-7, and IL-15 primarily activate both signal transducer and 
activator of transcription (STAT)5, whereas IL-21 mainly activates STAT3 (56).  Cross-talk 
also occurs with the Ras, PI3K (57), and nuclear factor-κB (NF-κB) (58) pathways.  While 
the shared signaling of the γc may contribute to the overlapping functions of these 
cytokines, signaling of their private receptors as well as coupling with other signaling 
pathways lends to the unique and pleiotropic effects of these cytokines (57). 
IL-2 has been the cytokine historically used in the clinic to improve transferred T cell 
persistence.  IL-2 signals through a low affinity state via a hetero-dimeric receptor with IL-
2/IL-15 receptor beta chain (IL-2/IL-15Rβ; also known as CD122) and γC subunits.  High 
affinity signaling is enabled by IL-2 receptor alpha chain (IL-2Rα) when it is present in the 
heterotrimeric receptor complex with IL-2Rβ and γc subunits (59).  IL-2 is a growth factor 
that promotes T cell activation and proliferation (60) while also being important for the 
differentiation of T cells to the TH2 phenotype (61).  The administration of IL-2 is used to 
boost T cell survival in vivo during adoptive therapy (62, 63).  However, prolonged systemic 
dosage of IL-2 is associated with severe toxicities including respiratory distress and 
vascular leak syndrome, resulting in limits to IL-2 usage in the treatment (62, 64).  
Additionally, IL-2 can even hinder the effectiveness of infused T cells via the expansion of 
regulatory T cells that induce peripheral tolerance (65) and the promotion of activation-
induced cell death (AICD) (66).  The focus is now shifting to investigating the other γc 
cytokines to (i) generate higher quality T cells in vitro and (ii) to better support adoptively 
transferred T cells in vivo. 
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 IL-15 has leapt into the spotlight in the past few years due to its potential for use in the 
immunotherapy field.  It is a homeostatic cytokine that appears to exert a preferential effect 
on the homeostatic proliferation of CD8 memory T cells (67, 68).  It has also been reported 
that IL-15 can induce rapid homeostatic proliferation of naïve T cells in lymphopenic 
conditions, with the resultant expanded cells possessing central memory characteristics 
(69).  Moreover, it was observed that in vitro culture with low-dose IL-15 resulted in 
proliferation without phenotypic change (67), which is an attribute of great potential with 
regard to following the paradigm shift toward generating T cells with maximal memory 
potential.   
IL-15 has been established to function in vivo by a transpresentation mechanism.  
Activated monocytes or dendritic cells present a membrane-bound IL-15 receptor alpha 
chain (IL-15Rα)/IL-15 complex to the IL-2/IL-15Rβ and γc receptor complex on the T cell 
(70) (Fig. 4).  IL-15Rα is the high affinity receptor that binds IL-15 resulting in qualitatively 
different signal transduction than that achieved by soluble IL-15 (71).  In addition, the IL-
15/IL-15Rα complex undergoes endosomal recycling back to the surface thereby extending 
the cytokine’s persistence in the system (70, 72) (Fig. 4).  Interestingly, the 
transpresentation of IL-15 occurs in the immunological synapse.  It is speculated that this 
severely restricts IL-15 exposure to prevent unintended immune stimulation (73).   
Consideration of the transpresentation mechanism is important in harnessing the 
cytokine’s potency and biological activity.  The use of IL-15/IL15Rα complexes resulted in 
increased potency over the soluble cytokine and was able to promote the eradication of 
established tumors via alleviating functional suppression of tumor-resident cells (74).  A 
non-human primate study indicated that IL-15 was far superior to IL-2 in generating long-
lived memory T cells (75).  In addition, safety has been evaluated in non-human primate 
models.  An intermittent dosing schedule was found to be well tolerated, and it was 
observed that memory CD8 and CD4 T cells as well as NK cells were detected in the 
peripheral blood in this lymphoreplete model (76).  The potential for IL-15 in modulating 
cellular responses in ACT therapies has excited the field and numerous clinical trials have 
been initiated and are rapidly gaining momentum.  The demonstrated biological responses 
of IL-15 make it an excellent candidate for incorporation into our CAR T cell therapy treating 
ALL MRD.   
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Figure 4.  Transpresentation of IL-15 by IL-15Rα to neighboring CD8+ T cells.  Type I 
or type II interferons induce coordinate expression of IL-15 and the IL-15Rα on monocytes 
or dendritic cells. The IL-15/IL-15Rα complex recycles from the cell surface through 
endosomal vesicles to be re-expressed at the cell surface.  IL-15 is presented in trans by 
IL-15Rα to T cells expressing the IL-2/15Rβ and γc receptor complex. 
 
Reprinted from: Waldmann T.A.  2006.  The biology of interleukin-2 and interleukin-15: 
implications for cancer therapy and vaccine design.  Nature Reviews Immunology 6(8):595-
601.  Reprinted by permission from Macmillan Publishers Ltd.  
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1.7 Specific Aims 
 The primary goal of this dissertation is translationally driven and seeks to develop an 
alternative approach to address a clinical need and contribute to furthering the therapeutic 
potential of adoptive cell therapy (ACT).  Three specific aims are pursued that bring forth 
novel information or improve upon an immunotherapeutic approach contributing to the 
above gaps in knowledge or prevailing clinical issues.  There is consensus that the 
persistence of adoptively transferred CAR T cells remains inconsistent and impacts the 
therapeutic efficacy of ACT.  More specifically, persistence of transferred T cells may pose 
to be more challenging in low or sequestered TAA environments.  With that clinical context 
in mind, our approach capitalized on the pleiotropic effects and unique mechanistic features 
of IL-15 to develop a membrane-bound IL-15/IL-15Rα fusion protein (mIL15) to be co-
expressed on CAR T cells.  The overarching hypothesis of this dissertation is that mIL15 
sustains costimulation to improve CAR T cell persistence and antitumor activity whilst 
preserving memory potential.   
Specific  Aim 1:  IL-15 mediates numerous immunomodulatory effects that are beneficial for 
ACT, including supporting the homeostasis of long-lived TCM, and is therefore a 
costimulatory molecule suitable for improving the persistence of CAR T cells.  Incorporating 
the prevailing in vivo mechanistic action of IL-15, we generated mIL15.  In this specific aim 
we hypothesize that mIL15 can sustain STAT5 signaling to costimulate CAR T cells by 
mimicking transpresentation.  Additionally, as part of the translational aspect of this project, 
we aimed to generate sufficient numbers of functional and clinically relevant mIL15-CAR T 
cells.  Using a clinical platform to genetically modify and expand mIL15-CAR T cells, these 
cells will be evaluated by: (i) phosflow to assess the mIL15 costimulatory effect via pSTAT5 
induction (ii) extended phenotyping for T cell and memory-associated markers using flow 
cytometry, and (iii) assess redirected specificity by a chromium release assay (CRA) and 
IFNγ production in response to CD19neg and CD19+ targets. 
Specific  Aim 2:  IL-15 can enhance in vivo antitumor activity and support homeostasis of 
CD8 TCM, which persist long-term without requiring contact with antigen.  We hypothesize, 
therefore, that mIL15-CAR T cells will possess enhanced antitumor activity in vivo and 
persist in vivo independently of TAA.  Immunocompromised mice will be used to assess 
mIL15-CAR T cell performance (antitumor activity and/or T cell persistence) under three 
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models: (i) a high-dose leukemia xenograft, (ii) a preventative low-dose disseminated 
leukemia xenograft, and (iii) T cell engraftment in the absence of TAA.     
Specific  Aim 3: The differentiation fate of long-term persisting cytokine and CAR co-
modified T cells is ambiguous and it is unknown whether intrinsic factors play a role in 
addition to the extrinsic elements.  IL-15 plays a critical role in the homeostatic maintenance 
of CD8 TCM.  We therefore hypothesize that persisting mIL15-CAR T cells will possess 
attributes associated with TCM.  Moreover, intrinsic elements will be representative of their 
differentiation state.  We sought to characterize long-term persisting mIL15-CAR T cells by 
first modeling the persistence in vitro to assess: (i) mIL15 and CAR phenotype by flow 
cytometry, (ii) mIL15 functionality by phosflow and functionality of CAR by IFNγ production 
assessed by flow cytometry, (iii) gene expression analysis by nCounter, (iv) phenotyping of 
transcription factors and surface markers associated with T cell differentiation state, (v) 
memory-associated function via assessment of IL-2 production, and (vi) CCR7 subset 
viability by Annexin V staining.  In vivo assessments followed up by assessing mIL15-CAR 
T cells persisting in immunocompromised mice in the absence of TAA and evaluated: (i) 
phenotyping of surface markers associated with T cell differentiation state, (ii) mIL15 and 
CAR phenotype, and (iii) CAR functionality by IFNγ production in response to CD19+/- 
targets assessed by flow cytometry.   
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CHAPTER 2 
Generation of Clinically Relevant CD19-specific 
T Cells Co-expressing mIL15 
 
2.1  Introduction 
CARs are used to retarget T cell specificity to a desired surface expressed TAA (37).  
Although adoptive transfer of CAR T cells have shown objective clinical responses in 
treating B cell leukemias, successful outcomes in adoptive immunotherapy are associated 
with persistence of transferred antigen-specific T cells (43, 63, 77, 78).  CAR-modified T 
cells are designed to receive costimulation for activation, survival, and proliferative signaling 
via the introduced immunoreceptor when engaged with a TAA (79).  This approach, even 
with the addition of other costimulatory molecules, predictably lead to in vivo accumulation 
of T cells only in a TAA-dependent manner (41, 42).  In low level TAA environments, 
infused T cells may not receive sufficient CAR-mediated signaling for robust persistence.  
This raises concerns for their capacity to persist at therapeutic levels to mediate durable 
tumor surveillance in leukemic relapse prevention or to treat MRD.  Clinical trials will now 
be increasingly targeting the treatment of MRD as patients are enrolled earlier in their 
disease course and are receiving concomitant chemotherapy.  Thus, optimizing adoptively 
transferred T cell persistence under low TAA conditions is paramount to improving clinical 
response and this aspect remains aggressively pursued.    
Administration of exogenous interleukin IL-2 has been the cytokine historically relied 
upon to enhance survival of adoptively transferred T cells (62, 63).  Systemic high-dose IL-2 
has proven to potentiate dose-limiting toxicities that include respiratory distress and 
vascular leak syndrome (62, 64, 80), as well as risks AICD that may limit the therapeutic 
response of transferred T cells (81, 82).  While low-dose IL-2 has been shown to be better 
tolerated, it appears to contribute to peripheral tolerance and the production of regulatory T 
cells (65, 83, 84).  IL-2 is also used in the in vitro expansion of T cells for adoptive therapy 
and is associated with inducing a differentiated effector phenotype (53), which have been 
demonstrated to have far poorer in vivo persistence and therapeutic potential than other 
less differentiated T cell subsets (52).  Contrasting the detrimental biological effects of IL-2, 
IL-15 possesses a plethora of immunomodulatory attributes desirable to adoptive therapy.  
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It is a pro-survival cytokine required for the homeostatic maintenance of long-lived CD8 
memory T cells (85, 86), inhibits AICD (87), enhances in vivo antitumor activity (88), and 
reverses T cell anergy (89).  With this valuable arsenal, IL-15 has been ranked the most 
important immunotherapeutic agent for cancer treatment (90) and has been used in 
metastatic melanoma and renal carcinoma trials with recently registered trials with natural 
killer (NK) cell and T cell immunotherapies (www.clinicaltrials.gov: NCT01385423, 
NCT01369888, NCT01875601).  
Clinical trials, thus far, have administered soluble recombinant IL-15 and pre-clinical 
studies have engineered antigen-specific human T cells that secrete monomeric IL-15 (91-
93).  However, unlike IL-2 which is secreted, IL-15 is uniquely transpresented in the context 
of IL-15Rα to responding T cells by the producing cells (i.e., dendritic cells) (94, 95).  
Limitations exist to the use of monomeric IL-15 as it is an unstable low molecular weight 
protein resulting in a short serum half-life thus necessitating frequent supra-physiologic 
dosing to attain biological responses in vivo (76, 96, 97).  Mimicking physiologic 
transpresentation by coupling IL-15 with a soluble form of IL-15Rα remedies this 
shortcoming and has shown greater potency and antitumor efficacy of T cells in vivo (97), 
likely due in part to the qualitatively different signaling achieved by transpresentation which 
result in more robust activation of the cells (71).  Moreover, it was demonstrated that 
targeting complexed IL-15 to the tumor microenvironment, and thus to responding immune 
cells, further enhanced the antitumor effect (98).   
The hypothesis of this chapter is that expression of mIL15 on CAR T cells will function 
by the physiologic mechanism of transpresentation and will induce enhanced STAT5 
costimulation.  This work aims to generate pre-clinical data for the development of a Phase 
I clinical trial testing the therapeutic efficacy of mIL15-CAR T cells in treating MRD and is 
therefore also focused on generating mIL15-CAR T cells that can meet specific clinically 
relevant criteria, including generating sufficient numbers of modified T cells, retaining 
redirected specificity, and a quality phenotype that includes the expression of memory–
associated surface markers.  Here we show the co-modification of CAR T cells with mIL15 
in primary human cells that are independent of exogenous cytokine stimulation with the 
generated mIL15-CAR T cells suitable for adoptive transfer.   
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2.2  Results 
2.2.1  mIL15 Plasmid Construction 
To provide human primary T cells with self-sustained IL-15 signaling that mimics the 
primary in vivo mechanism of action of transpresentation, we designed a tethered IL-15 
fusion protein to be expressed on the surface of the CAR T cell.  The expression of IL-15 is 
highly regulated at multiple levels, but with several critical elements functioning at the post-
translational level, including the signal peptide and coding sequence (99).  Alternate codon 
usage and signal peptides have been shown to increase IL-15 expression levels (91, 100).  
The mIL15 construct is codon-optimized and consists of a fusion of IL-15 cDNA 
(NM_000585.4) to the full length IL-15Rα (NM_002189.3) with a flexible linker and is 
inserted within a Sleeping Beauty (SB) expression plasmid.  The signal peptides for IL-15 
and IL-15Rα were omitted and the IgE signal peptide (gb|AAB59424.1) was used for the 
mIL15 construct (Fig. 5A).  The mIL15 DNA sequence was codon optimized and 
synthesized by GeneArt (Regensburg, Germany) and subsequently subcloned into a SB 
transposon plasmid.  SB transposons are used as part of a non-viral gene transfer 
approach that is directly translatable to the clinic as it is used in some CAR T cell clinical 
trials for genetic modification of the T cells (IND#s: 11470, 14577, 14739) (101, 102).  
Translation of this tethered IL-15 fusion protein is expected to synthesize a membrane-
bound IL-15 that, based on similar molecules (103, 104), is expected to emulate 
presentation of IL-15 in context with IL-15Rα (Fig. 5B).   
2.2.2  Generation and Expression of mIL15 and CAR on Primary Human T Cells 
To keep with the direct translational applicability of this study, the genetically modified 
T cells were generated and ex vivo propagated using clinically compliant methods (Fig. 6) 
(102, 105). Primary normal donor human T cells were co-electroporated with a CD19-
specific CAR transposon, with or without the mIL15 transposon, and the SB-11 transposase 
to generate mIL15-CAR T cells and the conventional CAR T cells to serve as a clinically 
relevant comparison.  The CAR used was ‘2nd generation’, thus comprised of CD3ζ and 
CD28 signaling endodomains (41). Propagation of the genetically modified T cells was 
achieved by recursive stimulation (Stim) with a K562 artificial antigen presenting cell line 
(aAPC) variant expressing CD19 antigen, as well as 41BBL and CD86 co-stimulatory 
molecules. The presence of CD19 on the aAPC allows for the selective outgrowth of 
antigen-specific T cells while the costimulatory molecules improve in vitro expansion (106).  
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Figure 5.  Schematics of mIL15.  (A) Sleeping Beauty DNA plasmid map for mIL15 [IL15-
IL15Ra-Flag(Coop)/pSBSO] for the expression of a fusion protein consisting of IL-15 linked 
with the full-length IL-15Rα.  (B) A schematic representing the protein structure of mIL15 
consisting of IL-15 linked with the full-length IL-15Rα.  Abbreviations: hEF-1alpha/p, human 
elongation factor-1 alpha promoter; TM, transmembrane domain, BGH, polyadenylation 
signal from bovine growth hormone; IR/DR, Sleeping Beauty inverted repeat; ColE1, E. coli 
origin of replication; Kan/R, gene encoding kanamycin resistance for bacterial selection; 
Kan/p, prokaryotic promoter. 
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Figure 5.  Schematics of mIL15 
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Figure 6.  Generation and ex vivo expansion of mIL15-CAR T cells using a clinical 
platform.  Schematic of the clinically compliant methods adopted for generating and 
numerically expanding mIL15 and CAR co-modified T cells.  PBMC were electroporated 
with mIL15 and CAR Sleeping Beauty (SB) DNA transposons and SB transposase.  Cells 
were then cocultured with γ-irradiated K562 (Clone 9)-derived aAPC (modified to express 
CD19, CD64, CD86, and CD137L) and, unless otherwise stated, had supplementation with 
IL-21 (30ng/ml).  The genetic modification and expansion of CAR T cells was similarly 
performed, but using only the CAR SB transposon and SB transposase during 
electroporation with subsequent cultures supplemented with IL-21 (30ng/ml) and IL-2 
(50U/ml).    
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Transient transfection levels of CAR were similar between CAR and mIL15-CAR T cells.  
The mIL15 was detected at modest levels in mIL15-CAR T cells (Fig. 7A).  After four Stims, 
nearly all T cells expressed CAR and expression was equivalent between CAR and mIL15-
CAR T cells (Fig. 7B).  The mIL15 molecule was stably co-expressed with the CAR at 51 ± 
14% (mean ± SD), and a minimal expression of mIL15 without the CAR was observed (2 ± 
4%; mean ± SD; Fig. 7A,C).  CAR mean fluorescence intensity (MFI) was equivalent 
between CAR T cells and mIL15+CAR+ T cells.  However, mIL15negCAR+ T cells showed 
significantly lower CAR MFI compared to mIL15+CAR+ T cells (P < 0.001; Fig. 7D), but the 
functional implications remain unknown.  These data show that mIL15 and CAR can be 
stably co-expressed in primary T cells.        
2.2.3  Numeric Expansion of Clinically Significant Numbers of mIL15-CAR T Cells 
After redirecting T cell specificity with the CAR, suitable numbers of these modified T 
cells must be generated to allow for adoptive transfer of therapeutic doses of CAR T cells.  
To assess whether mIL15 could provide enhanced costimulation sufficient for sustaining in 
vitro numeric expansion, mIL15-CAR T cells were propagated as previously described but 
without exogenously added IL-21 (Fig. 6) and compared to CAR T cells that received (i) no 
cytokine supplementation (baseline growth control), (ii) IL-15 complex (soluble cytokine 
control), or (iii) IL-2 and IL-21 (clinical or positive control).  Unlike CAR T cells that received 
no cytokine supplementation, numeric expansion of mIL15-CAR T cells was achieved in the 
absence of exogenous cytokine supplementation (P < 0.0001; Fig. 8A).  And, while mIL15-
CAR T cell expansion was equivalent to CAR T cells supplemented with IL-15 complex, 
these cells could not parallel the expansion of conventional CAR T cells supplemented with 
IL-2 and IL-21 (P < 0.0001; Fig. 8A).  This may have been due, in part, to the persistent 
overgrowth of NK cells at early time points (Stim 2) which was observed to comprise 
greater than 70% of the cells in the culture but was not an issue in conventional CAR T cell 
cultures (P < 0.01; Fig. 8B,C).  Despite CD56 depletion of mIL15-CAR T cell cultures, 
phenotyping after ex vivo expansion (Stim 4) revealed moderate levels of CD3negCD56+ and 
CD3negCD56neg populations in T cell cultures.  These non-T cell subsets cumulatively 
comprised 19% - 55% of the culture and a concomitant decrease in the outgrowth of 
desirable CD8+ T cells for adoptive transfer was observed (Fig. 8D).  IL-15 may have 
played a role in supporting the growth of the non-T cell subsets, as CAR T cell cultures 
supplemented with IL-15 complex also showed these subsets cumulatively comprise up to 
86% of the cells in culture (Fig. 8D).   
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Figure 7.  Stable co-expression of mIL15 and CAR on T cells after propagation on 
aAPC.  (A) Transient (24-hours post-electroporation) and stable (Stim 4) expression of 
mIL15 and CAR on Sleeping Beauty-modified T cells.  A representative flow plot is shown 
for one of 10 normal donors.  Gate frequencies are displayed in the top right corner of the 
plot.  (B) Frequency of expression of CAR on CAR T cells and mIL15-CAR T cells.  
Horizontal bar represents the mean.  (C) Frequencies of mIL15 and/or CAR expressing 
subsets of mIL15-CAR T cells.  Data are mean ± SD, n = 4.  (D) The CAR mean 
fluorescence intensity (MFI) on CAR and mIL15-CAR T cells.  The mIL15-CAR T cells were 
sub-divided based on their mIL15 expression.  ***P < 0.001, ns = not significant, paired t 
test (B), one-way ANOVA (C). 
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Figure 7.  Stable co-expression of mIL15 and CAR on T cells after propagation on 
aAPC  
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Figure 8.  Numerical expansion of mIL15-CAR T cells on aAPC without exogenous 
cytokines is accompanied by an NK cell expansion.  (A) Rate of CAR-specific 
expansion of mIL15-CAR T cells with no exogenous cytokine administration and CAR T 
cells supplemented with IL-2 (50U/ml) and IL-21(30ng/ml), IL-15 complex (5ng/ml), or 
unsupplemented.  At Stim 2, cultures containing > 15% CD3-CD56+ cells were 
paramagnetic bead sorted to deplete CD56+ cells.  Data are expressed as mean ± SD, n = 
6. ****P < 0.0001, ns = not significant, two-way RM ANOVA (Tukey’s post-test).  (B) 
Expression of CD3 and CD56 on cells at Stim 2.  Representative flow plots are shown for 
one of three normal donors.  (C)  Frequencies of CD3-CD56+ NK cells detected in cultures 
at Stim 2 from (b).  Data are expressed as mean ± SD, n = 3. **P < 0.01, one-way ANOVA 
(Tukey’s post-test).  (D) Frequencies of T cell sub-populations co-expressing combinations 
of CD3, CD4, CD8, or CD56.  Data are expressed as mean ± SD, n = 3. 
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 Figure 8.  Numerical expansion of mIL15-CAR T cells on aAPC without exogenous 
cytokines is accompanied by an NK cell expansion 
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In generating CAR T cells for adoptive therapy, the focus in ex vivo propagation is on 
driving high numeric expansion of CAR+ T cells.  In accordance with GMP protocols that 
yield high numbers of CAR T cells (102), the conventional CAR T cell cultures were 
supplemented with IL-2 and IL-21.  This study capitalized on the reported synergistic 
proliferative effect of IL-21 with IL-15 on CD8+ T cells (107) to increase expansion of CD8+ 
mIL15-CAR T cells.  With IL-21 supplementation to the culture protocol, mIL15-CAR T cells  
demonstrated comparable expansion to conventional CAR T cells, yielding 2.3 x 107 – 7.4 x 
1010 and 6.1 x 108 – 4.4 x 1010 CAR+ T cells, respectively  (Fig. 9).  In sum, while mIL15 
may provide some costimulatory support during ex vivo expansion, IL-21 is a necessary 
addition to enable the generation of clinically relevant numbers of mIL15-CAR T cells.   
2.2.4  Enhanced costimulation of mIL15-CAR T Cells Via pSTAT5 Induction 
Additional investigation of the costimulatory capability of mIL15 was performed by 
phosflow assessing phosphorylated signal transducer and activator of transcription 5 
(pSTAT5), the primary signaling molecule involved in IL-15 receptor complex signal 
transduction (108).  Unlike cytokine unsupplemented CAR T cells, mIL15-CAR T cells 
(receiving no exogenous cytokines) demonstrated sustained pSTAT5 levels (P < 0.01; Fig. 
10A,B).  Moreover, the costimulation intensity was below that induced by the supra-
physiologic dosing of soluble IL-15 in CAR T cells (P < 0.05; Fig. 10B), suggesting that the 
phosphorylation of STAT5 molecules was not saturated and thus mIL15 may induce more 
of a physiologically relevant signal strength. 
A primary reason for designing mIL15 as membrane-bound and with IL-15Rα, was to 
mimic the mechanism of IL-15 transpresentation that occurs in vivo.  To assess whether 
mIL15 can transpresent IL-15, a co-culture experiment was performed where CAR and 
mIL15-CAR T cells were co-cultured at a ratio greater than 1:4 and at high density to 
ensure cell-cell contact.  IL-15-specific or Flag antibodies were used to distinguish the two 
populations.  Unlike CAR T cells cultured alone, those in co-culture with mIL15-CAR T cells 
were able to receive IL-15 signal induction in trans, as indicated by sustained pSTAT5 
levels (Fig. 10C).  Together these data show that mIL15 provided sustained costimulation 
that induced STAT5 signal transduction and that this costimulation could be initiated in 
trans to mimic physiologic mechanisms.  
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Figure 9.  Numerical expansion of mIL15-CAR T cells on aAPC with IL-21 
supplementation.  Rate of CAR-specific T cell expansion of mIL15-CAR T cells cultured 
with exogenous IL-21 (30ng/ml) and CAR T cells supplemented with IL-2 (50U/ml) and IL-
21(30ng/ml).  Cultures exceeding > 15% CD3-CD56+ cells were paramagnetic bead sorted 
to deplete CD56+ cells.  Data are expressed as mean ± SD, n = 6, ns = not significant, two-
way RM ANOVA (Bonferroni post-test).    
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Figure 10.  Induction of pSTAT5 by mIL15.  Functionality of mIL15 was validated by 
phosflow of pSTAT5 in CAR and mIL15-CAR T cells under serum and cytokine starved 
conditions.  (A) A representative histogram showing the flourescence intensity of pSTAT5 in 
CAR and mIL15-CAR T cells (n = 6).  CAR T cells treated with soluble IL-15 (100ng/ml) for 
1-hour prior to fixation served as the positive control whereas unsupplemented CAR T cells 
indicate baseline pSTAT5 levels.  (B) Mean flourescence intensity (MFI) of pSTAT5 of 
modified T cells from (A).  Horizontal bar represents the mean. *P < 0.05, **P < 0.01, one-
way ANOVA.  (C)  The representative historgram shows pSTAT5 flourescence intensity of 
CAR T cells in co-culture with mIL15-CAR T cells (transpresented mIL15) at a ratio of 1:4, 
CAR T cells supplemented with IL-15, and unsupplemented CAR T cells (n = 4).  Histogram 
is gated on IL-15neg cells.   
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2.2.5  Immunophenotype and Function of mIL15-CAR T Cells is Unaltered by mIL15    
 Concerns have arisen that T cells generated for adoptive therapy undergo excessive 
culture time, excessively driven expansion, or exposure to cytokines such as IL-2 that 
promote T cell differentiation toward terminal effector cells, thereby diminishing antigen-
specific T cell therapeutic potential (17, 109, 110).  For that reason expanded CAR T cells, 
also considered the infusion product for adoptive transfers, are assessed for surface 
markers that may indicate the cell product’s in vivo or clinical potential.  The 
immunophenotype of CAR and mIL15-CAR T cells was not significantly altered by mIL15 
expression.  CAR and mIL15-CAR T cells nearly all expressed CD3, CD8, and CD45RO.  
CAR and mIL15-CAR T cells expressed: CD62L ranging from 57% - 85% and 64% - 88%; 
CCR7 ranging from 3% - 31% and 7% - 31%, CD27 ranging from 7% - 50% and 5% - 87%; 
and CD28 ranging from 28% - 77% and 25% - 95%, respectively (Fig. 11A-C).  Only a low 
level of IL-7Rα expression by mIL15-CAR T cells was noted (P = 0.0470).  The moderate to 
high expression levels of various memory-associated markers (17, 18, 21, 111) for both 
sets of modified T cells indicates a heterogeneous mix of T cell differentiation subsets.  
There is no indication of dominance of the potentially more therapeutically limited terminally 
differentiated effector or effector memory subsets, which would be characterized by a lack 
of CD62L and CCR7.  To the contrary, these modified T cells display characteristics 
predictive of in vivo persistence and treatment responses (52, 112-114).  After ex vivo 
expansion of the modified T cells, it is important to validate, for clinical purposes, that the 
modified T cells retain their redirected T cell specificity toward CD19.  A chromium release 
assay was conducted to assess the function of the T cells in the expansion product.  CD19+ 
and CD19neg EL4 targets were plated with CAR and mIL15-CAR T cells at across a range 
effector to target ratios.  As expected, both CAR and mIL15-CAR T cells demonstrated 
specific lysis of CD19+ tumor targets across all effector to target ratios with minimal lysis of 
CD19neg tumor targets (Fig. 12A).  Another measure of T cell responsiveness to TAA was 
with the assessment of IFNγ production after six hours of co-culture with CD19+ and 
CD19neg tumor targets, and no target and lymphocyte activating cocktail (LAC) served as 
baseline and maximal activation references, respectively.  Both T cell groups had similar 
levels of IFNγ production in response to CD19+ targets and almost no background 
stimulation from targets lacking CD19 (Fig. 12B).  Both CAR and mIL15-CAR T cells 
maintained redirected specificity toward TAA.  Thus, the genetically modified T cells that 
were generated are clinically relevant and suitable for adoptive transfer experiments.   
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Figure 11.  Phenotype of ex vivo expanded mIL15-CAR T Cells.  CAR and mIL15-CAR 
T cells were phenotyped after expansion at Stim 4 for expression of T cell surface markers 
associated with T cell phenotype and differentiation state.  (A) The plot indicates 
frequencies of cells expressing CD3, CD4, CD8, CD45RA, CD45RO, IL-7Rα, CD62L, 
CCR7, CD27, and CD28 markers.  Horizontal line indicates the mean value.  *P = 0.047, n 
> 4, paired t test.    (B) Representative flow plot for one of four normal donors showing 
expression of CD62L and CCR7.  (C) Representative histograms showing expression of 
CD27, CD28, and IL-7Rα (shaded) or isotype control (black), n = 8.   
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Figure 11.  Phenotype of ex vivo expanded mIL15-CAR T Cells 
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Figure 12.  In vitro effector function is not altered by mIL15 expression.  (A) CAR T 
cell (left panel) and mIL15-CAR T cell (right panel) specific lysis rates of CD19+ or CD19neg 
targets from a four-hour chromium release assay.  Data are represented as mean ± SD, n = 
3.  (B) IFNγ production by CAR and mIL15-CAR T cells after 6 hours of stimulation with 
CD19+ (tCD19+ EL4 and NALM-6) or CD19neg (EL4) targets, lymphocyte activating cocktail 
(LAC; positive control), or media alone (negative control).  Histograms were gated on 
CD3+CAR+ cells.  Representative flow plots for a normal donor are shown, n = 4.    
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2.3  Discussion 
 Attaining durable and robust CAR T cell persistence post-infusion continues to hamper 
ACT therapeutic potential.  The approach undertaken in this study to address the issue of 
persistence was by co-modification of CAR T cells with a membrane-bound IL-15 fusion 
protein that would act to provide supplemental costimulatory signaling.  This work aimed to 
generate pre-clinical data for the development of a Phase I clinical trial testing the 
therapeutic efficacy of mIL15-CAR T cells.  In this section of the study, we aimed to 
generate mIL15-CAR T cells suitable for adoptive transfer that would be relevant for 
translation to the clinic.  Using clinically compliant methods, mIL15 and CAR co-expressing 
T cells were generated and numerically expanded to numbers sufficient for clinical 
application.  We showed that expression of mIL15 on CAR T cells resulted in sustained 
pSTAT5 costimulation and mimicked the transpresentation mechanism of IL-15.  The data 
herein suggest that mIL15-CAR T cells warrant further study of their therapeutic potential in 
vivo and will be addressed in Chapter 3. 
 The foundation of the mIL15 design used in this study was based on a soluble 
hyperagonist IL-15/IL-15Rα-sushi fusion protein (RLI) that linked IL-15 to the sushi region 
of IL-15Rα (103).  It has been identified that the sushi domain within IL-15Rα is responsible 
for the binding interactions between the cytokine and IL-15Rα (115).  Mortier et al. (103) 
demonstrated that this configuration was functional in inducing biological effects (i.e., 
proliferation) and that the linker between the IL-15 and sushi domain did not interfere with 
binding interactions.  In fact, it was found that the IL-15/IL-15Rα fusion protein containing 
the linker was more potent than complexed IL-15 and soluble IL-15Rα (103).  This 
advantageous design was incorporated into mIL15 but extended to utilize the full-length 
native IL-15Rα structure to secure mIL15 to the cell surface.  As it has been demonstrated 
that the cytoplasmic portion of IL-15Rα enables trans-endosomal recycling of IL-15 back to 
the cell surface (70), we chose to retain the cytoplasmic domain for the potential advantage 
it may offer in maintaining mIL15 protein expression.   
 The configuration of mIL15 demonstrated sustained pSTAT5 levels in mIL15-CAR T 
cells in cytokine unsupplemented conditions that abrogated pSTAT5 signal in conventional 
CAR T cells (Fig. 10).  This indicates that mIL15-CAR T cells are exogenous cytokine 
independent and induces signaling of the IL-2Rβ/γC receptor complex.  Since STAT5 
signaling has been shown to be the primary pathway activated by IL-15R complex signaling 
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(116), this study only assessed pSTAT5 as an indicator of signal transduction activity but by 
no means suggests that it is the only signaling molecule induced by mIL15-induced 
signaling.  It cannot be excluded that other STATs and other pathways, including MAPK 
and Akt, are activated and contribute to the biological responses of the modified T cells (27, 
108, 117, 118).  Rowley et al. (104), assessed cytokine signaling in murine CD8+ T cells 
induced by a transpresented membrane-bound IL-15/IL-15Rα similar to our construct but 
lacking the cytoplasmic region.  In addition to elevated levels of pSTAT5, pSTAT3 was 
moderately elevated and pSTAT1 was slightly elevated.  Alterations in pAkt and pERK 1/2 
were not observed.  However, relative to the positive control (50ng/ml IL-15), pSTAT5 
induction appeared to be quite weak (104) indicating that cytokine receptor activation may 
have been too low to foster signal transduction across multiple pathways.  The study used 
CD8 cells isolated from naïve mice which may explain the low level of cellular activation, as 
naïve T cells express low levels of IL-2Rβ (52, 119).  A chimeric cytokine receptor eliciting 
constitutive IL-2Rβ signaling expressed in genetically modified human TCM showed 
demonstrable levels of both pSTAT5 and p-Shc (120) illustrating greater and more inclusive 
signal transduction in a T cell subset that has higher IL-2Rβ expression.  Work investigating 
IL-2Rβ signaling at different intensities illustrated altered and divergent pathway utilization 
in response to cytokine receptor signal modulation (27).  These studies collectively suggest 
that in our system: (i) the more moderate IL-2Rβ induction, as suggested by the pSTAT5 
signaling, also likely stimulates other pathways to some level and (ii) that our cells would 
likely demonstrate varying responsiveness to mIL15 based on the modulation of IL-2Rβ 
levels that fluctuate with T-cell differentiation, with the potential of being insensitive to 
mIL15, such as with naïve T cells or in circumstances where IL-2Rβ becomes down-
modulated.   
 It has now been established that transpresentation of IL-15 is the primary mechanism 
of action in vivo (94, 121) that sensitizes IL-15RαnegIL-15β+γC+ cells to physiologic levels of 
IL-15 (103) and induces qualitatively different signaling than equivalent doses of soluble IL-
15 (71).  Since we are mimicking the membrane-bound configuration in our model, it is 
likely that for mIL15 to be most effective it should function in the dominant physiologic 
manner and engage in transpresentation.  In this study, it was demonstrated that mIL15 
could indeed be transpresented to mIL15neg T cells and induce a moderate pSTAT5 signal 
(Fig. 10C).  The capability to transpresent mIL15 may be advantageous in vivo.  Studies 
have shown that antitumor activity was greater when IL-15 was transpresented to immune 
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cells within the tumor site than if monomeric IL-15 was secreted within the tumor 
microenvironment (98, 104).  The caveat is that the activity of monomeric IL-15 is 
dependent on concentration and thus could potentially match the activity of transpresented 
IL-15 if a sufficiently high concentration could be secreted.  However, should a higher 
concentration of soluble IL-15 be needed to achieve a therapeutic outcome, it is possible 
that the risk for toxicity may increase.  It also cannot be excluded that mIL15 may signal to 
the modified T cells under additional mechanisms.  The crystal structure of IL-15 bound to 
IL-15Rα along with biochemical data have suggested the possibility of IL-15 presentation in 
cis to the IL-15Rβ/γC complex on a cell (115).  Subsequent in vitro analysis has indicated 
that cis-presentation can occur (122) and that signal transduction induced in cis versus in 
trans results in different dynamics of activation (123).  The biological implications of these 
varying signaling mechanisms relative to immunotherapeutic strategies remain ambiguous.   
 Groups have generated CAR T cells that secrete IL-15 (91-93).  Regarding expansion 
of modified T cells with aAPC stimulation in the absence of exogenous cytokines, our 
results (Fig. 8A) were concordant with Dotti et al. (93) in which expansion was achieved.  
However, results contrasted with Markley et al. (92) whose IL-15 transduced cell population 
declined after an initial phase of expansion and paralleled the 0.1 ng/ml soluble cytokine 
control.  However, this difference may be due, in part, to the different methods of generating 
genetically modified T cells (viral vs Sleeping Beauty systems) and/or propagation 
conditions (APC type and supplemented cytokines).  Unlike these two studies, we also 
observed severe overgrowth of NK cells at early time points during expansion (Fig. 8B,C) 
that prompted the use of IL-21 to promote CD8 T cell expansion.  The reported synergy 
between IL-15 and IL-21 stimulation on the proliferation of murine CD8 T cells (107) was 
similarly observed in our mIL15-CAR T cell cultures, where the addition of IL-21 yielded 
greater than a log increase in expansion and a shift from a roughly equal mix of CD4 and 
CD8 T cells to greater than 80% CD8 T cells.  This study showed that mIL15-modification 
did not alter redirected T cell specificity, which is in agreement with other studies assessing 
IL-15 and CAR co-modified T cells (91, 93, 124).  Those studies went on to show in vivo 
persistence and antitumor activity that indicates the potential for in vivo performance of 
mIL15-CAR T cells, which we will address in Chapter 3. 
 Numerous studies have shown the importance of IL-15 in generating and supporting 
memory CD8 T cell subsets (85, 86), and IL-15 and IL-21 have demonstrated a synergistic 
effect on expansion of memory-phenotype CD8 T cells (107).  Thus, it was anticipated that 
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a greater frequency of memory-associated markers (i.e., CCR7, CD62L, CD28, CD27, and 
IL-7Rα) would be observed in the mIL15-CAR T cell expansion product relative to that of 
CAR T cells.  Moreover, it has been shown that different cytokines and cytokine cocktails 
impact the phenotype of the expanded T cells (53, 125, 126).  Therefore, it was somewhat 
of an unexpected finding that the ex vivo expansion phenotype of mIL15-CAR and CAR T 
cells was relatively unaltered (Fig. 11).  Our observation is congruent with a study that 
expanded TEM- and TCM-derived CD8+ clones that resulted in similar in vitro phenotype, but 
divergent in vivo fitness (50).  One explanation for such results may be resultant of culture 
methods.  Studies that subjected modified T cells to multiple rounds of antigen stimulation 
observed fewer differences between various cytokine treatments in the expanded T cell 
product (50, 93).  Conversely, studies that observed differences due to cytokine treatment 
tended to limit antigen stimulation to one round (125, 126).  An additional factor that likely 
contributes to this observation is that Akt undergoes strong stimulation from integrated 
signals generated by cytokine, TCR, and CD28 signaling, which are all triggered during an 
encounter with APCs.  When the Akt pathway undergoes strong stimulation, activation of 
Akt results in translocation to the nucleus where it phosphorylates FOXO1 and inactivates 
its pro-memory transcription factor activities, thereby allowing for T cell differentiation to 
progress (25, 127).  It has been demonstrated that despite the similar in vitro phenotype of 
expanded T cells derived from TEM and TCM subsets, their performance markedly differed 
upon transfer in vivo into primates.  Only the TCM-derived T cells persisted and some 
showed reversion to a memory phenotype (50).  Our phenotyping was descriptive of cells 
that had recently undergone several rounds of T cell activating stimuli.  It is likely that the 
phenotype alters once the activating stimuli that dominate the signaling pathways cease, 
and it is likely that intrinsic elements then play a role in subsequent phenotypic changes.  
This aspect will be further investigated in Chapter 4.  The observations by Berger et al. (50), 
suggest that the mIL15-CAR T cells generated in this study retain potential for in vivo 
persistence and this will be assessed in Chapter 3.  In sum, the data presented in this 
chapter show the generation of clinically applicable mIL15-CAR T cells that possess 
exogenous cytokine-independent costimulation of STAT5.   
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CHAPTER 3 
In Vivo Persistence and Antitumor Efficacy of mIL15-CAR T Cells 
 
3.1  Introduction 
ALL patients presenting with MRD can span a dynamic range of detectable residual 
leukemic cells.  Initially, MRD was gauged by morphologic remission but now increasingly 
sensitive methods are being used to detect leukemic cells.  The range extends from 
0.00004% MRD by deep sequencing (128), to 0.001-0.01% by quantitative polymerase 
chain reaction and flow cytometry (129, 130), to 5% or higher by cytomorphology (131).  
The level of MRD is correlative with relapse, where molecular failure denotes a high-risk 
group that tends to be resistant to drugs and thus are candidates for SCT and ACT (132).  
Even patients with low-level MRD (0.001% < 0.01%) have clinical significance (133).  
Consequently, CAR T cells adoptively transferred to MRD patients are typically in a 
relatively TAA-poor environment.  These modified T cells are CAR-addicted to receiving 
survival signaling and consequently may fail to expand and persist after adoptive transfer.   
Clinical trials using CD19 CAR T cells have largely dealt with indolent or chronic B-cell 
malignancies rather than ALL and MRD, therefore the much of the existing CAR T cell 
persistence data is framed within that context.  Brentjens et al. (78) have reported results 
from an ongoing phase I clinical trial where CAR T cells (2nd generation CAR 19-28ζ) are 
being used to treat ALL patients with relapsed disease or MRD.  Infusion of CAR T cells 
induced a MRDneg status but it was also observed that higher T cell persistence was 
correlated with high tumor burden and there was eventual normal B cell recovery (78) 
suggesting that CAR T cells may not persist long enough to prevent relapse at a later time 
point and that CAR-dependent signaling is of limited help in this situation.  However, long-
term therapeutic evaluation wasn’t possible as patients later underwent HSCT.  Providing 
costimulation outside of the CAR by co-expressing CD80 and 4-1BBL was shown to 
improve persistence of infused 1st generation CAR T cells (42).  Yet similar to the 2nd 
generation T cells, which receive CD28 costimulation via CAR activation, the addition of 
external CD80/4-1BB costimulation did not maintain durable T cell persistence and only 
aided T cells in a TAA-dependent manner.  It is apparent that it is not a matter of just 
providing costimulation, but rather providing a signal that is context-dependent and suits the 
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conditions at a given time.  IL-15’s pleiotropic activities support T cells both during T cell 
encounter with antigens as an inflammatory cytokine, as well as in the absence of antigen 
as a homeostatic cytokine (86, 88).  Hence, IL-15 may collaborate appropriately with T cells 
in the variable conditions associated with MRD. 
  In Chapter 2, we generated clinically relevant mIL15-CAR T cells that displayed 
sustained pSTAT5 suggesting that they may be more suitable than conventional CAR T 
cells in a low-TAA environment.  To gather further preclinical data on mIL15-CAR T cells, 
we subsequently examined these cells in vivo.  Their potential for in vivo performance is 
supported by studies demonstrating that IL-15 can enhance in vivo antitumor activity as well 
as support homeostasis of CD8 TCM, which persist long-term without requiring contact with 
antigen (88, 134).  We, therefore, hypothesize that mIL15-CAR T cells will possess 
enhanced in vivo antitumor activity and be capable of persisting in vivo irrespective of TAA.   
 
3.2  Results 
3.2.1  Enhanced In Vivo Persistence of mIL15-CAR T cells in a High Tumor Burden Model 
 CARs have been designed to provide survival signaling upon engagement with TAA for 
improved in vivo persistence (41).  In a high-dose disseminated leukemia model (1 x 105 
NALM-6 tumor cells), it was previously shown that CAR T cells mediate significant 
antitumor activity (53).  However, in vivo persistence of these cells in the presence of 
abundant tumor antigen remained unknown and had any assessments been made the 
weekly T cell infusions would have been confounding.  Here we sought to (i) determine 
whether conventional CAR T cells persisted for any length of time in this high tumor burden 
model and (ii) whether additional costimulation from mIL15 would enhance CAR T cell 
persistence under prevalent TAA.  CAR and mIL15-CAR T cells, co-modified with firefly 
luciferase (ffLuc), were adoptively transferred into NSG mice given a high-dose 
disseminated NALM-6 leukemia (1 x 105 cells i.v. injected; Fig. 13A).  T cell persistence 
was longitudinally assessed by bioluminescent imaging (BLI) for T cell-associated ffLuc 
activity.  Already on the first day after T cell infusion, CAR T cell persistence was observed 
to be lower than that of the mIL15-CAR T cells, with measured flux ranging 7.5 x 105 – 8.9 x 
105 p/s/cm2/sr and 2.8 x 105 – 4.0 x 106 p/s/cm2/sr, respectively.  The mIL15-CAR T cell-   
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Figure 13.  Enhanced in vivo persistence of mIL15-CAR T cells when tumor antigen is 
prevalent.  (A) Schematic of experiment.  NSG mice were infused i.v. with 1 x 105 CD19+ 
NALM-6 cells followed the next day by i.v. infusion of 2 x 107 CAR+ffLuc+ T cells with or 
without co-expression of mIL15.  Infused T cell number was based on CAR+ T cells.  (B) 
Longitudinal BLI was performed to monitor T cell persistence from days 1 - 11.  Images 
represent photon flux from T cell-derived ffLuc activity.  (C) Longitudinal plotting of T cell 
flux.  Data are represented as mean ± SD, n = 5.  *P = 0.0009, unpaired t test. 
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Figure 13.  Enhanced in vivo persistence of mIL15-CAR T cells when tumor antigen is 
prevalent 
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treated mice had BLI that was detected during the course of the study and remained with 
significantly higher flux than CAR T cell treated mice at day 11 (P = 0.0009; Fig. 13B,C).  At 
14 days, the mice were sacrificed and peripheral blood, spleen, and bone marrow were 
harvested to assess the presence of human CD3 cells.  No human CD3+ cells were 
detected in the blood or tissues of mice treated with CAR T cells.  Mice receiving mIL15-
CAR T cells showed human CD3+ cells at frequencies of 9.1% - 52.8% in the blood, 0.8% - 
11.0% in the spleen, and 0.4% – 1.6% in the bone marrow.  Significant levels of chimerism 
were observed as compared to CAR T cell (P < 0.05, P < 0.05, P < 0.001, respectively) and 
tumor only-treated mice (P < 0.05, P < 0.05, P < 0.001, respectively; Fig. 14A,B).  This type 
of disseminated tumor model using 1 x 105 Nalm-6 cells is relatively aggressive with 
mortality occurring in untreated mice around 21 days after tumor injection.  Other studies 
using this tumor model treated mice with multiple CAR T cell infusions and while antitumor 
effects were observed, it was not a curative model (53). Hence, it was not unexpected that 
one infusion of mIL15-CAR T cells did not show significant antitumor activity.  Together 
these data show that despite the presence of CAR-activating TAA, mIL15-CAR T cells but 
not CAR T cells persisted.  
3.2.2  In Vivo Persistence and Antitumor Efficacy of mIL15-CAR T Cells in a Low Tumor 
Burden Model 
Assessment of mIL15-CAR T cell persistence was next performed in a preventative low-
TAA tumor model to assess transferred T cell engraftment and antitumor activity.  In such a 
scenario, adoptively transferred T cells may not immediately encounter CAR-stimulatory 
TAA to receive survival signaling; hence, persistence may not be sustained.  It has been 
previously shown that adoptively transferred CAR T cells (expressing a second generation 
CAR) only demonstrated TAA-dependent persistence (41), which thus poses concern for 
infusing CAR T cells into a low or sequestered TAA environment.  In this preventative tumor 
model, CAR-ffLuc and mIL15-CAR-ffLuc T cells were first engrafted in mice followed by i.v. 
dissemination of a low-dose of NALM-6 cells (1 x 104 cells; Fig. 15A).  CAR T cell BLI was 
undetectable at day six and only mIL15-CAR T cells persisted until the day of sacrifice (Fig. 
15B,C).  Total body flux was determined and was defined by a region of interest (ROI) that 
included the body and head, but not the tail. Total body flux showed mIL15-CAR T cell 
levels stabilize after 19 days post-infusion and remained significant at day 35 (P = 0.0027; 
Fig. 15C).  BLI images of mIL15-CAR T cells at days 30 and 35 showed localization of cells 
to the tibia and foot region.  Aggregations of T cells in those areas could putatively be within    
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Figure 14.  Tissue distribution of persisting mIL15-CAR T cells under high tumor 
burden.  At day 14, tissues and blood were harvested and analyzed by flow cytometry for 
the presence of CD3+ T cells in the three treatment cohorts.  (A) Representative flow plots 
show CD3 frequencies in the blood, spleen, and bone marrow, n = 5.  (B)  Plotted CD3 
frequencies in the blood, spleen, and bone marrow from (A).  Data are represented as 
mean ± SD, n = 5.  *P < 0.05, ***P < 0.001, one-way ANOVA. 
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Figure 14.  Tissue distribution of persisting mIL15-CAR T cells under high tumor 
burden  
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Figure 15.  Enhanced in vivo persistence of mIL15-CAR T cells under low tumor 
burden.  (A) Schematic of experiment.  NSG mice were first infused i.v. with 2 x 107 
CAR+ffLuc+ T cells with or without co-expression of mIL15.  Infused T cell number was 
based on CAR+ T cells.  After six days of engraftment, 1 x 104 rLuc+NALM-6 (CD19+) cells 
were i.v. injected.   (B) Longitudinal BLI was performed to monitor T cell persistence.  
Images represent photon flux from T cell-derived ffLuc activity.  (C) Longitudinal plotting of 
T cell flux derived from ROIs encompassing the body (left panel) and the femurs (right 
panel).  Background luminescence (grey area) was derived by imaging mice that received 
D-luciferin, but which did not receive ffLuc+ T cells.  Data are represented as mean ± SD, n 
= 4 – 5.  **P = 0.0027, ***P = 0.0007, unpaired t test.   
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Figure 15.  Enhanced in vivo persistence of mIL15-CAR T cells under low tumor 
burden   
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the bone marrow and thus may also involve the femur region.  Another ROI was created to 
hone in on each of the back legs and included the femur, tibia, and foot.  The mIL15-CAR T 
cell flux from this region indicated stable engraftment in the bone marrow by the fifth day 
after T cell infusion and remained at a significant level at day 35 (P = 0.0007).  The flux 
data do not indicate any trends of sustained uncontrolled exponential growth.  Interestingly, 
while bone marrow flux remained persistent between days five thru 14, there was an 
observed sharp decline in mIL15-CAR T cells elsewhere in the body (Fig. 15C). 
Tumor flux (NALM-6 rLuc activity) remained significantly lower in the mIL15-CAR mice 
compared to CAR-treated mice and tumor only mice demonstrating the antitumor activity of 
mIL15-CAR T cells (both P < 0.0001; Fig. 16A,B).    Tumor eradication by mIL15-CAR T 
cells was corroborated by CD19 staining of peripheral blood, spleen, and bone marrow.  No 
significant CD19+ tumor burden (< 0.5%) was detected in the blood, spleen bone, or 
marrow (P < 0.05, P < 0.0001, P < 0.01, respectively; Fig. 17A,B).  Notably, despite the 
tumor cells elimination from all of these locations, the mIL15-CAR T cells remained 
localized to the bone marrow (range: 0.1% - 2.8% of total cells), but their chimerism was at 
a significant frequency (P = 0.0050; Fig. 17A,C).  No human CD3+ cells were detected in 
the spleen or blood (Fig. 17A).  The CD3 flow cytometry data corroborated the flux data 
that indicated a peripheral decline of mIL15-CAR T cells while the bone marrow 
environment remained stable.   
Long-term evaluation of survival in this model showed enhanced therapeutic efficacy of 
mIL15-CAR T cell treatment resulting in 43% survival at 98 days as compared to 100% 
mortality in all other treatments by day 34  (Fig. 18).  Survival of mice treated with mIL15-
CAR T cells was significantly enhanced over mice treated with CAR-T cells (P = 0.045).  
One of the three surviving mice had a detectable population of human CD3+CD8+ cells at 
0.220% in the bone marrow (data not shown).  These data together indicate that mIL15-
CAR T cells were capable of engrafting and mounting an antitumor response in a low TAA 
environment thereby making them more therapeutically effective in mice than conventional 
CAR T cells. 
3.2.3  In Vivo Persistence of mIL15-CAR T Cells is CAR-independent 
To assess if mIL15-CAR T cells can indeed persist long-term in vivo without the need 
for CAR-dependent survival signaling, modified T cells (mIL15+/negCAR+ffluc+)  were infused   
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Figure 16.  In vivo anti-tumor activity of mIL15-CAR T cells.  (A) Longitudinal BLI was 
performed to monitor rLuc+NALM-6 tumor cell persistence.  Images represent photon flux 
from NALM-6 cell-derived rLuc activity.  (B) Longitudinal plotting of tumor flux.  Data are 
represented as mean ± SD, n = 4-5. ****P < 0.0001, one-way ANOVA.   
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Figure 17.  mIL15-CAR T cells clear tumor and remain localized to the bone marrow 
after an anti-tumor response.  At day 36, tissues and blood were harvested and analyzed 
by flow cytometry for the presence of CD3+ T cells and CD19+ tumor cells in the three 
treatment cohorts.  (A) Representative flow plots show frequencies of CD3 and CD19 in the 
peripheral blood (n = 3-5), spleen, and bone marrow, n = 4-5.  (B) Frequency of CD19+ cells 
in the blood (n = 3-5), spleen, and bone marrow, n = 4-5.  (B)  Plotted CD3+ cell frequencies 
in the bone marrow.  Data are represented as mean ± SD, n = 4-5.  *P < 0.05, **P < 0.01, 
****P < 0.0001, ns = not significant, one-way ANOVA (B), unpaired t test (C). 
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Figure 17.  mIL15-CAR T cells clear tumor and remain localized to the bone marrow 
after an anti-tumor response  
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Figure 18.  Efficacy of tumor immunotherapy with mIL15-CAR T cells.  Using the low 
tumor model, long-term overall survival of mice was assessed to day 98.  The experiment 
was carried out similarly to the previously described low tumor model.  Mice were engrafted 
with mIL15-CAR T cells (n = 7), CAR T cells (n = 8), or no T cells (n = 8) followed by NALM-
6 tumor challenge.  Fractions in parentheses represent the proportion of mice surviving to 
day 98.  *P = 0.045 (mIL15-CAR versus CAR T cell treatment), log-rank (Mantel-Cox).   
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into mice with no tumor or exogenous cytokine support and monitored for 48 days (Fig. 
19A).  Akin to the previous results, CAR T cell persistence was not observed in this model 
after day zero, whereas mIL15-CAR T cells exhibited sustained persistence throughout the 
duration of the experiment (Fig. 19B).    Both total body and femur flux of mIL15-CAR T 
cells at day 47 were at levels significantly above the baseline values of CAR T cells (P = 
0.0128 and P = 0.002, respectively; Fig. 19C), but were not indicative of any trends of 
sustained and uncontrolled exponential growth.  Blood and tissue analysis revealed that 
mIL15-CAR T cell engraftment was significant and primarily localized to the bone marrow 
and spleen (P = 0.0027 and P = 0.0081, respectively, Fig. 20).  Although inconsistent 
chimerism was observed in the blood, it was associated with higher chimerism in the spleen 
and liver, as observed by BLI.  Thus, it is suggested that mIL15 provides sufficient 
costimulation to sustain T cell persistence in a CAR-independent manner, which may make 
these T cells a more appropriate option for adoptive transfer in a low or sequestered TAA 
environment as may be the case with MRD. 
 
3.3  Discussion 
 Work in this chapter builds upon results from Chapter 2 providing the preclinical 
rationale for developing a phase I clinical trial using mIL15-CAR T cells to treat MRD.  In 
contrast to conventional CAR T cells, mIL15-CAR T cells persisted in mice independent of 
the presence of TAA and eradicated CD19+ leukemic cells in a low-dose disseminated 
tumor model indicating their suitability for translation to the clinic for the treatment of MRD. 
 CARs are designed with modular costimulatory endodomains, which in our model 
includes CD3ζ and CD28 signaling, to supply signals one and two for T cell activation (41).  
We observed that in the presence of abundant tumor, mIL15-CAR T cells showed 
enhanced persistence (Fig. 13,14) over the conventional CAR T cells, suggesting that IL-15 
signaling provided a third additive costimulatory signal.  The mechanism of this persistence 
was not investigated, but may be related to the prevention of AICD as IL-15 is reported to 
play a key role in resisting it (87). In addition to enhanced persistence under low tumor 
burden, mIL15-CAR T cells mediated significant antitumor activity (Fig. 15-17).  These 
results are in concordance with other studies that evaluated CAR T cells modified to 
secrete monomeric IL-15 in leukemia models (92, 93).  In those studies, CAR T cell 
persistence was assessed in reference to tumor exposure.  We additionally examined  
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Figure 19.  Long term in vivo engraftment of mIL15-CAR T cells in the absence of 
tumor.  (A) Schematic of experiment.  NSG mice were infused i.v. with 2 x 107 CAR+ffLuc+ 
T cells with or without co-expression of mIL15.  Infused T cell number was based on CAR+ 
T cells.  (B) Longitudinal BLI was performed to monitor T cell persistence from days 0 - 47.  
Images represent photon flux from T cell-derived ffLuc activity.  (C) Longitudinal plotting of 
T cell flux.  Background luminescence (gray shaded) was defined by flux obtained from 
mice not receiving ffLuc+ T cells.  These mice were given D-luciferin and imaged along with 
the treatment mice.  Data are represented as mean ± SD, n = 5, and representative of two 
similar experiments. *P = 0.0128, **P = 0.0021, unpaired t test. 
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Figure 19.  Long term in vivo engraftment of mIL15-CAR T cells in the absence of 
tumor  
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Figure 20.  In vivo localization of mIL15-CAR T cells in the absence of tumor.  At day 
48, tissues and blood were harvested and analyzed by flow cytometry for the presence of 
CD3+ T cells in mice treated with either mIL15-CAR or CAR T cells.  Representative flow 
plots (left panel) show frequencies of CD3 in the peripheral blood, spleen, and bone 
marrow.  Plotted frequencies of CD3+ cells in the tissues and blood (right panel).  Data are 
represented as mean ± SD, n = 5, and representative of two similar experiments.   **P = 
0.0027 (bone marrow), **P = 0.0081 (spleen), ns = not significant, unpaired t test.  
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persistence in the absence of TAA-dependent CAR signaling, where in the clinical setting of 
disease relapse or MRD, T cells may not encounter TAA for some time.  We confirmed that 
mIL15-CAR T cells persisted independent of TAA (Fig. 19,20) and it is concordant with 
other studies where engraftment was achieved by T cells engineered to exploit the IL-2/15 
cytokine signaling pathway by the expression of constitutively active STAT5 (135) or a 
chimeric cytokine receptor mediating constitutive CD122 signaling (120).  Together, it is 
indicated that costimulation via IL-15Rβ/Cγ signaling is sufficient to support CAR T cell 
persistence allowing for continued antitumor activity and that persistence could be 
maintained in a low or no tumor environment.   
 Notably, we observed different levels and patterns of engraftment of mIL15-CAR T 
cells in this preventative low-dose tumor model (Fig. 15,17) compared to the no tumor 
engraftment model (Fig. 19,20).  T cell abundance was inferred from the observed 
correlation of T cell levels with photon flux (42, 136), as well as our observations of photon 
flux and detected CAR T cell chimerism at sacrifice.   We noted that mIL15-CAR T cell 
abundance during the antitumor response declined (Fig. 13,15) which contrasted other 
results of IL-15-secreting CAR T cells that showed expansion, or increased flux signal, in a 
tumor model (93).  These observations highlight the issue of identifying what costimulation 
type and amount is sufficient in a tumor microenvironment to achieve optimal T cell function 
and expansion.  Our in vivo model used Nalm-6 tumor cells that lack the CD80 and CD86 
costimulatory molecules  (137), whereas the other model (93) used Daudi and Raji cells 
which express both costimulatory ligands (137, 138).  Moreover, it has been shown that 
enforcing expression of CD80 on Nalm-6 provided adequate costimulation to restore 
antitumor responses of CAR T cells (137).  Nalm-6 tumor cells have been shown to 
suppress the up-regulation of costimulatory molecules on T cells affecting T cell biological 
responses (139).  This may be a factor that contributed to (i) the extremely limited 
persistence of CAR T cells in the presence of TAA and (ii) the lack of expansion of mIL15-
CAR T cells in response to TAA.  These data cumulatively suggest that expression of 
mIL15 provides significant additive costimulation to enable persistence, but it is not fully 
compensatory under certain immunosuppressive conditions and emphasizes the 
importance of continued investigation of CAR designs that can provide fully competent T 
cell activation. 
 Another important observation was the differential chimerism that occurred in the 
preventative low-tumor mouse model as compared to tumor-free engraftment.  Quite 
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strikingly, after the antitumor response, mIL15-CAR T cells in that model remained localized 
only to the bone marrow (Fig. 15,17).  In contrast, mIL15-CAR T cells that engrafted in the 
absence of tumor were detected in the peripheral blood and spleen in addition to the bone 
marrow (Fig. 19,20).  The observed retention of CAR T cells to the bone marrow was 
congruent with a syngeneic murine model of CAR T cells targeting B-ALL (140).  In 
contrast, in a lymphoma model using the more costimulatory Raji tumor cell line in NSG 
mice, a definitive population of IL-15 secreting CAR T cells were observed in the spleens at 
over 106 days after tumor challenge (92).  Perhaps this contrasting observation is due to 
the different time points of observation, as our results are reflective of T cell status at 36 
days after tumor challenge.  Assessments of murine CD8 T cells in the bone marrow 
suggest that this site is a niche for antigen-independent proliferation of memory CD8 T cells 
that display a more activated state than those from peripheral lymphoid organs (141, 142).  
Hence, it is plausible that in our model, repopulation of the spleen could occur at a later 
time.  An additional aspect proposed to operate concomitantly is that repetitive antigen 
stimulation, and perhaps the suppressive nature of the Nalm-6, promoted a high degree of 
differentiation with subsequent loss of terminally differentiated cells.  The observed bone 
marrow-resident population remaining after tumor challenge may not have undergone as 
extensive a differentiation, putatively due to being less differentiated at the time of infusion, 
having less contact with antigen, and/or having sufficient mIL15 costimulation.  
Nonetheless, this population remained to repopulate and thus resided in the bone marrow.  
It has been clearly illustrated that repetitive antigen stimulation induces differentiation that 
consequently affects function and longevity (17, 21, 143).  Hombach et al (144) 
demonstrated that the transfer of less differentiated CCR7+ CAR T cells results in a 
CCR7neg phenotype after exposure to antigen.  The use of a 3rd generation CAR with CD3ζ, 
CD28, and OX40 signaling supported the survival and effector function of these responding 
CCR7neg cells (144).  Pairing mIL15 with this 3rd generation CAR may assist in maintaining 
or even boosting CAR T cell levels during antitumor responses, hence yielding a larger 
resident population after the tumor is cleared.  A readily translatable approach is to pair 
mIL15 with the 2nd generation CAR that has CD3ζ and 4-1BB signaling capacity.  This CAR 
is currently being used in clinical trials and has led to objective clinical responses (77, 145) 
and direct comparisons indicate that 4-1BB signaling may prove to be superior to CD28 
signaling in CAR T cells both in vitro (146) and in vivo (H. Singh, unpublished data).  
Moreover, IL-15 has been shown to induce 4-1BB on T cells and 4-1BB/4-1BBL interactions 
sustain memory CD8 T cell survival independent of antigen (147).  Cancer immunotherapy 
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with a targeted antibody fusion protein presenting IL-15 and 4-1BBL improved therapeutic 
efficacy over each as an individual treatment (148).  The cooperative relationship between 
IL-15 and 4-1BB strongly suggests that combining mIL15 with the 4-1BB-signaling CAR 
holds significant potential for augmenting therapeutic response. 
 MRD detected by sensitive methods such as deep sequencing can detect extremely 
low levels of TAA in a patient (0.00004% MRD) (128) making delayed TAA encounter for 
CAR T cells a likely scenario.  Our assessment of mIL15-CAR antitumor activity, therefor, 
utilized a preventative disseminated tumor model in which infused T cells would not 
immediately encounter TAA, and when tumor was present it was initially at a low level.  
Testing mIL15-CAR T cell antitumor activity could also have been diversified to include 
established subcutaneous tumor models using Raji or Daudi cell lines to assess antitumor 
activity with sequestered TAA.  An immunocompetent syngeneic B-ALL murine model (140) 
could be used to assess the performance of mIL15-CAR T cells in treating MRD, which may 
be a more clinically relevant assessment of performance of adoptively transferred CAR T 
cells.  This mouse model of B-ALL recapitulates disease pathology and mice may be 
conditioned with chemotherapy prior to adoptive T cell transfer for treating residual disease.  
Other elements to disease treatment with mIL15-CAR T cells could also be studied with this 
model, including immune reconstitution post-conditioning and adoptive transfer, and T cell 
memory subset composition throughout and antitumor response.  The caveat with this 
approach is the requisite development of the murine CAR and mIL15 for use in this model.  
The results described in this chapter showed long-term persistence of mIL15-CAR T 
cells and potent antitumor activity that enhanced therapeutic efficacy, as seen by significant 
long-term survival after tumor challenge.  Together this indicates that mIL15-CAR T cells 
would be suitable for the treatment of MRD or sequestered TAA and supports the impetus 
to translate this approach to the clinic.  However, it must be considered that further 
improvements may yet be made regarding enhancing the magnitude of T cells during and 
after tumor challenge in an immunosuppressive tumor model.  Therefore, determining the 
optimal CAR signaling to pair with mIL15 remains an important consideration. 
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CHAPTER 4 
Characterization of Long-term Persisting mIL15-CAR T Cells 
 
4.1  Introduction 
 Intrinsic and extrinsic factors coalesce to dictate the fate of T cells and shape the 
composition of heterogeneous populations of effector and memory CD8 T cells.  TCR 
signaling, costimulatory ligands, and inflammatory cytokines are the extrinsic factors 
providing the three signals required for T-cell activation (149-151).  Additionally, γC 
cytokines are integral in T cell proliferation, survival, and memory.  Intrinsically, numerous 
transcription factors have roles in T cell differentiation, including T-box expressed in T cells 
(T-bet), EOMES, T-cell factor 1 (TCF-1), BLIMP-1, and BCL-6 (reviewed in reference (16)).  
The unique amalgam of signals during antigen encounter results in varying degrees of 
differentiation with some T cells intrinsically biased toward a long or short-term fate (25, 26, 
152).  T cell differentiation is accompanied by phenotypic and functional changes.  Less 
differentiated cells express CD62L and CCR7, have longevity, and can produce IL-2; 
whereas, those features are lost and effector functions are gained as differentiation 
progresses (16, 17).  These functional features of T cell differentiation have implications on 
the therapeutic efficacy of ACT.  It has been demonstrated that less differentiated T cells 
possess higher therapeutic potential (50, 52, 153) and the immunotherapy field is 
evaluating the importance of preserving T cell memory potential.  Little knowledge exists on 
the characteristics and intrinsic mechanisms of long-term persisting CAR T cells.  
Moreover, questions exist as to the state of cytokine-modified CAR T cells, being that they 
receive continual cytokine signaling.  With IL-15’s well-known effects on the homeostatic 
maintenance of TCM, we therefore hypothesize that persisting mIL15-CAR T cells will 
possess attributes associated with TCM.  Moreover, intrinsic elements will be representative 
of their differentiation state.  
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4.2  Results 
4.2.1  Modeling Long-term Persistence In Vitro 
Observing the long-term persistence of mIL15-CAR T cells in vivo, we aimed to model 
this in an in vitro setting to enable characterization of the persisting T cells.  Expanded 
(Stim 4) mIL15+/negCAR+ T cells were put into long-term culture without further antigen re-
stimulation.  CAR T cells received IL-15 complex or no cytokine supplementation while 
mIL15-CAR T cells received no exogenous cytokines and were maintained for 65 days 
(Fig. 21A).  Significant persistence of mIL15-CAR T cells was observed in comparison to 
cytokine unsupplemented CAR T cells, which were rapidly lost (P < 0.0001; Fig. 21B).  By 
day 65 mIL15-CAR T cells appeared to show a gradual decline from their initial numbers (P 
< 0.01) whilst CAR T cells receiving IL-15 complex demonstrated an increased fold change 
in cell number resulting in significantly differing levels of persistence between the two 
groups (P < 0.001; Fig. 21B).  Unlike the mIL15-CAR T cells, it appeared that soluble 
cytokine supplementation enabled CAR T cells to sustain growth within the first 15 days (P 
< 0.05), after which both groups did not demonstrate significant changes in cell number 
(Fig. 21B).  CAR T cells supplemented with IL-2 paralleled the response of CAR T cells 
supplemented with IL-15 complex, suggesting that in the vitro T cell maintenance was not 
specific to IL-15 or mIL15 (data not shown).  Moreover, the observed soluble cytokine-
induced T cell growth may have been due to stronger cytokine signal induction from the 
dosing used, as pSTAT5 induction was stronger with the use of soluble cytokines (Fig. 10 
and unpublished observations).  Further analyses of T cells persisting at the end of the 
withdrawal experiment refer to the cells as ‘WD-T cells’ to denote this day 65 time point of 
the samples.  Annexin V staining of cells remaining at the end of the experiment indicated 
that both WD-CAR and WD-mIL15-CAR T cells had similar viability (Fig. 21C).  These data 
suggest that WD-mIL15-CAR T cells had sufficient costimulation to sustain T cell viability, 
but had inadequate stimulation for the growth that the exogenous cytokines induced and is 
a desirable characteristic in the context of homeostasis and safe long-term in vivo 
persistence.   
4.2.2  CAR and mIL15 Expression and Functionality in WD-T Cells 
While persistence is the primary aim of this study, surviving T cells would be of no 
clinical utility if they down-modulated expression of the CAR or mIL15, and/or  if these  
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Figure 21.  Modeling long-term persistence in vitro.  (A) Schematic summarizing the 
withdrawal experiment for assessing long-term persistence of mIL15+/-CAR+ T cells after 
withdrawal of antigen.  T cells obtained for the withdrawal assay had been stimulated on 
aAPC four times and maintained for 10 days with respective cytokines used during 
expansion.  During the 65-day exogenous cytokine withdrawal, the mIL15-CAR T cells 
received no cytokine supplementation while CAR T cell control treatments received either, 
IL-15 complex (5ng/ml) or no cytokines.  (B)  Fold change in number of T cells at 15, 30, 50, 
and 65 days during withdrawal conditions.  Data represent mean ± SD, n = 3. *P < 0.05, 
****P < 0.0001, ns = not significant, two-way RM ANOVA (Tukey’s post-test).  (C)  
Representative histogram showing Annexin V staining (left panel) and plotted live T cell 
(Annexin Vneg) frequencies (right panel).     
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molecules are non-functional.  CAR and mIL15-CAR T cells entered the withdrawal assay 
expressing high levels of CAR (97% - 98% and 92% - 98%, respectively; Fig. 22A).  The 
majority of WD-CAR and WD-mIL15-CAR T cells retained CAR expression (61 ± 20% and 
82 ± 19%, respectively; mean ± SD; Fig. 22B,C).  Unexpectedly, the WD-mIL15-CAR T 
cells showed a low surface expression of mIL15 (range: 13% - 81%).  However, intracellular 
levels were detected at moderately high levels (range: 54% - 98%; Fig. 22B,D).  Despite 
the majority of mIL15 being detected intracellularly, expression levels were sufficient to 
induce cytokine signaling that, compared to unsupplemented WD-CAR T cells, yielded 
elevated levels of pSTAT5 and Bcl-2, a pro-survival molecule downstream of STAT5 
signaling (154-156) (Fig. 23A). Whether the intracellularly detected mIL15 participated in 
the induction of cytokine signaling is unknown.  IL-15, bound to IL-15Rα, is known to persist 
without degradation in endosomes and recycle to the surface (71), thus allowing for the 
possibility that recycling kinetics may have altered.  Notwithstanding, the pSTAT5 pathway 
was transducing cytokine signaling in WD-mIL15-CAR T cells.  To be of benefit as a clinical 
application, CAR T cells must remain responsive to TAA, to which both WD-CAR (cytokine 
supplemented) and WD-mIL15-CAR T cells produced equivalent levels of IFNγ in response 
to CD19+ targets (P > 0.05; Fig. 23B).  Thus, despite the long-term absence of TAA, WD-
mIL15-CAR T cells retained functional mIL15 and redirected CAR responses, which 
furthers their potential clinical utility.     
 4.2.3  Persistence of mIL15-CAR T Cells Does Not Involve Initial Molecular Programming   
With deference to the crucial role that IL-15 plays in the homeostasis of CD8+ T cell 
memory (85, 86), it was postulated and shown that mIL15 could support long-lived T cells in 
the absence of CAR or TCR signaling (Fig. 19B,C; Fig. 21B).  Subsequent investigation 
sought to determine whether these long-lived T cells possessed traits associated with CD8+ 
T cell memory.  Some studies suggest that within the heterogeneous population of effector 
T cells there may be intrinsic programming predetermining cells to long or short-lived fates 
(157).  Despite the observed phenotypic similarities between CAR T and mIL15-CAR T 
cells (Fig. 11), the possibility existed for cell intrinsic factors to play a role in the observed 
prolonged persistence of WD-mIL15-CAR T cells.  To assess whether mIL15 conferred a 
survival advantage via molecular programming in the infusion product (Stim 4 expanded T 
cells), we compared CAR and mIL15-CAR T cells by digital gene expression analysis using 
a 479 gene lymphocyte-specific CodeSet (Appendix 1).  Surprisingly, we found only four 
genes differentially expressed (2-fold cutoff, P < 0.01, FDR q value < 0.05; Appendix 2),  
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Figure 22.  CAR and mIL15 expression on WD-T cells.  (A) Representative flow plots 
showing CAR and mIL15 expression on T cells during the withdrawal assay at day 0 and 
(B) at day 65 (top panel), with FLAG staining detecting intracellular localization of mIL15 
(bottom panel).  (C) Frequencies of T cells staining positive for CAR.  Horizontal bar 
represents the mean.  (D) Frequencies of T cells staining positive for surface-detected and 
intracellularly-detected mIL15.  Horizontal bar represents the mean.  Data are 
representative of 3 donors. 
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Figure 22.  CAR and mIL15 expression on WD-T cells   
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Figure 23.  WD-mIL15-CAR T cells maintain pSTAT5 induction and antigen-specific 
reactivity.  WD-CAR T cells supplemented with IL-15 complex and WD-mIL15-CAR T cells 
were assessed for functionality after antigen withdrawal.  (A) Continued functionality of 
mIL15 was validated by phosflow of pSTAT5 and intracellular staining for Bcl-2 expression.  
For the pSTAT5 assay, samples were serum and cytokine starved for 12 hours.  CAR T 
cells treated with soluble IL-15 (100ng/ml) 1-hour prior to fixation served as the positive 
control.  For Bcl-2 analysis, two days prior to Bcl-2 staining, some CAR T cells were 
washed and resuspended in complete media without cytokine supplementation to serve as 
the baseline control.   The representative  histograms show the flourescence intensity of 
pSTAT5 (left panel) and Bcl-2 (right panel).  (B) IFNγ production by WD-T cells stimulated 
for 6 hours with CD19+ (tCD19+ EL4 and NALM-6) or CD19neg (EL4) targets, LAC (positive 
control), or media alone (negative control).  Histograms were gated on CD3+ and CAR+ 
cells.  All data are representative of three donors.   
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Figure 23.  WD-mIL15-CAR T cells maintain pSTAT5 induction and antigen-specific 
reactivity  
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with the difference in IL7ra expression corroborated by phenotyping (Fig. 11A).  These 
results indicated no overt molecular survival advantage of mIL15-CAR T cells. 
4.2.4.  Molecular Profiling of WD-mIL15-CAR T Cells Describes a State of Low 
Differentiation 
With the indistinguishable nature of CAR and mIL15-CAR T cells, subsequent 
investigation focused on identifying attributes of WD-mIL15-CAR T cells that are associated 
with long-lived T cells.  Stark differences emerged when comparing long-term persisting 
WD-mIL15-CAR to Stim 4 mIL15-CAR T cells, where 98 genes were significantly 
differentially expressed (2-fold cutoff, P < 0.01, FDR q value < 0.05; Fig. 24A,B).  
Functional gene annotation was performed using DAVID Bioinformatics Resources 
(http://david.abcc.ncifcrf.gov) to cluster the significant genes into broad categories (158, 
159).  The most notable groups included the following: induction of apoptosis, regulation of 
cytokine production, homeostatic process, regulation of cell size, regulation of T cell 
differentiation, positive regulation of T cell activation, and Wnt signaling pathway (Fig. 24C).  
These functional clusters are relevant to processes affecting T cell differentiation status and 
suggest that aspects of differentiation may be a key factor involved in WD-mIL15-CAR T 
cell persistence. 
Transcripts encoding key regulators of effector differentiation and related cytotoxic 
molecules showed diminished expression in WD-mIL15-CAR T cells: Tbx21 (encoding T-
BET), Prdm1 (encoding BLIMP-1), Il2ra (encoding IL-2Rα), Infg (encoding IFNγ), Prf1, 
Gnly, Gzmh, Gzmb, Cd11b, and Ctla4 (Fig. 24A; Fig. 25A,B).  Inversely, a pro-memory 
transcriptional profile, indicative of a low level of differentiation, was represented by WD-
mIL15-CAR T cells: Tcf7 (encoding TCF-1), Eomes, Bcl2, Bach2, Lef1, Bcl6, Foxp1, Ccr7 
(encoding CCR7), and Il7ra (encoding IL-7Rα) (Fig. 24B; Fig. 25A,B) (16, 52, 160-163).  
The observed down-regulation of Sell (encoding CD62L) and Cd28 (encoding CD28) by 
WD-mIL15-CAR T cells did not conform to the pro-memory transcriptional profile.  IL-15 has 
been implicated in the generation of CD28neg CD8 T cells (164-166).  Unexpectedly, Foxo1 
did not show a paralleled increased up-regulation with the other genes in the pro-memory 
profile, rather a non-significant decrease of 1.5-fold was observed in WD-mIL15-CAR T 
cells relative to mIL15-CAR T cells.  This observation is rather perplexing as Foxo1 is a 
transcription factor central to memory T cell differentiation in that it directly or indirectly 
regulates the expression of Tcf7, Eomes, Sell, Ccr7, and Il7ra (163, 167, 168).  Instead,   
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Figure 24.  Differential gene expression between mIL15-CAR T cells and long-term 
persisting WD-mIL15-CAR T cells.  Multiplexed digital gene profiling was used to analyze 
gene expression for mIL15-CAR T cells obtained from cultures after the 4th aAPC 
stimulation cycle and WD-mIL15-CAR T cells persisting long-term (> 65 days) after antigen 
and exogenous cytokine withdrawal.  Heat maps of significantly differentially expressed 
genes (2-fold differential expression cutoff, P < 0.01, and FDR q value < 0.05) that were (A) 
down-regulated and (B) up-regulated in WD-mIL15-CAR T cells relative to mIL15-CAR T 
cells, n = 3.  (C) All significantly differentially expressed genes were functionally classified 
using DAVID Bioinformatics Resources.  Select groups relevant to T cell persistence and 
differentiation status are displayed.      
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Figure 24.  Differential gene expression between mIL15-CAR T cells and long-term 
persisting WD-mIL15-CAR T cells  
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Figure 25.  Molecular profiling of WD-mIL15-CAR T cells describes a state of low 
differentiation.  Comparison of select significantly differentially expressed genes between 
expanded mIL15-CAR and persisting WD-mIL15-CAR T cells.  The selected genes are 
associated with long-lived central memory or short-lived effector T cells, which are 
described as having low and high levels of differentiation, respectively.  (A)  Plots of 
normalized mRNA counts for selected genes from the multiplexed digital gene profiling.  
Lines connecting data points match donors.  (B) Classification of the subset of genes in (A) 
by function.  Bars represent the mean fold change in gene expression of WD-mIL15-CAR T 
cells relative to mIL15-CAR T cells.  Asterisk indicates protein expression was verified by 
flow cytometry. 
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Foxo3 was significantly up-regulated 2.1-fold (Fig. 24B), but its role in CD8 T cell 
differentiation remains ill-defined. 
Some transcription factors have been found to function in pairs with graded reciprocal 
activity controlling effector and memory T cell differentiation.  The ratio of T-bet and Eomes 
is one such pairing, with the ratio lowest in early memory T cell differentiation states (16, 
26).  We observed that mIL15-CAR and WD-mIL15-CAR T cells indeed had altered mRNA 
ratios of T-bet and Eomes (20:1–94:1 and 2:1–9:1, respectively), with WD-mIL15-CAR T 
cells representative of the low ratio associated with memory stages.  Together these data 
suggest that in the absence of antigen WD-mIL15-CAR T cells exhibit an overall profile that 
is characteristic of less differentiated T cells.     
4.2.5  WD-mIL15-CAR T Cells Possess Phenotypic and Functional Characteristics 
Associated with a Low Differentiation State 
Protein expression of specific transcription factors and surface markers associated with 
T cell differentiation status corroborated the observed low differentiation molecular profile of 
WD-mIL15-CAR T cells.  Memory-associated transcription factor TCF-1 (16) was increased 
in WD-mIL15-CAR T cells whereas effector-associated transcription factors, T-BET and 
BLIMP-1 (16), were concurrently decreased in these cells (Fig. 26A).  Contrasting mIL15-
CAR T cells, WD-mIL15-CAR T cells showed significantly greater frequencies of the 
memory-associated surface markers IL-7Rα (P = 0.0454), CD27 (P = 0.0148), and CCR7 
(P = 0.0091) were observed (Fig. 26B,E).  This protein-level expression pattern of 
transcription factors and surface markers corresponds with the molecular profile established 
in section 4.3.4 (Fig. 25A,B).  WD-IL15-CAR T cell expression of IL-7Rα ranged 4% - 34%, 
CCR7 expression ranged 41% - 92%, and CD27 expression was greater than 99%.  
Although at a diminished expression level relative to mIL15-CAR T cells, CD62L+ cells were 
not absent but present at an average frequency of 18% (Fig. 26B,E).  WD-mIL15-CAR T 
cells re-expressed CD45RA to 76 ± 20%.  While the majority of cells were 
CD45RA+CD45RO+ a substantial population of CD45RA+CD45ROneg cells emerged within 
the culture (31 ± 17%, mean ± SD, P = 0.0233; Fig. 26C,E).  CD122 (IL-2Rβ) expression is 
highly expressed on memory cells but has decreased expression on less differentiated T 
cell subsets, such as in naïve or memory stem cells (17, 119, 169).  CD122 MFI on mIL15-
CAR T cells (30 ± 8, mean ± SD) significantly differed from that found on WD-mIL15-CAR T 
cells (15 ± 3, mean ± SD; P = 0.0040; Fig. 26D).    
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Figure 26.  WD-mIL15-CAR T cells possess phenotypic characteristics associated 
with less differentiated T cells.   Validation of select genes found to be differentially 
expressed and phenotypic characterization of persisting WD-mIL15-CAR T cells compared 
to mIL15-CAR T cells.  (A) Representative histograms of transcription factor expression for 
TCF-1, T-BET, and BLIMP-1.  (B) Representative histograms of surface expressed 
molecules associated with T cell differentiation status.  (C) Representative flow plots 
showing co-expression of CD45RA and CD45RO.  Gate frequencies are displayed in the 
top right corner of the plots.  (D) Representative histogram of CD122 expression.  (E)  
Frequencies of respective markers from (B) and (C) represented as interleaved box and 
whiskers bars with the horizontal bar denoting the median.  All data are representative of 
greater than five donors.  *P < 0.05, ** P < 0.01, *** P < 0.001, paired t test. 
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T cell subsets were assessed to further describe the changes in differentiation and 
memory potential.  With the observed high co-expression of CD45RA and CD45RO, T cell 
subsets were defined by CD45RO and CCR7 expression (18, 170, 171).  In increasing 
differentiation, the subsets are as follows: naïve or memory stem cell (TN or TSCM; 
CD45ROnegCCR7+), central memory (TCM; CD45RO+CCR7+), effector memory (TEM; 
CD45ROnegCCR7neg), and effector memory RA (TEMRA; CD45RO+CCR7neg).  Ex vivo 
expansion generates predominantly differentiated mIL15-CAR T cells with a 
CD45RO+CCR7- effector memory phenotype (P < 0.0001 for comparisons of within mIL15-
CAR T cell groups comparing memory subsets; Fig. 27A).  After antigen withdrawal, the 
memory composition shifted to favor CD45ROnegCCR7+ WD-mIL15-CAR T cells (P < 0.01) 
and a sharp decline in the previously dominating CD45ROnegCCR7neg subset was observed 
(P < 0.0001; Fig. 27A).  The altered composition of CD45RO-CCR7 subsets at the end of 
withdrawal was resultant of a significant increase in CD45ROnegCCR7+ cell number (up to 
eight-fold) with concomitant decreases in cell number of CD45RO+CCR7+ and 
CD45RO+CCR7neg subsets (P < 0.001, P < 0.001, and P < 0.0001, respectively).  
Surprisingly, CD45ROnegCCR7neg T cells persisted long-term, albeit without increasing in 
number (Fig. 27).  With the increase in CD45ROnegCCR7+ T cells, further examination was 
done to determine whether T cells in this subset were antigen-experienced as opposed to 
naïve.  Further gating on the CD45ROnegCCR7+ subset of WD-mIL15-CAR T cells 
confirmed CD45RA expression (95% ± 4, mean ± SD), which may be expressed by either 
TN or TSCM.  Assessing CD95 enabled differentiation between TN or TSCM subsets since TN 
do not express CD95 (52).  Additional staining showed that CD45ROnegCCR7+ T cells 
expressed CD95 similarly to the other antigen-experienced subsets (Fig. 27B).  Together 
these data suggest that subsets supported by mIL15 during antigen withdrawal represent 
the least and most differentiated T cell subsets.  
The net gain of this low differentiation subset corresponded with an acquired capacity 
for IL-2 production (P  < 0.0001), a hallmark feature of memory cells (18).  It was observed 
that merely 2-8% of mIL15-CAR produced IL-2 upon stimulation whereas 25-46% of WD-
mIL15-CAR T cells produced IL-2 (Fig. 28 A,B).  In sum, within the heterogeneous mix of 
WD-mIL15-CAR T cell subsets, T cells whose persistence was promoted or supported were 
CD45ROnegCCR7+ and CD45ROnegCCR7neg, respectively.  Despite describing a bulk 
population, a molecular and phenotypic profile emerged showing that within the persisting 
subsets some T cells possessed traits associated with an early state of differentiation.  The  
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Figure 27.  Long term in vitro populations of WD-mIL15-CAR T cells become enriched 
with CD45RA+CCR7+ and CD45RA+CCR7neg subsets.  (A) Memory subset (based on 
CD45RO and CCR7) composition (top panel) and cell number (bottom panel) of mIL15-
CAR T cells before and after withdrawal assay conditions.  Data are plotted as interleaved 
box and whiskers with the horizontal bar denoting the median.  Data is representative of 
greater than five donors.  ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns = not significant, n 
> 5, two-way ANOVA (Bonferroni’s post-test).  (B) Representative histogram of one of four 
donors showing CD95 expression on WD-mIL15-CAR T cells amongst the memory subsets 
from (A).  Histograms are gated on each of the corresponding subsets.  The vertical bar in 
the plot denotes a reference line based on isotype staining.                   
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Figure 28.  WD-mIL15-CAR T cells acquire the capability to produce IL-2.  (A) 
Representative histograms of IL-2 intracellular staining of expanded mIL15-CAR T cells and 
persisting WD-mIL15-CAR T cells after lymphocyte activation cocktail (LAC) or no 
stimulation.  (B) Frequency of LAC-stimulated T cells producing IL-2 from (A).  ****P < 
0.0001, n = 6, paired t test.   
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presence of such a phenotype for WD-mIL15-CAR T cells remaining after long-term antigen 
withdrawal strengthens its potential for clinical application.    
4.2.6  mIL15 Supports CCR7+ T Cell Subset Viability  
To determine whether the promotion of memory phenotype in our system was due 
specifically to mIL15, a 65-day withdrawal assay was conducted comparing WD-mIL15-
CAR T cells to WD-CAR T cells cultured with soluble IL-2 or IL-15 complex (Fig. 29A).  It 
was observed that CD45RA expression was elevated amongst the treatment groups (P > 
0.05; Fig. 27).  In contrast, CCR7 expression was 21% - 35% on WD-CAR T cells receiving 
IL-2, 17% - 31% on WD-CAR T cells receiving IL-15 complex, and 46% - 91% on WD-
mIL15-CAR T cells (Fig. 27C).  CCR7 expression was significantly enhanced in WD-mIL15-
CAR T cells relative to CAR T cells supplemented with IL-2 or soluble IL-15 complex (both 
P < 0.05).  Viability of CCR7neg and CCR7+ subsets was assessed by Annexin V staining.  It 
was found that irrespective of the type of cytokine stimulation (IL-2, IL-15 complex, or 
mIL15), CCR7neg T cells showed equal frequencies of live cells.  In contrast, CCR7+ T cells 
exposed to mIL15 had significantly higher viability than the CAR T cells receiving IL-2 or IL-
15 complex (both P < 0.05; Fig. 29D,E).  These data suggest that mIL15 is sufficient to 
support the CCR7+ phenotype which thus contributes to maintaining the less differentiated 
CD45ROnegCCR7+ T cell subset. 
4.2.7  mIL15-CAR T Cells Persisting In Vivo in the Absence of TAA Show the Emergence of 
an Early Differentiated CD45ROnegCCR7+ Memory Subset  
The mIL15-CAR T cells were, once again, tested in vivo to further investigate memory 
subset maintenance and to determine whether the in vitro observations could be 
recapitulated.  The mIL15-CAR T cells were adoptively transferred into NSG mice with no 
tumor or exogenous cytokine support and assessed after 50 days.  T-cell expression of 
CD45RO and CCR7 was observed in a tissue-specific manner.  T cells highly expressed 
CD45RO in the bone marrow, but CD45RO+ T cells were at low frequencies in peripheral 
blood and spleen (Fig. 30A).  Interestingly CCR7+ T cell frequency was inversely 
associated with CD45RO expression where higher expression was observed in the blood 
and spleen (Fig. 30A).  T cell differentiation, in the blood and spleen, recapitulated in vitro 
observations of the preferential persistence of CD45ROnegCCR7+ and CD45ROnegCCR7neg 
T cells (Fig. 30B).  Strikingly, the bone marrow contained the highest proportion of 
CD45RO+CCR7- T cells and nearly all of the T cells in the bone marrow were found to be  
78 
 
Figure 29.  Tethered IL-15 supports survival of CCR7+ CAR-modified T cells.  (A) 
Schematic summarizing the withdrawal experiment comparing IL-2, IL-15 complex, and 
mIL15 on CD45RA and CCR7 phenotype.  During the 65-day antigen withdrawal, the 
mIL15-CAR T cells received no exogenous cytokine supplementation while CAR T cell 
control treatments received either IL-2 (50 U/ml) or IL-15 complex (5 ng/ml).  T cells 
persisting at the end of the assay are referred to as WD-T cells.  (B) A representative 
histogram of CD45RA expression and (C) CCR7 expression on WD-T cells.  (D) 
Representative histograms showing Annexin V levels in CCR7neg and CCR7+ WD-T cell 
subsets.  Histograms were gated on the lymphocyte population to avoid non-specific CCR7 
staining.  (E) Graph plotting frequencies of live (Annexin Vneg) WD-T cell treatment cohorts 
in the CCR7neg and CCR7+ subsets.  Data are represented as mean ± SD.  *P < 0.05, ns = 
not significant, two-way ANOVA (Tukey’s post-test).  All data are representative of three 
donors.  Color legend: WD-CAR T cells supplemented with IL-2 (black), WD-CAR T cells 
supplemented with IL-15 complex (grey), and WD-mIL15-CAR T cells (magenta).  
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Figure 30.  Long-term in vivo persisting mIL15-CAR T cells are maintained at diverse 
levels of differentiation with different distribution patterns.  NSG mice were i.v. 
injected with 20 x 106 mIL15-CAR T cells.  After 50 days analysis of peripheral blood, 
spleen, and bone marrow was performed to assess differentiation of T cells persisting long-
term in the absence of CAR activation.  (A) Representative histograms of CD45RO (upper 
panel) and CCR7 (lower panel) expression on in vivo mIL15-CAR T cells.  (B) Memory 
subset composition of the in vivo T cells in reference to in vitro WD-mIL15-CAR T cells.  
Graphed data is represented as mean ± sem.  *P < 0.05, **P < 0.01, *** P < 0.001, two-way 
ANOVA (Tukey’s post-test).    
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the more differentiated subsets (P < 0.0001 for CD45RO+CCR7neg versus 
CD45ROnegCCR7+ or CD45RO+CCR7+; P < 0.001 for CD45ROnegCCR7neg versus 
CD45ROnegCCR7+ or  CD45RO+CCR7+;  Fig. 30B).  Similar to in vitro observations, T cells 
in the blood and organs expressed moderate levels of CAR and modest levels surface-
detected mIL15 (Fig. 31AB).  After ex vivo numeric expansion, T cells derived from the 
organs retained antigen-specific function by the production IFNγ in response to CD19+ 
targets (Fig. 31C).  Together these data suggest that while mIL15-CAR T cells can persist 
in vivo long-term as various memory subsets, they are also maintained as a substantial 
subset of early differentiated cells, which are thought to be a desirable population for ACT. 
 
4.3  Discussion 
There is sparse information on the maturation fate of cytokine-modified T cells.  It has 
not been elucidated whether such cells can behave in a physiologically relevant manner 
and modulate their activation to form or maintain memory; or, if they are merely dominated 
by extrinsic input that generates over-activated T cells in perpetual overdrive.  With IL-15’s 
well-known effects on the homeostatic maintenance of TCM, we expected that persisting 
mIL15-CAR T cells would be characterized primarily as TCM.  Contrary to our hypothesis, 
we did not observe a promotion of that subset.  Rather, and most surprisingly, we found the 
emergence of a low differentiation CD45ROnegCCR7+ subset with a memory-like molecular 
profile and phenotype rarely observed in CAR T cell studies.   
Transition from a higher to lower differentiation state of mIL15-CAR T cells after antigen 
withdrawal was observed on a molecular level (Fig.25) and corroborated by phenotypic 
assessment (Fig.26).  The modulation of key transcription factors associated with T cell 
differentiation state (i.e., TCF-1, LEF-1, T-bet, BLIMP-1, EOMES, and Bcl-6) supports the 
important involvement of intrinsic elements in directing mIL15-CAR T cell fate after antigen 
withdrawal.  That we did not observe intrinsic differences between CAR T cells and mIL15-
CAR T cells after ex vivo expansion is not entirely surprising.  In another study, T cells 
derived from TCM and TEM subsets both displayed a similar effector phenotype prior to 
infusion into primates, yet demonstrated differing in vivo fitness (50).  A plausible 
explanation for this observation likely involves the dominance of extrinsic factor signaling 
from CAR-triggering (mimicking TCR and CD28 signaling), costimulatory signaling (i.e. 
CD27 and CD28), and cytokine signaling (i.e., IL-21 and mIL15 or IL-2) that converge upon  
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Figure 31.  Long-term in vivo persisting mIL15-CAR T cells express CAR and remain 
responsive to TAA.  (A)  Representative histograms show expression of CAR and mIL15, 
with CAR detection using the CAR idiotype antibody (clone 136.20.1) and (B) plotted 
frequencies of marker expression from (A) represented as mean ± sem.  Plots and graphs 
(A,B) show T cell frequencies after gating on human CD3+ and mouse CD45- cells in the 
peripheral blood (n = 5), spleen (n = 9), and bone marrow (n = 9).   (C) Cells isolated from 
spleen, liver, or bone marrow were ex vivo expanded on aAPC to generate sufficient cell 
numbers for assessing intracellular IFNγ production in response to CD19- and CD19+ 
targets, n = 7 from three tissue sources and four mice.  Histograms were gated on CD3.   
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Figure 31.  Long-term in vivo persisting mIL15-CAR T cells express CAR and remain 
responsive to TAA  
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the PI3K/Akt pathway to modify the cell’s molecular profile.  In recent years, studies have 
unraveled that the PI3K/Akt pathway is central to integrating such signaling and acts as a 
rheostat in T cell differentiation (Fig. 2) (25, 27).  It has been shown that strong induction of 
Akt does not sustain CD8 T cell memory, but consequently induces terminal differentiation 
(26, 27, 172).  An additional consideration is the role of epigenetics in T cell memory.  It has 
been shown that knock-out mice of the methyltransferase Dnmt1 or methyl DNA binding 
protein MBD2 yielded reduced memory T cells and aberrant memory differentiation (173, 
174).  In T cells, epigenetic changes have been shown to act on cytokine gene loci in 
effector and memory subsets, and BLIMP-1 can regulate CD8 T cell memory via epigenetic 
modifications (175-177).  This additional level of regulation may offer explanation for our 
observations regarding the lack of phenotypic differences noted in ex vivo expanded T 
cells, and raises questions as to whether IL-15/mIL15 signaling may contribute to any 
epigenetic programming.   
The finding that Foxo1 did not increase in parallel with other related pro-memory 
transcription factors in WD-mIL15-CAR T cells was unanticipated (Fig. 24).  We found Il7ra, 
Ccr7, Eomes, Bach2, Bcl-6, and Tcf7 to be significantly up-regulated in WD-mIL15-CAR T 
cells, yet studies have described Foxo1 to directly or indirectly regulate these genes (127, 
163, 167, 168, 178, 179).  A possible explanation to account for this paradoxical 
observation involves Foxo3.  It was found that Foxo3 was significantly up-regulated in the 
WD-mIL15-CAR T cells.  The study of FOXOs in T cell memory has been largely assessed 
with FOXO1 while the role of FOXO3 in this context is not fully understood.  Both FOXO1 
and FOXO3 integrate into the PI3K/Akt axis of T cell memory regulation, as their activity is 
inhibited by Akt (178).  T cell-specific deletion of Foxo1 does not result in spontaneous T 
cell activation, but rather plays a role in regulating genes critical for naïve T cell 
homeostasis (168).  Results from Foxo3-deficient mice have been somewhat conflicting, 
but like Foxo1 they do not show lymphocytes with spontaneous activation (180).  However, 
it took conditional deletion of Foxo1, Foxo3, and Foxo4 in hematopoietic stem cells to 
induce aberrant cell cycle and apoptosis features (181).  These studies suggest that there 
may be some level of redundancy amongst the FOXOs.  The dominant Foxo3 transcription 
over Foxo1 in our system was associated with an increased proportion of the less 
differentiated CD45ROnegCCR7+ subset and is a novel observation.  This model may be 
useful in further examining the roles of FOXO1 and FOXO3 in mature T cells and their 
regulation in the maintenance of memory.  In this study, we observed modulation of 
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transcript levels of Foxo1 and Foxo3 that revealed intriguing results with much potential for 
elucidating the incompletely defined relationships of this family of transcription factors in 
mature T cell differentiation and homeostasis.  Present understanding of FOXO regulatory 
mechanisms and instituted gene expression programs indicate that the function of this 
family of transcription factors is largely in response to alterations in environmental 
conditions and cellular stress (ie., oxidative stress and AMP-activated protein kinase 
activity) (182).  Moreover, FOXOs are regulated by cytoplasmic shuttling and post-
translational modifications (PTMs), including phosphorylation, methylation, ubiquitylation, 
and acetylation (182).  Thus, future investigation into the context-dependent roles of 
FOXOs in T cells must assess cellular/environmental status along with the various PTMs of 
FOXOs in the different memory subsets of T cells.  Determining whether FOXO3 is involved 
in the generation or maintenance of the CD45ROnegCCR7+ subset would contribute to the 
limited knowledge of this recently identified subset and, in general, to FOXO3 mechanisms 
in mature T cell differentiation or homeostasis. 
We observed that mIL15-CAR T cells persist in a spectrum of memory states, including 
a substantial population exhibiting very low differentiation, delineated as CD45ROnegCCR7+ 
(Fig. 27).  This subset also expressed high levels of CD45RA, CD27, TCF-1, and modest 
frequency of cells also expressed IL-7Rα and CD62L.  A study with IL-15-secreting CAR T 
cells that evaluated the long-term in vivo phenotype of persisting T cells observed 
increased CD45RA expression and a small subset (~6%) of CD45RA+CCR7+ cells in the 
spleen (92).  Though our long-term engraftment was not nearly as high as in the reported 
study, we observed a 24% average frequency of the CD45ROnegCCR7+ subset in the 
spleen.  The caveat being that our T cell manufacture technique uses more rounds of aAPC 
stimulation, thus likely decreasing memory potential in the cells.  Additionally our in vivo 
model was TAA-free whereas the other study assessed T cells from mice that survived 
tumor challenge.  Contrasting our results, antigen-specific T cells modified to express 
constitutively activate STAT5, and assayed after 20 days in vivo, demonstrated an effector 
phenotype characterized by high levels of T-BET, effector molecule expression, and 
diminished IL-2 production (183).  Yet, other studies examining the mechanisms of STAT5 
have shown constitutive STAT5 to promote greater memory populations or supported both 
memory and effector T cells, which is more in line with our results (154, 184).  Polyclonal 
TCM-derived cells expressing chimeric cytokine receptors signaling through CD127 or 
CD122 cytoplasmic domains activated STAT5 and resulted in moderate to low expression 
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of memory associated molecules, respectively (120).  However, CD45RA/RO staining was 
not performed and thus memory subsets could not be defined.  These data collectively 
suggest that (i) providing only STAT5 activity may not necessarily recapitulate the signaling 
networks that promote a low differentiation state or (ii) the STAT5 activity level was 
inappropriate for early memory formation or maintenance.  Our data showed that mIL15-
CAR T cells are representative of several memory subsets and indicated that some of these 
cells received an appropriate level of mIL15 costimulation to maintain a low differentiation 
state. 
 Our TSCM-like population of WD-mIL15-CAR T cells could be described as 
CD45RA+CD45ROnegCCR7+CD122+CD95+ which was similar for the majority of markers to 
other studies  describing TSCM (52, 126) but for the expression level of CD62L and CD28, 
which was at a lower frequency in our CD45ROnegCCR7+ WD-mIL15-CAR T cells.  This 
may indicate that the CD62LnegCD28neg cells within the CD45ROnegCCR7+ T cell subset are 
further along in the differentiation spectrum than TSCM described by other groups (52, 126).  
The generation of CD45ROnegCCR7+ that are CD62LnegCD28neg has, to our knowledge, not 
been reported and the functional consequences of the lack of these markers in this putative 
low differentiation subset is unknown.  The down-modulation of CD28 may be due to IL-15 
costimulation in the mIL15-CAR T cells.  IL-15 has been shown to induce proliferation of 
memory CD8 T cells which resulted in a loss of CD28 in actively dividing T cells in vitro 
(164, 166).  While these CD28neg CD8 memory T cells showed no proliferative defects to IL-
15 (166), it was also found that IL-21 countered the IL-15-induced down-modulation of 
CD28 (185). Thus, the addition of IL-21, or a membrane-bound IL-21, could be considered 
should the preservation of CD28 expression be desired in the mIL15-CAR T cells.  CD62L 
down-modulation was observed in WD-mIL15-CAR T cells, but not to the same extent as 
CD28.  Unlike with CD28, it is unknown whether IL-15 may play a role in this modulation.  
This observed phenomenon may also be indicative of the complexity of memory T-cell 
phenotypes and while the CCR7+CD62Lneg memory T cell subset is not one of the 
archetypal memory subsets observed and discussed, this subset has been detected in mice 
after viral infection (186).        
Gattinoni et al. (2011) generated low differentiation TSCM (CD45RA+CD45ROnegCD62L+ 
CCR7+IL-7Rα+CD95+) from naïve T cells using a glycogen synthase kinase 3β (GSK-3β) 
inhibitor to activate the Wnt pathway (52).  In contrast, Cieri et al. (2013) generated similar 
TSCM, albeit CD45RO+, using IL-7 and IL-15 (126).   Our TSCM-like population of WD-mIL15-
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CAR T cells (CD45RA+CD45ROnegCCR7+CD122+CD95+) only had access to IL-15-induced 
signaling from mIL15.  Cieri et al. (2013) reported that IL-15 alone could generate a small 
population of TSCM, but far superior numbers were generated when IL-7 was used in 
combination with IL-15 (126).  This, however, does support our observation of the 
promotion of a low differentiation subset solely with IL-15-mediated signaling.  Additionally, 
the inclusion of IL-7-mediated signaling in some manner (i.e., membrane-bound IL-7 
expressed on T cells) is a valid consideration for us to augment the development or 
maintenance of this desirable population in our mIL15-CAR T cell cultures and potentially in 
vivo.  We also noted the up-regulated expression of genes related to the Wnt-signaling 
pathway (Tcf 7, Lef1, and Axin2; Fig. 24), which are reported to be regulated by Akt (187).  
Moreover, since Axin2 is a direct target of the Wnt pathway through TCF-1 and LEF-1 
activity, its up-regulated status suggests that Wnt signaling is active in WD-mIL15-CAR T 
cells.  Akt signal strength is involved with regulating the Wnt pathway where weaker 
signaling sustains a memory phenotype (26).  FOXOs have been shown to interact with β-
catenin and could therefore be a contributor to modulating T cell differentiation (188), but 
this still needs to be further investigated.  There is still much to unravel with the cross-talk 
between the PI3K/Akt and Wnt/β-catenin pathways.  Delving into how Wnt signaling may be 
active in some populations of mIL15-CAR T cells when they receive only IL-15-based 
signaling instead of exogenous Wnt pathway agonists may help to elucidate this 
connection.  Moreover, the observation of putative Wnt pathway activation in our system 
indirectly suggests that signaling induced by mIL15 only weakly signals the PI3K/Akt 
pathway so as to not inhibit the Wnt pathway.  Further validation of this observation would 
contribute to knowledge on how the PI3K/Akt node acts as a rheostat to modulate T cell 
differentiation.  In order to be better able to modulate CAR T cell phenotype and in vivo 
fitness, valuable information may be gained by further unravelling the specific pathway 
stimulation that is achieved in the TSCM-like mIL15-CAR T cells.        
Our data showed the presence of the CD45ROnegCCR7+ population in the peripheral 
blood and spleen of NSG mice at 50 days after adoptive transfer (Fig. 30).  In contrast, 
Gattinoni et al. (2011) adoptively transferred polyclonal TSCM (generated by GSK-
3β inhibition) with CD8-depleted PBMC (for human cytokines and costimulation) into NSG 
mice.  At four weeks after transfer, cells that were found in the spleen uniformly showed an 
effector phenotype (52).  This is in contrast to Cieri et al. (2013) where polyclonal TSCM 
adoptively transferred into a GVHD model maintained high CD62L and low IL-7Ra 
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expression, but CD45RAneg, on T cells in the peripheral blood at two weeks in primary 
recipients and one week in secondary recipients (126).  It is an interesting observation that 
TSCM generated via cytokine signaling persisted in vivo with a less differentiated phenotype 
than TSCM produced by pharmacological methods.  The mIL15-CAR T cells continued to 
receive cytokine costimulation, thus it was anticipated that they retain some memory 
potential in the absence of TAA.  But, the TSCM having received IL-7 and IL-15 in vitro 
appeared to carry with them some lasting effects that limited differentiation in comparison to 
TSCM given GSK-3β inhibition.  Determining the mechanism for this disparity (i.e., 
epigenetics and post-translational modifications) could have clinical implications as 
pharmacological methods of modulating T cell differentiation have been proposed for use in 
the clinic, but other more robust approaches may be found.  Moreover, if epigenetics or 
some other post-translational regulatory mechanism is at play with IL-7 and IL-15 signaling, 
understanding if such processes operate in mIL15-CAR T cells could assist in identifying 
methods to further manipulate CAR T cell differentiation state.            
Homeostatic proliferation, IL-7, and IL-15 have been shown to be integral in generating 
CD45RA+CCR7+ early memory populations (126, 189).  We uniquely showed that in vitro 
mIL15, and not soluble IL-2 or IL-15, played a role in preserving the CCR7+ subset.  It has 
been demonstrated that differential signaling is induced between soluble IL-15 and 
transpresented IL-15 (71), and thus it may plausible that the particular surface expression 
level and specific signaling induced by the membrane-bound or transpresented nature of 
mIL15 could be providing appropriate costimulatory signaling in CCR7+ subsets.  Or, it may 
be a phenomenon of mIL15 providing just the ‘right’ amount of signaling.  Moreover, it is 
likely that the soluble cytokines present in vitro are at supra-physiologic levels that induced 
strong pathway activation, which is known to result in T cell differentiation (27).  
This study assessed the bulk characteristics of cells and thus could not make 
conclusions regarding lineage relationships between T cell subsets.  Studies reporting on 
the generation of TSCM have indicated their results to be consistent with a linear 
differentiation model (17, 52, 126).  In contrast, it has been reported that CD45RA+CCR7+ 
cells emerged from TCM after culture with IL-7 and IL-15 in the absence of antigenic 
stimulation (189).  In our withdrawal assay, we observed a decline in CD45RO+CCR7+ T 
cell numbers with a concomitant increase of the CD45ROnegCCR7+ subset.  This may be 
due to cell death in the CD45RO+CCR7+ subset with proliferation in CD45ROnegCCR7+ 
subset.  However, that seems like an unlikely outcome considering the numerous studies 
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reporting that IL-15 is critical to supporting TCM (134, 190).  Alternatively, observations by 
Geginat et al. (2003) showed a proportion of sorted TCM de-differentiated to a 
CD45ROnegCCR7+ in the presence of IL-7 and IL-15 in the absence of antigen (189).  
Sorting the subpopulations prior to antigen withdrawal may identify which process is at work 
in our model and contribute to knowledge on the model of T cell differentiation.  Moreover, 
identification of the source subset(s) for TSCM could then fold into methods for developing 
clinically relevant methods to augment TSCM in the infusion product for CAR T cell therapies.  
Sorting these subsets and individually testing their antitumor potency with in vivo models 
would contribute knowledge to more clearly identify which T cell subset would possesses 
the greatest therapeutic potential. 
The characterization of mIL15-CAR T cells in this thesis was performed in the absence 
of TAA.  From this we have determined the memory potential of these cells and assembled 
a profile of the intrinsic factors involved, which had been undefined for long-term persisting 
CAR T cells.  Future directions, though, should next assess mIL15-CAR T cells after tumor 
challenge to determine how the T cell memory profile has changed and how their in vivo 
fitness changes subsequent to tumor challenge.  Much investigation has been conducted 
on T cell differentiation during infection, but is much less studied in the context of tumor 
challenge.  As discussed in Chapter 3, mIL15 may have more optimal function with other 
CAR configurations.  Assessing how the different CAR configurations alter the mIL15-CAR 
T cell molecular profile in response to tumor challenge may provide much needed 
information on optimizing CAR T cell therapy for different tumors or tumor 
microenvironments (i.e., lack of CD80/86, tumor burden level, lack of CD4 help, and 
immunosuppression by TREGs and TGF-β).  
Nonetheless, while mechanisms for the generation of such early differentiated cells 
remain to be fully elucidated, we showed that these subsets were promoted in our system 
via costimulation from mIL15.  While more differentiated subsets of WD-mIL15-CAR T cells 
were found to persist long-term, their in vivo functional capacity is anticipated to be poor 
(22).  The preserved memory potential that we observed in our system is an important 
factor as it has been demonstrated by numerous studies that the greatest therapeutic 
potential is mediated by the least differentiated T cell subsets (52, 126).  While it is currently 
not feasible to treat patients with naturally occurring TSCM, due to their low circulating 
frequency, identification of strategies to generate clinically relevant numbers of genetically 
modified TSCM would greatly contribute to the advancement of CAR T cell-based therapies.  
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The results presented herein showed that, in our system, mIL15 promoted a TSCM-like 
population of CAR-modified T cells, and thus bolsters the rationale for using mIL15 in 
further developing clinically-compliant strategies to augment this desirable T cell subset in 
immunotherapy infusion products.         
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CHAPTER 5 
General Discussion and Future Directions 
 
5.1  Dissertation Summary 
Adoptive transfer of CAR T cells have demonstrated great potential in treating various 
leukemias, however persistence of infused T cells remains an impediment to advancing 
therapeutic outcome (43, 63, 77, 78) in the general field as well as with our focus on 
treating low TAA in MRD.  The primary aim of this dissertation was therefore to develop and 
test a novel cellular immunotherapy approach to resolve this standing clinical issue.  Our 
strategy to address this deficit utilized the pleiotropic effects of IL-15 (85, 86, 191): (i) to 
support initial survival of infused T cells that are a heterogeneous mixture of differentiation 
states and (ii) for the long-term maintenance of subsets that remain responsive to IL-15, 
which are typically less-differentiated and long-lived T cells.   
We generated mIL15 to keep the cytokine targeted to responding CAR T cells and to 
mimic the transpresentation mechanism by which IL-15 functions in vivo.  Using clinically 
compliant methods, we demonstrated the generation of mIL15-CAR T cells qualitatively 
suitable for adoptive transfer.  The mIL15-CAR T cells showed enhanced STAT5 
costimulation relative to cytokine unsupplemented CAR T cells.  Moreover, it was 
demonstrated that mIL15 could mimic transpresentation and induce STAT5 signaling on 
CAR T cells that did not express mIL15.   
In immunocompromised NSG mice bearing a disseminated CD19+ leukemia, the 
mIL15-CAR T cells demonstrated both persistence and an antitumor effect, whereas the 
CAR T cell counterpart could not maintain significant persistence despite the presence of 
TAA.  In a preventative model where CAR and mIL15-CAR T cells were engrafted first 
followed by the introduction of a disseminated CD19+ leukemia, only the mIL15-CAR T cells 
were found to persist, eradicate tumor cells, and extend survival.  It was also shown that 
mIL15-CAR T cells were capable of persisting independently of TAA.   
It is uncharted territory as to the differentiation status of persisting cytokine-modified 
CAR T cells.  It is unknown what role intrinsic factors may play in supporting these surviving 
T cells.  Since IL-15 was selected, in part, for its critical role in supporting long-lived 
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memory CD8 T cell subsets, it was hypothesized that TCM subsets would persist 
preferentially.  Characterization of the mIL15-CAR T cells that persisted long-term was in 
the absence of TAA.  In vitro assays showed that surviving WD-mIL15-CAR T cells 
maintained pSTAT5 activity and Bcl-2 levels whereas control CAR T cells showed 
diminished levels of these molecules indicating that mIL15 was still functional.  Comparing 
the long-term persisting WD-mIL15-CAR T cells to the earlier ex vivo expanded mIL15-CAR 
T cells, it was noted that WD-mIL15-CAR T cells significantly expressed genes associated 
with a less differentiated state.  This was validated by flow cytometry for specific memory 
and differentiation-related transcription factors and cell-surface markers.  Moreover, WD-
mIL15-CAR T cells acquired the capability to produce IL-2, a hallmark of less differentiated 
memory cells.  Assessing the subset composition, it was revealed that WD-mIL15-CAR T 
cells persisted preferentially as the least differentiated (CD45ROnegCCR7+) and most 
differentiated (CD45RO+CCR7neg) subsets.  The CD45ROnegCCR7+ subset would 
classically be known as TN.  However WD-mIL15-CAR T cells in that subset were found to 
be CD95+ and CD122+, both markers associated with antigen-experienced T cells and TSCM.  
Therefore, the molecular profile and phenotypic assessment of the bulk population 
suggested that some cells within make up a TSCM-like subset that is less differentiated than 
TCM.  This in vitro WD-mIL15-CAR T cell subset composition was recapitulated in vivo, but 
was tissue-dependent.  It was found that WD-mIL15-CAR T cells persisting in the bone 
marrow took on a more activated phenotype of CD45RO+CCR7neg whilst the peripheral 
blood and spleen contained the highest frequencies of the CD45ROnegCCR7+ subset.  This 
capacity to sustain a less differentiated memory potential in vivo further reinforces their 
suitability for use in the clinic.  This also brings to light the importance of determining the 
mechanism of generation and maintenance of such T cell subsets as this knowledge could 
ultimately be harnessed for the generation of optimal T cell subsets for ACT.  The results in 
this dissertation provide pre-clinical data that can now be translated into a clinical trial to 
evaluate mIL15-CAR T cell persistence and disease-free survival of post-HSCT patients 
with MRD. 
 
5.2  Treating MRD: A Focus on Forming Durable Immunologic Memory 
 At the genesis of this project, the primary aim was to achieve CAR T cell persistence 
under low TAA so that it may translate to the clinic for treating patients with MRD or 
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sequestered TAA.  We achieved this with the mIL15-CAR T cells (Figs. 15,19).  A 
treatment approach was developed for a subset of patients that needed improved treatment 
options.  However, with results from clinical trials and observations from this study, we 
propose that treating MRD may be a more desirable approach over treating bulky disease 
for several reasons.   
First, it may make T cell therapy safer.  Clinical trials treating bulky disease, while 
achieving some remarkable results with complete remissions, have also had severe 
treatment related toxicities, including tumor lysis syndrome and cytokine storms (77, 145, 
192).  Such toxicities can be correlated to the level of tumor burden at time of infusion (78).  
Hence, treating MRD would be anticipated to have a lower magnitude of toxicities.   
Second, lower tumor burden may allow for the establishment of immunologic memory 
and durable CAR T cell immunosurveillance for extended protection against relapse.  In the 
successful study by Kalos et al., T cells were detected persisting in patients after high tumor 
burden was eradicated (77).  And while CD8 CARneg T cells displayed some markers 
associated with memory, CD8 CAR+ T cells did not express any of these markers other 
than low levels of CD27.  In general, the CAR+ T cells displayed a highly differentiated 
TEMRA phenotype (145).  It is well accepted that repetitive antigen exposure and exposure to 
strong stimuli, (i.e., strong TCR stimulation and inflammatory cytokines) leads to 
progressive differentiation and loss of function (21, 22, 25, 193).  Therefore, the low-TAA 
environment associated with MRD may foster a more pro-memory environment, in the 
sense of a lower magnitude of antigenic stimulation, less repetitive stimulation, and the 
generation of lower levels of inflammatory cytokines.  With mIL15-CAR T cells able to 
persist under low TAA, there is potential for CAR T cells to reside as memory cells after 
tumor is cleared and to maintain immunosurveillance for durable protection against relapse. 
 
5.3  Application to Other CARs and Cell Therapies 
 The use of mIL15 is, by no means, limited to the CD19-specific CAR.  Moving mIL15 
into therapies treating solid tumors could provide assistance not only with persistence, but 
also against tumor microenvironment suppressive factors, for which solid tumors are 
notorious (194).  IL-15 has been shown to counter the immunosuppressive effects of 
transforming growth factor-β (195, 196), as well as regulatory T cells (197, 198). Hence, 
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mIL15 could be paired with most any other CAR targeting solid tumors, however the most 
logical target to move to first may be melanoma.  IL-15 has recently entered into the clinic 
and its first implementation was in the treatment of melanoma, either as a monotherapy 
(NCT01946789) or infused with autologous lymphocytes (NCT01369888).  Murine models 
with B16 revealed superior antitumor effect with the use of a soluble IL-15/IL-15Rα sushi 
domain fusion protein (RLI) (199) or antibody fusion protein (98).  A CAR targeting 
melanoma is toward the MAGE1 antigen (200).  Preclinical data using RLI (a soluble IL-
15/IL-15Rα hyperagonist) also showed significantly enhanced antitumor activity against 
colorectal cancer (199) and a targeted form specific for GD2 (201), which is found on 
neuroblastoma.  CARs targeting these tumors are in clinical trials (36) and could thus be 
readily translated to trials including mIL15.  The utility of mIL15 is diverse, but these solid 
tumor targets are suggested to be the most promising. 
 
5.4  Combination Therapies 
5.4.1. Combining mIL15-CAR T Cells and Small Molecule Inhibitors 
 Cancer cells may overexpress anti-apoptotic proteins such as Bcl-2 or possess 
persistently activated pathways (i.e., STAT5 and STAT3) that result in aberrantly high 
resistance to natural apoptotic mediators or pharmacologic agents.  Combining the 
approaches of drugs and immunotherapy to utilize more than one apoptotic pathway could 
increase tumor cell death and decrease therapeutic resistance.  The use of small molecule 
inhibitors may shift the balance enough between the pro- and anti-apoptotic molecules 
within tumor cells to sensitize them toward death or decrease resistance to killing during 
encounter with tumor-specific T cells.   
 Elevated Bcl-2 expression has been found in hematologic malignancies [i.e., acute 
myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL)] and solid tumors 
(i.e., melanoma, breast and ovarian cancer) (202-206).  Persistently activated STAT3 or 
STAT5 has been observed in AML, CLL, chronic myelogenous leukemia, large granular 
lymphocytic leukemia, and leukemia cell lines (207-210).  Small molecule inhibitors 
targeting Bcl-2, STAT3, or STAT5 have shown efficacy in inducing apoptosis (207, 208, 
211, 212).  Moreover, the addition of a Bcl-2 inhibitor to CAR T cells in co-culture with 
lymphoma and leukemia cells enhanced T cell-induced apoptosis (213).  However, the 
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inhibitor also caused T cells to undergo some level of apoptosis, which may pose a problem 
for clinical application.   
 In our study, we showed that pSTAT5 and Bcl-2 levels were sustained by mIL15-CAR 
T cells (Fig. 23).  This would suggest that mIL15-CAR T cells may have some level of 
resistance to the apoptotic-inducing effects of these small molecule inhibitors of this 
pathway, and indeed they may.  The mIL15-CAR T cells were able to resist pSTAT5 
abrogation by a STAT5 inhibitor that CAR T cells could not (L. Hurton, unpublished 
observation).  Thus, this may be a viable complementary approach that could be used to 
boost antitumor activity by mIL15-CAR T cells.       
5.4.2. Combining Cell Therapies 
Single agent treatment of cancer is not always successful in the long run.  The cancer 
cells find a way to evade complete eradication and the patients relapse in time.  A 
multipronged approach should be implemented, thus increasing therapeutic potential.  
Physiologically, T cells and NK cells function coordinately in an orchestrated immune 
response to eliminate the pathogen.  NK cell therapies are entering into the clinic for 
various malignancies.  Moreover, they can be reliably and significantly expanded ex vivo to 
obtain sufficient numbers for adoptive transfer (214).  Combining CAR T cells with NK cells 
in adoptive immunotherapy may be advantageous to diversify the antitumor response.  
Rather than targeting a single antigen, the innate activities of the NK cells may allow for 
epitope spreading leading to a more well-rounded response that could plausibly decrease 
the risk of tumor antigen escape (215).  Another aspect of the combination therapy could be 
NK-promoting effects from the T-cell transpresented mIL15.  Though a recent study 
suggested that the homeostasis of human NK cells in not dependent on IL-15 (216), other 
work on human NK cells indicates otherwise.  Huntington et al. demonstrated that IL-15/IL-
15Rα complexes, but not monomeric IL-15, induced extensive human NK cell proliferation 
(217).  In a clinical trial, it was reported that after multiple doses of IL-15, NK cells were 
found to increase 4 to 10 fold (218).  Moreover, we observed massive expansions of NK 
cells in cultures that only had mIL15 cytokine availability (Fig. 8).  Moreover, we 
demonstrated that mIL15 can be transpresented and induce cytokine signaling in another 
cell (Fig. 10).  Together, this would suggest that a combination therapy using ex vivo NK 
cells and mIL15-CAR T cells may mediate superior antitumor effects. 
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5.5  Clinical Safety  
In humans, dysregulated IL-15 production, elevated serum levels, or abnormal IL-15 
signaling is associated with autoimmune diseases and may be involved in the pathogenesis 
of T-cell LGL leukemia (219, 220).  Moreover, transgenic mice engineered to maximally 
overexpress IL-15 develop leukemia (221).  It has also been reported that one IL-15-
transduced T cell culture resulted in a clonal expansion, though the etiology was not 
definitively identified (222).  In contrast, constitutive STAT5 expression in lymphocytes did 
not prompt transformational events (135, 154).  Similarly, our study demonstrated 
enhanced engraftment of T cells without any overt dysregulated proliferation or activation in 
vitro or in vivo.  The molecular profiling by NanoString showed the down-regulation of 
activation genes (i.e., IL-2Rα and CD38; Fig. 24) and we did not observe any 
splenomegaly in mIL15-CAR treated mice in the preventative or TAA-free mouse models 
(L. Hurton, unpublished observations).  Despite the promising therapeutic potential of 
mIL15-CAR T cells, concerns about the long-term safety of T cells receiving chronic IL-15 
signaling are justified and must be addressed for clinical implementation.  A clinically used 
approach to conditionally ablate genetically-modified T cell is by additional co-modification 
of the cells with an inducible caspase-9 suicide gene.  Exposure to a dimerizer drug 
effectively induces apoptosis in the modified T cells (93, 223).   
 
5.6  Clinical Implications 
Clinical trials will now be addressing the targeting of minimal burdens of CD19+ 
malignancy as patients are enrolled earlier in their disease course and receive concomitant 
chemotherapy.  The intended goal of mIL15 was to enhance T-cell costimulation in situ to 
support T-cell persistence independently of CAR activation, to sustain antitumor activity in a 
low TAA environment, and preserve T cell memory potential.  We have demonstrated that 
mIL15-CAR T cells can stand up to the challenge of a TAA-poor environment.  Their use in 
the clinic should not require the use of exogenous IL-2, thereby improving the safety profile 
in that regard.  In comparison to trials using CAR T cells to treat bulky disease, it is 
anticipated that there will be fewer events of tumor lysis syndrome and cytokine storm since 
mIL15-CAR T cells will be infused under low bio-burden conditions.  Finally, mIL15-CAR T 
cells were specifically generated to possess enhanced persistence after adoptive transfer.  
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This should translate into establishing durable immunologic memory that would enable 
extended immunosurveillance resulting in improved disease-free survival of MRD patients.  
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CHAPTER 6 
Materials and Methods 
 
6.1  Plasmids 
6.1.1  mIL15 (IL-15/IL15-Rα fusion) Transposon 
 The mIL15 construct fuses the IL-15 cDNA sequence (NM_000585.4) to the full-length 
IL-15Ra (NM_002189.3) with a glycine-serine linker (SG3SG4SG4SG4SG3 
SLQ) and has a C-terminal FLAG (x3) epitope tag (DYKDDDDK).  In line with these reports, 
the signal peptides for IL-15 and IL-15Rα were omitted and the IgE signal peptide 
(gb|AAB59424.1) was used for the mIL15 fusion protein. This construct will produce an IL-
15 that is membrane-bound, but also presented in the context of IL-15Rα.  Mortier et al. 
created a similar IL-15 fusion protein, albeit in a secretable configuration, and demonstrated 
that this fusion protein with a covalent linker was functional.  Moreover, this construction 
had increased potency over non-covalently linked IL-15 and soluble IL-15Rα (103).  The 
mIL15 DNA sequence was codon-optimized for expression in human cells and the DNA 
plasmid, IL15-IL15Ra-FLAG_pMK-RQ, was synthesized by GeneArt (Regensburg, 
Germany).   IL15-IL15Ra-FLAG_pMK-RQ and GlySer-EGFP-mIgG1/pSBSO underwent 
digestion with Nhe and Xho restriction enzymes to obtain the mIL15 insert and pSBSO 
vector backbone respectively.  The resulting fragments were excised and gel purified 
(AIAquick Gel Extraction Kit, Quagen) and subsequently ligated using T4 DNA ligase 
(Promega) yielding IL15-IL15Rα-Flag/pSBSO.  Transformation of C2925 bacteria 
(Invitrogen) with the plasmid and selecting clones for amplification, both under kanamycin 
drug selection, was followed by large-scale amplification plasmid DNA.  The DNA was 
purified with EndoFree Plasmid Maxi Kit (Quiagen).  Prior to use in cell transfection, the 
plasmid was validated by analytical digestion and had a spectrophotometer A260/A280 value 
of 1.80 – 2.00. 
6.1.2  CD19-specific CAR Transposons 
Generation of the SB transposon encoding the second generation CD19-specific CAR 
(CD19RCD28/pSBSO) under the human elongation factor-1α promoter has been 
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previously described (224).  A CD19-specific CAR co-expressing an enhanced ffLuc, 
designated CAR-ffLuc, (CD19RCD28-T2A-Flag-ffLuc/pT2SBSO) was used for in vivo 
monitoring of T cells by BLI.  Generation of the plasmid (produced by S. Olivares) is as 
follows.  Sleeping beauty plasmid CD19RCD28mz-T2A-Flag-FFluc (CoOp)/pT2SBSO, co-
expressing the human codon optimized CD19-specific CAR and the luciferase reporter 
gene from firefly (Photinus pyralis) via a self-cleaving 2A peptide from Thosea asigna virus, 
was derived from the CD19RCD28mz-T2A-hΔTK (CoOp)/pΔSBSO plasmid.  The sleeping 
beauty inverted-direct repeats (IRs/DRs) T1 were replaced with the hyperactive IRs-DRs 
T2, to improve transposition, and the firefly luciferase reporter gene replaced the hΔTK 
transgene.  In the first step, plasmids CD19RCD28mz-T2A-hΔTK (CoOp)/pΔSBSO and 
CD19RCD28mZ (CoOp)/pT2SBSO were digested with StuI-KpnI and ClaI-KpnI restriction 
enzymes, respectively, with an extra blunting reaction after the ClaI digestion in order to 
create compatible blunted ends. The resulting fragments were purified by gel 
electrophoresis and ligated using T4 DNA ligase to create intermediate plasmid-I, 
CD19RCD28mz-T2A-hΔTK (CoOp)/pT2SBSO.  The second step consisted of replacing the 
T2A-hΔTK transgene with a T2A-flag tag fusion and a more suitable multiple cloning site to 
facilitate the cloning of the reporter gene.  This T2A-flag-MCS was created by polymerase 
chain reaction (PCR) primer annealing and TOPO-TA cloning for validation of the 
sequence.  Once the sequence was validated, plasmids CD19RCD28mz-T2A-hΔTK 
(CoOp)/pT2SBSO and T2A-Flag-MCS/TOPO were digested with BspE1 and SpeI 
restriction enzymes.  The resulting fragments were purified by gel electrophoresis and 
ligated using T4 DNA ligase to create intermediate plasmid-II, CD19RCD28mz-T2A-Flag 
(CoOp)/pT2SBSO.  The final step in the process was to introduce the firefly luciferase 
transgene in-frame with the flag-tag.  The firefly luciferase gene was digested out from the 
previously made plasmid Flag-FFLuc-HyTK (CoOp)/pT2SBSO using SnaBI and EcoRV 
restriction enzymes.  The same restriction enzymes were used to digest the accepting 
vector followed by a dephosphorylation reaction to prevent vector self-ligation due to the 
resulting compatible blunt ends.  The resulting fragments were purified by gel 
electrophoresis and ligated using T4 DNA ligase to create the final plasmid, 
CD19RCD28mz-T2A-Flag-FFluc (CoOp)/pT2SBSO.   
6.1.3  SB11 Transposase 
The hyperactive transposase (SB11) is under the control of a cytomegalovirus (CMV) 
promoter in the pKan-CMV-SB11 SB transposase as previously described (224). 
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6.1.4  Truncated CD19 Transposon 
A truncated CD19 plasmid (dCD19-F2A-Neo/pSBSO) was constructed by cloning the 
extracellular and transmembrane domains of codon-optimized human CD19 (Accession: 
M84371) from a GeneArt generated vector into a pSBSO plasmid linking with neomycin 
resistance via a F2A self-cleavable peptide sequence (performed by S. Olivares). 
6.1.5  rLuc-mKate Reporter  
The rLuc-mKate reporter (rLuc8.6-535-T2A-mKateS158A/pLV430G) is a lentiviral 
vector used for modifying tumor cell lines used for imaging tumor burden during in vivo 
experiments.  The sequences for rLuc8.6-535 and mKateS158A were derived previous 
descriptions (225, 226), codon optimized as previously reported (227) and synthesized by 
GeneArt (Regensburg, Germany) as a B1 rLuc8.6-535-T2A-mKateS158A B2 construct.  
The B1 and B2 sites are lambda phage recombination sites used in Gateway 
Recombination Cloning Technology (Invitrogen) synthesizing the construct via BP reaction 
into pDONR221. Subsequently, rLuc8.6-535-T2A-mKateS158A/ pDONR221 was 
recombined into pLV430G (228), a self-inactivating lentivirus encoding an internal U3 
promoter from murine stem cell virus (Performed by B. Rabinovich).  Lentiviral particles 
were packaged by transfecting 293METR cells with rLuc8.6-535-T2A-
mKateS158A/pLV430G using Lipofectamine 2000 (Invitrogen).  Virus was harvested 48 
hours post-transfection and concentrated using 100kDa NMWL filters (Millipore) to yield the 
final viral particle supernatant used for transductions (performed by J. Krishnamurthy). 
 
6.2  Cell Lines and Their Propagation 
All cell lines in this study were maintained in complete media [RPMI 1640, 10% heat-
inactivated fetal bovine serum (Hyclone), and 1% Glutamax-100 (Gibco)] in humidified 
conditions at 5% CO2 and 37˚C. 
6.2.1  K562-derived aAPC (Clone 9) 
K562-derived aAPC (Clone 9) were acquired from the University of Pennsylvania 
courtesy of Dr. Carl June and were generated by retroviral transduction with CD64, CD86, 
CD137L, and truncated CD19 as described previously (106).  Validation of co-expression of 
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antigen and co-stimulatory molecules (CD19, CD86, and CD137L) were performed before 
addition to T-cell cultures. 
6.2.2  NALM-6 and rLuc+mKate+NALM-6 
NALM-6, a pre-B cell leukemia, was obtained from American Type Culture Collection 
(Manassas, VA).  Generation of the rLuc+mKate+NALM-6 cells underwent lentiviral 
transduction with viral particles encoding rLuc and mKate (from vector rLuc8.6-535-T2A-
mKateS158A/pLV430G) by plating NALM-6 cells with the viral particles and polybrene 
(Millipore) followed by centrifuging plates at 2000rpm for 1.5 hours.  After outgrowth of 
transduced cells, mKate+ cells were subsequently FACS Aria (BD Biosciences) sorted 
(performed by J. Krishnamurthy).     
6.2.3  EL4 and dCD19+EL4 
The EL4 cell line, a murine T-lymphoma, was acquired from ATCC.  The dCD19+EL4 
cells were generated by electro-transferring the dCD19 and SB11 plasmids into EL4 using 
the Amaxa mouse T cell nucleofector kit (cat.no. VPA-1006; Lonza, Basel, Switzerland) 
with subsequent selection under 0.8mg/ml G418 (InvivoGen, San Diego, CA) in culture 
media (performed by T. Mi). 
 
6.3  Generation and Ex Vivo Expansion of mIL15 and CAR-modified T Cells 
Anonymized normal human donor blood bank buffy coats were obtained from the Gulf 
Coast Regional Blood Center (Houston, TX) and mononuclear cells were isolated by Ficoll-
Paque density gradient centrifugation (GE Healthcare) followed by cryopreservation.  The 
mIL15+/-CAR+ T cells were generated and propagated based on modified standard 
operating protocols used to generate clinical-grade CD19-specific T cells using the 
Sleeping Beauty system (105, 229) and depicted in Figure 2.  Cryopreserved PBMC were 
thawed the day of electroporation (day 0) and rested for 2-3 hours in complete RPMI media.  
Viable cells were enumerated based on Trypan blue exclusion using a Cellometer 
automated cell counter (Auto T4 Cell Counter, Nexcelom Bioscience) with the 
‘PBMC_human_frozen’ program.  A total of 2 x 107 live PBMC were resuspended with 
selected DNA plasmids in 100µl of human T cell nucleofector solution (Human T cell Kit, 
Lonza) were used per electroporation reaction.  Electroporation reactions for CAR-
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modification of cells contained 15µg of CAR transposon (CD19RCD28/pSBSO) and 5 µg of 
SB11 transposase (pKan-CMV-SB11) DNA.  Electroporation reactions for mIL15 and CAR 
co-modification of cells contained 7.5µg of mIL15 transposon (IL15-IL15Rα-Flag/pSBSO), 
7.5µg of CAR transposon (CD19RCD28/pSBSO), and 5 µg of SB11 transposase (pKan-
CMV-SB11) DNA.  PBMC that were modified for in vivo experiments instead used the CAR-
ffLuc (CD19RCD28-T2A-Flag-ffLuc/pT2SBSO) transposon in the same quantities that were 
used for the CAR transposon.  Each complete reaction was transferred to a single cuvette 
and electroporated with program U-14 using Nucleofector II (Lonza).  Transfected cells 
were transferred to a 6-well plate containing phenol-free RPMI supplemented with 20% 
FBS and 1x Glutamax-100.  After resting the cells for 2-3 hours a half media change was 
performed with fresh phenol-free media supplemented with 1x Glutamax-100 to achieve a 
final supplementation of 10% FBS, in which the cells were cultured overnight.  On day 1, 
electroporated cells were phenotyped and stimulated with γ-irradiated (100Gy) K562 (Clone 
9) aAPC based on their CAR expression with additional aAPC stimulations every 10 ± 2 
days.  Co-cultures used a ratio of 1:2 CAR+ T cells to aAPC and were maintained in 
complete media.  Co-cultures were supplemented with only human IL-21 (30ng/ml, 
PeproTech) during the first week (given 3 times), after which mIL15-CAR T cell cultures 
continued to receive only IL-21 while CAR T cells received IL-21 and either human IL-2 
(50U/ml, Aldeleukin; Novartis, Switzerland) or  a soluble IL-15/IL15-Ra-Fc complex (5ng/ml) 
3 times per week.  The IL-15/IL15-Rα-Fc complex, referred to as IL-15 complex, is a 2:1 
molar ratio combination of human IL-15 (PeproTech) and human IL-15Rα-Fc chimera (R&D 
Systems) containing 5ng/ml of IL-15, thus dosing of IL-15 is denoted by its IL-15 content 
since not all of the cytokine is in complexed form.  This formulation was used as it has been 
reported that complexing IL-15 with IL-15Rα increases the potency of IL-15 (96, 97).  Some 
cytokine supplementation was modified for specific assays and conditions are defined in 
other sections.  The cultures were monitored for excessive outgrowth of CD3-CD56+ NK 
cells, which if exceeding 15% were depleted from the cultures using CD56 microbeads 
(Miltenyi Biotec) and LS columns (Miltenyi Biotec) per the manufacturer’s instructions.  
Viable T cells were enumerated at the end of each aAPC stimulation cycle (Stim) based on 
Trypan blue exclusion using a hemocytometer for the first Stim and Cellometer counts 
(‘activated T cell’ program) for subsequent Stims.  Inferred CAR+ T cell numbers were 
calculated by multiplying the CD3+CAR+ cell fold expansion from the first Stim with the 
relative starting cell number which would then be multiplied by the CAR-specific T cell 
expansion from subsequent Stims. 
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6.4  Immunophenotyping 
Up to 1 x 106 were stained with fluorochrome-chrome conjugated antibodies: 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein 
conjugated to cyanine dye (PerCP-Cy5.5), allophycocyanin (APC), AlexaFluor-488, and 
AlexaFluor-647, which unless otherwise stated, were obtained from BD Biosciences.  
Unless otherwise stated, antibodies were used at 1:20, 1:40, 1:25, 1:33, 1:20, and 1:20 
dilutions, respectively, in a 100µl volume of buffer.  Staining for cell surface markers and 
corresponding Isotype controls was conducted in FACS buffer [phosphate-buffered saline 
(PBS), 2% fetal bovine serum (FBS), 0.1% sodium azide) for 30 minutes at 4˚C.  
Intracellular staining was done following fixation and permeabilization for 20 minutes at 4˚C 
with BD Cytofix/Cytoperm with antibodies diluted in 1x Perm/Wash buffer for 30 minutes at 
4˚C (BD Biosciences).  Annexin V staining was conducted in 1x annexin binding buffer (BD 
biosciences).  Antibodies used for immunostaining were against human: Bcl-2 (1:5 dilution, 
clone Bcl-2/100), Fc (to detect CAR; clone H10104, Invitrogen), IL-15 (1:6.7 dilution for 
APC; clone 34559, R&D Systems), BLIMP-1 (clone 646702, R&D Systems), CAR idiotype 
(clone 136.20.1)(230), CD3 (clone SK7), CD4 (cloneRPA-T4), CD8 (clone SK1), CD25 
(clone M-A251), CD27 (clone L128), CD28 (clone L293), CD19 (clone HIB19), CD45RA 
(clone HI100), CD45RO (clone UCHL1), CD56 (clone B159), CD62L (clone DREG-56), 
CD122 (clone Mik-β3), CD127 (1:8.3 dilution; clone 40131, R&D Systems), CCR7 (1:45 
dilution for PerCP-Cy5.5; clone G043H7, BioLegend), IL-2 (clone MQ1-17H12), IFNγ (clone 
B27), pSTAT5 (pY694) [1:5 dilution; clone 47/Stat5(pY694)], T-BET (1:20 for PerCP-Cy5.5; 
clone 4B10, BioLegend), and unconjugated rabbit anti-TCF1 (1:20 dilution; clone C725.7, 
Thermo Scientific).  Polyclonal goat anti-rabbit IgG-DyLight650 (1:100 dilution; Thermo 
Scientific) was used as a secondary antibody to detect TCF1.  Annexin V (1:20 dilution; BD 
Bioscience) and anti-FLAG (1:200 dilution; Prozyme) were also used.  Data acquisition was 
on a FACSCalibur using Cell Quest version 3.3 (BD Biosciences).  Analyses were with 
FlowJo software (version 7.6.5, TreeStar). 
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6.5  Validation of pSTAT5 Induction by mIL15 
Ex vivo expanded T cells were assessed at > 10 days after the 4th aAPC stimulation.  
Cells were washed in PBS to remove residual cytokines from culture media.  The cells were 
then transferred to fresh serum-free culture medium (RPMI supplemented with 1% 
Glutamax) at a high density of 2 x 106/ml and serum and exogenous cytokine starved for 12 
hours.  Starved CAR T cells indicate baseline or control levels of pSTAT5 while CAR T cells 
treated with 50-100 ng/ml IL-15 one hour prior to fixation served as the positive control.  
The cells were pelleted to remove the supernatant, then immediately fixed with 6ml of 37˚C 
1x PhosFlow Lyse/Fix Buffer (BD Biosciences), and further incubated in a water bath for 15 
minutes at 37˚C.  The cells were pelleted again to remove the supernatant, then 
permeabilized by adding 3ml of 4˚C BD PhosFlow Perm Buffer III (BD Biosciences) while 
vortexing, incubated on ice for 20 minutes, and then washed with FACS buffer.  Cells were 
stained with pSTAT5 (pY694) antibody for 20 minutes at room temperature in the dark, 
washed and resuspended in FACS buffer for flow cytometry analysis.  For assessing 
transpresentation of mIL15, CAR and mIL15-CAR T cells were co-cultured at a 1:4 ratio for 
16 hours in serum and exogenous cytokine free medium and then processed as previously 
described.  
 
6.6  Chromium Release Assay 
The antigen-specific cytolytic activity of T cells was assessed in a standard 4-hour 
CRA, as previously described (231).  Genetically modified T cells were incubated with 2 x 
105 51Cr-labeled target cells (EL4, CD19+EL4, or NALM-6) in V-bottomed 96-well plates 
(Costar).  The percentage of specific lysis was calculated from the release of 51Cr, as 
previously described, using a TopCount NXT (Perkin-Elmer) (231).   
 
6.7  Intracellular Cytokine Production 
Production of cytokines was assessed by intracellular cytokine staining of T cells.  T 
cells were co-cultured with CD19+ or negative targets (EL4, CD19+EL4, or NALM-6) at an 
effector to target ratio of 1:5 in 200µl of culture media in a round bottom, 96-well plate.  T 
cells were incubated alone as a negative control and with the addition of LAC [PMA 
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(phorbol 12 myristate 13 acetate) and ionomycin; BD Biosciences) as a positive control.  
Brefeldin-A (GolgiPlug, BD Biosciences) was added to all cultures to block exocytosis of 
cytokines produced in response to antigenic stimulation.  Cultures were incubated for 6 
hours at 37˚C and then stained for surface markers followed by fixation and 
permeabilization and staining for intracellular proteins. 
 
6.8  In Vivo Experiments Assessing T Cell Persistence and Antitumor Activity 
Human tumor xenograft models were performed under the approved protocol of the 
Institutional Animal Care and Use Committee at MDACC.  All in vivo murine experiments 
used age and sex-matched humanized NSG mice (NOD.Cg-PrkdcscidIL2rγtm1Wjl/SzJ, The 
Jackson Laboratory).   
6.8.1  In Vivo Bioluminescence Imaging 
Serial non-invasive bioluminescence imaging (BLI) was performed to measure 
persistence of mIL15-CAR and CAR T cells co-expressing ffLuc.   BLI for ffLuc activity was 
acquired 10 minutes after subcutaneous administration of D-Luciferin potassium salt 
(215µg/mouse, Caliper) as has been previously described (53, 232).  Serial non-invasive 
BLI was also done to monitor tumor burden of rLuc+NALM-6 cells.  BLI for rLuc activity was 
acquired 20 minutes after intraperitoneal injection of freshly diluted Enduren Live Cell 
Substrate (68µg/mouse, Promega) as has been previously described (232).  Imaging was 
performed on anesthetized mice in an anterior posterior position using Xenogen IVIS 100 
series system (Caliper Life Sciences).  Imaging for T cells and tumor were performed on 
alternate days.  T cell and tumor flux (measured as photons/s/cm2/steradian) were 
quantified by measuring photon signal within a delineated region of interest (ROI) which 
encompassed the entire mouse, except the tail.  An addition ROI was established for T cell 
flux, termed ‘femur ROI’ and encompassed the femur, tibia, and foot region of the mouse.  
Living Image software (v2.50, Xenogen; Caliper Life Sciences) was used to process the BLI 
data.   
6.8.2  Tissue Preparation 
At the end of some experiments, mice were euthanized by cervical dislocation and 
peripheral blood and tissues were harvested (spleen and bone marrow).  Spleens were 
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manually homogenized in 2% FBS/PBS and passed through a 40µm cell strainer (BD 
BioSciences).  To obtain the bone marrow, the femurs were flushed with 2% fetal bovine 
serum in phosphate buffered saline (FBS/PBS) using 30G needles (BD Biosciences).  ACK 
lysing buffer (Gibco-Invitrogen) was used to lyse red blood cells in all samples followed by 
washes with 2% FBS/PBS.  Cells were stained for the presence of T cells (CD3), tumor 
(CD19), and murine lymphocytes (CD45).    
6.8.3  Persistence of CAR and mIL15-CAR T Cells in a High Tumor Burden Model 
On day -1, mice were intravenously (i.v.) injected via tail vein with 1 x 105 NALM-6 cells 
to establish a disseminated leukemia model.  On day 0, mice (n = 5/group) in two treatment 
cohorts received mIL15+CAR+ffLuc+ T cells or CAR+ffLuc+ T cells (cultured with IL-2 and IL-
21) injected i.v. at 2 x 107 CAR+ T cells per mouse.  T cell persistence (ffLuc) was 
longitudinally monitored by BLI until day 14 when mice were sacrificed and tissues were 
harvested for analysis of CD3 by flow cytometry.  
6.8.4  Persistence and Efficacy of CAR and mIL15-CAR T Cells in a Low Tumor Burden 
Model 
T cells were engrafted first in this preventative tumor model mimicking MRD, where on 
day 0 two treatment cohorts (n = 5/group) were i.v. injected with 2 x 107 CAR+ T cells: (i) 
mIL15+CAR+ffLuc+ T cells and (ii) CAR+ffLuc+ T cells.  On day 6, 1 x 104 rLuc+NALM-6 were 
i.v. injected.  T cell and tumor BLI were monitored until death or sacrifice (day 36) when 
tissues were harvested for analysis of CD3 and CD19 by flow cytometry.  To assess 
survival over a longer duration, another experiment was conducted in a similar fashion with 
survival as the experimental endpoint followed to 98 days and tested the following cohorts: 
(i) mIL15+CAR+ffLuc+ T cells plus NALM-6 (n = 7), (ii) CAR+ffLuc+ T cells plus NALM-6 (n = 
8, cultured with IL-2 and IL-21), and (iii) NALM-6 only.  As in the previous experiment, 
NALM-6 cells were i.v. injected after T cell engraftment at 1 x 104 cells per mouse.  T cell 
persistence was followed by BLI until mortality or euthanasia occurred.  Mice were 
considered at the experimental endpoint if they developed hind-limb paralysis or were 
otherwise moribund. 
6.8.5  In Vivo Persistence of CAR and mIL15-CAR T Cells in the Absence of TAA 
To test T cell persistence in the absence of antigen, 2 x 107 CAR+ T cells were i.v. 
injected into mice in two treatment cohorts (n = 5/group): (i) mIL15+CAR+ffLuc+ T cells and 
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(ii) CAR+ffLuc+ T cells.  BLI was performed to monitor T cell persistence until sacrifice at 
days 48.  Tissues were harvested for analysis of CD3 and CD19 by flow cytometry.  Some 
spleen, liver, and bone marrow samples were ex vivo expanded on K562 (Clone 9) aAPCs 
at an initial stimulation one isolated cell to 5 aAPCs with subsequent stimulations at 1:1.  
Expanded cells were tested for antigen-specific function by assessing IFNγ production in 
response to tumor cell targets, as described in section 6.7. 
   
6.9  Assays Characterizing Long-term mIL15-CAR T Cell Persistence in the Absence 
of TAA  
6.9.1  In Vitro Phenotypic and Functional Characterization   
Persistence and function of T cells after antigen and exogenous cytokine withdrawal 
were tested using genetically-modified T cells that had undergone four aAPC stimulation 
cycles.  After the fourth Stim, the T cell cultures continued to be maintained with exogenous 
cytokine supplementation, as described in section 6.3, for 10 days after which T cells were 
enumerated and transferred to fresh complete RPMI to establish the following treatment 
groups for the withdrawal assay: (i) mIL15-CAR T cells, (ii) CAR T cells, (iii) CAR T cells 
supplemented with IL-15 complex (5ng/ml, 2x/week).  Cells were enumerated at days 15, 
30, 50, and 65.  T cells persisting > 65 days after antigen withdrawal, referred to as ‘WD-T 
cells’, were then assessed for mIL15 and CAR expression.  To verify that mIL15 was 
functional, pSTAT5 and Bcl-2 levels were assessed in WD-T cells per phosflow and 
intracellular staining described in sections 6.5 and 6.7, respectively.  To test whether the 
WD-T cells were still functional and responsive to antigen stimulation, they were challenged 
with CD19+/- targets and IFNγ production was measured by intracellular cytokine staining as 
previously described in section 6.7.  IL-2 production was assessed upon stimulation with 
LAC and the analysis of intracellular staining was performed by flow cytometry.  WD-T cells 
were enumerated and re-stimulated with aAPC at a ratio of 1:1 and supplemented with 
exogenous cytokines as described for stimulations in section 6.3.  
6.9.2   nCounter System Digital Gene Expression Analysis  
The day 0 CAR and mIL15-CAR T cells, as well as WD-mIL15-CAR T cells persisting 
at day 65 were phenotyped and pellets of > 5 x 105 cells were frozen at -80˚C for later gene 
expression analysis by the nCounter System (NanoString Technologies).  Gene expression 
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was analyzed for mIL15-CAR and CAR T cells obtained from cultures after more than 8 
days after the fourth aAPC stimulation.  The WD-mIL15-CAR T cells were those persisting 
long-term (>65 days after antigen withdrawal) in cultures from the antigen and exogenous 
cytokine withdrawal assays.  Cells used for analysis had been pelleted and frozen at -80˚C.  
At the time of analysis, RLT buffer (Qiagen) was added to samples prior to thawing at a 
ratio of 166ul of buffer per 1 x 106 cells.  RNA lysates were immediately processed and 
analyzed using nCounter Analysis System (NanoString Technologies) to detect genes of 
interest (233) using a lymphocyte-specific CodeSet (Appendix 1).  This CodeSet was 
generated from RefSeq accession numbers for chosen mRNA transcripts that were used to 
generate the reporter and capture probe pairs constituting the lymphocyte gene panel.  
Multiplexed target-specific color-coded reporter and biotinylated capture probes for mRNA 
species of interest were hybridized for >12 hours at 65˚C in a thermocycler (Peltier Thermal 
Cycler, Bio-Rad), processed in the cCounter PrepStation (NanoString Technologies), and 
then analyzed using the nCounter Digital Analyzer (NanoString Technologies).  Reference 
genes (ACTB, G6PD, OAZ1, POLR1B, POLR2A, RPL27, RPS13, TBP), which together 
span a dynamic range of RNA expression, were included in the CodeSet and were used to 
normalize transcript levels to account for variation of transcript levels between samples and 
in the amount of total RNA present in samples.  The count data was positive-, negative-, 
and housekeeping gene-normalized per nCounter guidelines using the nCounter RCC 
Collector Worksheet (v1.6.0, NanoString Technologies) as previously described (234) and 
filtered to remove genes with low counts of less than 10 in greater than 60% of samples.  
Statistical analysis were performed by edgeR software (235) via RobiNA Java interface 
(236).  Statistical evaluation of differential gene expression was performed using edgeR 
with implemented statistical methods based on a negative binomial dispersion (235, 237-
239).  Genes considered to be significantly differentially expressed demonstrated an 
absolute fold change ≥ 2, a p-value cut-off of 0.01, and a FDR significance value (q) less 
than 0.03 with the Benjamini-Hochberg method (240) used for multiple testing correction.  
These significant differentially expressed genes were represented in a heatmap generated 
using Qlucore Omics Explorer (v.2.3, Qlucore).  Gene Ontology classification of significant 
genes was examined by DAVID functional annotation (http://david.abcc.ncifcrf.gov/)(158, 
159). 
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6.9.3  In Vivo Characterization of Persisting mIL15-CAR T Cells  
NSG mice were infused with 2 x 107 mIL15-CAR T cells (n = 9) that were allowed to 
engraft at least 50 days.  Peripheral blood, spleen, and bone marrow were harvested for 
analysis by flow cytometry with staining for IL-15, CAR, CD45RA, CD45RO, IL-2Rα, IL-
7Ra, CD27, and CCR7.   
6.10  Statistical Analysis 
We performed statistical analyses using Prism (GraphPad Software, v.6.02).  Cell 
count and flux values were log transformed for statistical analysis.  Paired (in vitro data) and 
unpaired (in vivo data) t tests were used to compare two groups. One-way ANOVA was 
used to compare three groups.  Two-way ANOVA was used for multiple comparisons of two 
factors.  Two-way RM ANOVA compared multiple groups over time.  Survival was analyzed 
with log-rank (Mantel-Cox).    
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APPENDICIES 
Appendix A.  nCounter Analysis System Lymphocyte-specific CodeSet 
Gene Name Accession 
Target 
Region Target Sequence 
ABCB1 NM_000927.3 3910-
4010 
TATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAGAAACAACGCATTGCC
ATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGC 
ABCG2 NM_004827.2 285-385 AGGATTTAGGAACGCACCGTGCACATGCTTGGTGGTCTTGTTAAGTGGAAACTGCTGCTTTAGAGTTTGTTTGGAAGGTCCGGGTGACTCATCCCAACAT 
ACTB NM_001101.2 1010-1110 
TGCAGAAGGAGATCACTGCCCTGGCACCCAGCACAATGAAGATCAAGATCATTGCTCCTCCTG
AGCGCAAGTACTCCGTGTGGATCGGCGGCTCCATCCT 
ADAM19 NM_023038.3 1690-1790 
GAGAAGGTGAATGTGGCAGGAGACACCTTTGGAAACTGTGGAAAGGACATGAATGGTGAACA
CAGGAAGTGCAACATGAGAGATGCGAAGTGTGGGAAGA 
AGER NM_001136.3 340-440 GAAAGGAGACCAAGTCCAACTACCGAGTCCGTGTCTACCAGATTCCTGGGAAGCCAGAAATTGTAGATTCTGCCTCTGAACTCACGGCTGGTGTTCCCAA 
AHNAK NM_001620.1 15420-15520 
GGATTTGACCTGAATGTTCCTGGGGGTGAAATTGATGCCAGCCTCAAGGCTCCGGATGTAGAT
GTCAACATCGCAGGGCCGGATGCTGCACTCAAAGTCG 
AIF1 NM_032955.1 315-415 AAAAGCGAGAGAAAAGGAAAAGCCAACAGGCCCCCCAGCCAAGAAAGCTATCTCTGAGTTGCCCTGATTTGAAGGGAAAAGGGATGATGGGATTGAAGGG 
AIM2 NM_004833.1 607-707 ACGTGCTGCACCAAAAGTCTCTCCTCATGTTAAGCCTGAACAGAAACAGATGGTGGCCCAGCAGGAATCTATCAGAGAAGGGTTTCAGAAGCGCTGTTTG 
AIMP2 NM_006303.3 507-607 CCCTCTCCCTGCTTGTGCTGCACAGGCTGCTCTGTGAGCACTTCAGGGTCCTGTCCACGGTGCACACGCACTCCTCGGTCAAGAGCGTGCCTGAAAACCT 
AKIP1 NM_020642.3 570-670 GAACATCTCTAAGGACCTCTACATAGAAGTATATCCAGGGACCTATTCTGTCACTGTGGGCTCAAATGACTTAACCAAGAAGACTCATGTGGTAGCAGTT 
AKT1 NM_005163.2 1772-1872 
TTCTTTGCCGGTATCGTGTGGCAGCACGTGTACGAGAAGAAGCTCAGCCCACCCTTCAAGCC
CCAGGTCACGTCGGAGACTGACACCAGGTATTTTGATG 
ALDH1A1 NM_000689.3 11-111 ATTGCTGAGCCAGTCACCTGTGTTCCAGGAGCCGAATCAGAAATGTCATCCTCAGGCACGCCAGACTTACCTGTCCTACTCACCGATTTGAAGATTCAAT 
ANXA1 NM_000700.1 515-615 GAAATCAGAGACATTAACAGGGTCTACAGAGAGGAACTGAAGAGAGATCTGGCCAAAGACATAACCTCAGACACATCTGGAGATTTTCGGAACGCTTTGC 
ANXA2P2 NR_003573.1 257-357 ATATTGTCTTCTCCTACCAGAGAAGGACCAAAAAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTGGGCCTATT 
APAF1 NM_181869.1 1160-1260 
TTCTGATGAAACTGCAGAATCTTTGCACACGGTTGGATCAGGATGAGAGTTTTTCCCAGAGGC
TTCCACTTAATATTGAAGAGGCTAAAGACCGTCTCCG 
ARG1 NM_000045.2 505-605 AAGGAACTAAAAGGAAAGATTCCCGATGTGCCAGGATTCTCCTGGGTGACTCCCTGTATATCTGCCAAGGATATTGTGTATATTGGCTTGAGAGACGTGG 
ARRB2 NM_004313.3 1652-1752 
CATTAATTTTTTGACTGCAGCTCTGCTTCTCCAGCCCCGCCGTGGGTGGCAAGCTGTGTTCAT
ACCTAAATTTTCTGGAAGGGGACAGTGAAAAGAGGAG 
ATF3 NM_001030287.2 600-700 GGCTCAGAATGGGAGGACTCCAGAAGATGAGAGAAACCTCTTTATCCAACAGATAAAAGAAGGAACATTGCAGAGCTAAGCAGTCGTGGTATGGGGGCGA 
ATM NM_000051.3 30-130 ACGCTAAGTCGCTGGCCATTGGTGGACATGGCGCAGGCGCGTTTGCTCCGACGGGCCGAATGTTTTGGGGCAGTGTTTTGAGCGCGGAGACCGCGTGATA 
ATP2B4 NM_001684.3 7640-7740 
CTTCCCATAGTATCATCTGTCCTCTGGAATGACTCTCCTGTCCCTAAAGGGGTTAAGAGAGAG
ATCACCTAGAAATCCCTCTGGACACTTGTGGGTTCTT 
AXIN2 NM_004655.3 1035-1135 
CTTGTCCAGCAAAACTCTGAGGGCCACGGCGAGTGTGAGGTCCACGGAAACTGTTGACAGTG
GATACAGGTCCTTCAAGAGGAGCGATCCTGTTAATCCT 
B2M NM_004048.2 25-125 CGGGCATTCCTGAAGCTGACAGCATTCGGGCCGAGATGTCTCGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATCCA 
B3GAT1 NM_018644.3 145-245 CTGGACAGCGACCCCTTCTCAGACTCCAGTTGGGCCGGACTCTCCAAACCTGCTTCCGCAATGGGTGGGTTGTGAGTGCTGGTAATGAGGAGCCGTGGGT 
BACH2 NM_021813.2 3395-3495 
TGTGGCACTGTTCATCTGCTGTCCCGAAGAAACCGAGAACACATTTGGTGCACACTACAGCGG
TCTTAGCAGCAATACTGTTCCGAAGTATCCTCTCCTC 
BAD NM_004322.2 195-295 CAGCTGTGCCTTGACTACGTAACATCTTGTCCTCACAGCCCAGAGCATGTTCCAGATCCCAGAGTTTGAGCCGAGTGAGCAGGAAGACTCCAGCTCTGCA 
BAG1 NM_004323.3 1490-1590 
CTCTTGTGATCGTGTAGTCCCATAGCTGTAAAACCAGAATCACCAGGAGGTTGCACCTAGTCA
GGAATATTGGGAATGGCCTAGAACAAGGTGTTTGGCA 
BATF NM_006399.3 825-925 CACTGTGGGTTGCAGGCCCAATGCAGAAGAGTATTAAGAAAGATGCTCAAGTCCCATGGCACAGAGCAAGGCGGGCAGGGAACGGTTATTTTTCTAAATA 
BAX NM_138761.2 694-794 ATTTTTCTGGGAGGGGTGGGGATTGGGGGACATGGGCATTTTTCTTACTTTTGTAATTATTGGGGGGTGTGGGGAAGAGTGGTCTTGAGGGGGTAATAAA 
BCL10 NM_003921.2 1250-1350 
TGAAAATACCATCTTCTCTTCAACTACACTTCCCAGACCTGGGGACCCAGGGGCTCCTCCTTT
GCCACCAGATCTACAGTTAGAAGAAGAAGGAACTTGT 
BCL11B NM_022898.1 3420-3520 
GAGATGTAGCACTCATGTCGTCCCGAGTCAAGCGGCCTTTTCTGTGTTGATTTCGGCTTTCATA
TTACATAAGGGAAACCTTGAGTGGTGGTGCTGGGGG 
BCL2 NM_000633.2 1525-1625 
CCAAGCACCGCTTCGTGTGGCTCCACCTGGATGTTCTGTGCCTGTAAACATAGATTCGCTTTC
CATGTTGTTGGCCGGATCACCATCTGAAGAGCAGACG 
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BCL2L1 NM_138578.1 1560-1660 
CTAAGAGCCATTTAGGGGCCACTTTTGACTAGGGATTCAGGCTGCTTGGGATAAAGATGCAAG
GACCAGGACTCCCTCCTCACCTCTGGACTGGCTAGAG 
BCL2L1 NM_001191.2 260-360 ATCTTGGCTTTGGATCTTAGAAGAGAATCACTAACCAGAGACGAGACTCAGTGAGTGAGCAGGTGTTTTGGACAATGGACTGGTTGAGCCCATCCCTATT 
BCL2L11 NM_138621.2 2825-2925 
TGTTGGCACCAGAACTTAAAGCGATGACTGGATGTCTCTGTACTGTATGTATCTGGTTATCAAG
ATGCCTCTGTGCAGAAAGTATGCCTCCCGTGGGTAT 
BCL2L11 NM_138621.4 257-357 CGGACTGAGAAACGCAAGAAAAAAAGACCAAATGGCAAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACCGAGAAGGTAGACAATTGCAGCCTGCGGAG 
BCL6 NM_001706.2 675-775 GTTGTGGACACTTGCCGGAAGTTTATTAAGGCCAGTGAAGCAGAGATGGTTTCTGCCATCAAGCCTCCTCGTGAAGAGTTCCTCAACAGCCGGATGCTGA 
BCL6B NM_181844.3 2135-2235 
CTTTATTTGTTCTAGGGCAGCTCTGGGAACATGCGGGATTGTGGAATTGGGTCAGGAACCCTC
TCTGGTATTCTGGATGTTGTAGGTTCTCTAGCAGTCT 
BHLHE41 NM_030762.2 655-755 CGCCCATTCAGTCCGACTTGGATGCGTTCCACTCGGGATTTCAAACATGCGCCAAAGAAGTCTTGCAATACCTCTCCCGGTTTGAGAGCTGGACACCCAG 
BID NM_197966.1 2095-2195 
GCTTAGCTTTAGAAACAGTGCAACACTGGTCTGCTGTTCCAGTGGTAAGCTATGTCCCAGGAA
TCAGTTTAAAAGCACGACAGTGGATGCTGGGTCCATA 
BIRC2 NM_001166.3 1760-1860 
TGGGATCCACCTCTAAGAATACGTCTCCAATGAGAAACAGTTTTGCACATTCATTATCTCCCAC
CTTGGAACATAGTAGCTTGTTCAGTGGTTCTTACTC 
BLK NM_001715.2 990-1090 AGCTTCTTGCTCCAATCAACAAGGCCGGCTCCTTTCTTATCAGAGAGAGTGAAACCAACAAAGGTGCCTTCTCCCTGTCTGTGAAGGATGTCACCACCCA 
BMI1 NM_005180.5 1145-1245 
CCTGGAGAAGGAATGGTCCACTTCCATTGAAATACAGAGTTCGACCTACTTGTAAAAGAATGA
AGATCAGTCACCAGAGAGATGGACTGACAAATGCTGG 
BNIP3 NM_004052.2 325-425 CACCTCGCTCGCAGACACCACAAGATACCAACAGGGCTTCTGAAACAGATACCCATAGCATTGGAGAGAAAAACAGCTCACAGTCTGAGGAAGATGATAT 
BTLA NM_001085357.1 890-990 GCACCAACAGAATATGCATCCATATGTGTGAGGAGTTAAGTCTGTTTCTGACTCCAACAGGGACCATTGAATGATCAGCATGTTGACATCATTGTCTGGG 
C21orf33 NM_004649.5 1340-1440 
TTGAGTTAATCAGCGTAAGGGGATTTCTAAAGCAGGCAATCCCTGTAGCCGCAGAGAATAAAC
GCCTTCCCAAAATGGCAACTTCCCACAGCCACATTTC 
CA2 NM_000067.2 575-675 AGCTGTGCAGCAACCTGATGGACTGGCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAGAAAGTTGTTGATGTGCTGGATTCC 
CA9 NM_001216.2 960-1060 CAGGTCCCAGGACTGGACATATCTGCACTCCTGCCCTCTGACTTCAGCCGCTACTTCCAATATGAGGGGTCTCTGACTACACCGCCCTGTGCCCAGGGTG 
CARD9 NM_052813.2 1850-1950 
CGCTGACTTGGCCTGGAACGAGGAATCTGGTGCCCTGAAAGGCCCAGCCGGACTGCCGGGC
ATTGGGGCCGTTTGTTAAGCGGCACTCATTTTGCGGAGG 
CASP1 NM_033292.2 575-675 ACAGGCATGACAATGCTGCTACAAAATCTGGGGTACAGCGTAGATGTGAAAAAAAATCTCACTGCTTCGGACATGACTACAGAGCTGGAGGCATTTGCAC 
CAT NM_001752.2 1130-1230 
ATGCTTCAGGGCCGCCTTTTTGCCTATCCTGACACTCACCGCCATCGCCTGGGACCCAATTAT
CTTCATATACCTGTGAACTGTCCCTACCGTGCTCGAG 
CBLB NM_170662.3 3195-3295 
TAATGTCGAAGTTGCCCGGAGCATCCTCCGAGAATTTGCCTTCCCTCCTCCAGTATCCCCACG
TCTAAATCTATAGCAGCCAGAACTGTAGACACCAAAA 
CCBP2 NM_001296.3 1345-1445 
GAACAGATGGGAACCAGCTCAATTGGGTGTCCACTCAAAGTGCTCTCTCCAGGGGCCTCAGT
GACTGTGTTGCTAAACCCAGTGGTCAGTTCTCAGTTCT 
CCL3 NM_002983.2 681-781 CTGTGTAGGCAGTCATGGCACCAAAGCCACCAGACTGACAAATGTGTATCGGATGCTTTTGTTCAGGGCTGTGATCGGCCTGGGGAAATAATAAAGATGC 
CCL4 NM_002984.2 35-135 TTCTGCAGCCTCACCTCTGAGAAAACCTCTTTGCCACCAATACCATGAAGCTCTGCGTGACTGTCCTGTCTCTCCTCATGCTAGTAGCTGCCTTCTGCTC 
CCL5 NM_002985.2 280-380 AGTGTGTGCCAACCCAGAGAAGAAATGGGTTCGGGAGTACATCAACTCTTTGGAGATGAGCTAGGATGGAGAGTCCTTGAACCTGAACTTACACAAATTT 
CCNB1 NM_031966.2 715-815 AACTTGAGGAAGAGCAAGCAGTCAGACCAAAATACCTACTGGGTCGGGAAGTCACTGGAAACATGAGAGCCATCCTAATTGACTGGCTAGTACAGGTTCA 
CCND1 NM_053056.2 690-790 TTGAACACTTCCTCTCCAAAATGCCAGAGGCGGAGGAGAACAAACAGATCATCCGCAAACACGCGCAGACCTTCGTTGCCCTCTGTGCCACAGATGTGAA 
CCR1 NM_001295.2 535-635 CATCATTTGGGCCCTGGCCATCTTGGCTTCCATGCCAGGCTTATACTTTTCCAAGACCCAATGGGAATTCACTCACCACACCTGCAGCCTTCACTTTCCT 
CCR2 NM_001123041.2 20-120 ACATTCTGTTGTGCTCATATCATGCAAATTATCACTAGTAGGAGAGCAGAGAGTGGAAATGTTCCAGGTATAAAGACCCACAAGATAAAGAAGCTCAGAG 
CCR4 NM_005508.4 35-135 GGTCCTTCTTAGCATCGTGCTTCCTGAGCAAGCCTGGCATTGCCTCACAGACCTTCCTCAGAGCCGCTTTCAGAAAAGCAAGCTGCTTCTGGTTGGGCCC 
CCR5 NM_000579.1 2730-2830 
TAGGAACATACTTCAGCTCACACATGAGATCTAGGTGAGGATTGATTACCTAGTAGTCATTTCA
TGGGTTGTTGGGAGGATTCTATGAGGCAACCACAGG 
CCR6 NM_031409.2 935-1035 CTTTAACTGCGGGATGCTGCTCCTGACTTGCATTAGCATGGACCGGTACATCGCCATTGTACAGGCGACTAAGTCATTCCGGCTCCGATCCAGAACACTA 
CCR7 NM_001838.2 1610-1710 
TTCCGAAAACCAGGCCTTATCTCCAAGACCAGAGATAGTGGGGAGACTTCTTGGCTTGGTGAG
GAAAAGCGGACATCAGCTGGTCAAACAAACTCTCTGA 
CD160 NM_007053.2 500-600 TTGATGTTCACCATAAGCCAAGTCACACCGTTGCACAGTGGGACCTACCAGTGTTGTGCCAGAAGCCAGAAGTCAGGTATCCGCCTTCAGGGCCATTTTT 
CD19 NM_001770.4 1770-1870 
AGATTCACACCTGACTCTGAAATCTGAAGACCTCGAGCAGATGATGCCAACCTCTGGAGCAAT
GTTGCTTAGGATGTGTGCATGTGTGTAAGTGTGTGTG 
CD19R-scfv SCFV013.1 204-304 GGCACCGACTACAGCCTGACCATCTCCAACCTGGAGCAGGAGGACATCGCCACCTACTTTTGCCAGCAGGGCAACACACTGCCCTACACCTTTGGCGGCG 
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CD19RCD28 MDA_00002.1 2-102 CAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGTGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACT 
CD2 NM_001767.2 1400-1500 
TGGGTCTCACTACAAGCAGCCTATCTGCTTAAGAGACTCTGGAGTTTCTTATGTGCCCTGGTG
GACACTTGCCCACCATCCTGTGAGTAAAAGTGAAATA 
CD20-scfv      
(rutuximab) SCFV002.1 8-108 
GCTGTCCCAGAGCCCCGCCATCCTGAGCGCCAGCCCTGGCGAGAAGGTGACCATGACCTGC
CGGGCCAGCAGCTCTGTGAGCTACATGCACTGGTATCAG 
CD226 NM_006566.2 163-263 TAAACAGGATACGATAAAAGTCCTTAACCAAGACGCAGATGGGAAGAAGCGTTAGAGCGAGCAGCACTCACATCTCAAGAACCAGCCTTTCAAACAGTTT 
CD244 NM_016382.2 1150-1250 
AAGAGGAACCACAGCCCTTCCTTCAATAGCACTATCTATGAAGTGATTGGAAAGAGTCAACCTA
AAGCCCAGAACCCTGCTCGATTGAGCCGCAAAGAGC 
CD247 NM_198053.1 1490-1590 
TGGCAGGACAGGAAAAACCCGTCAATGTACTAGGATACTGCTGCGTCATTACAGGGCACAGG
CCATGGATGGAAAACGCTCTCTGCTCTGCTTTTTTTCT 
CD27 NM_001242.4 330-430 CCAGATGTGTGAGCCAGGAACATTCCTCGTGAAGGACTGTGACCAGCATAGAAAGGCTGCTCAGTGTGATCCTTGCATACCGGGGGTCTCCTTCTCTCCT 
CD274 NM_014143.2 684-784 TAGGAGATTAGATCCTGAGGAAAACCATACAGCTGAATTGGTCATCCCAGAACTACCTCTGGCACATCCTCCAAATGAAAGGACTCACTTGGTAATTCTG 
CD276 NM_001024736.1 2120-2220 
ACATTTCTTAGGGACACAGTACACTGACCACATCACCACCCTCTTCTTCCAGTGCTGCGTGGA
CCATCTGGCTGCCTTTTTTCTCCAAAAGATGCAATAT 
CD28 NM_006139.1 305-405 GCTTGTAGCGTACGACAATGCGGTCAACCTTAGCTGCAAGTATTCCTACAATCTCTTCTCAAGGGAGTTCCGGGCATCCCTTCACAAAGGACTGGATAGT 
CD300A NM_007261.2 0-100 CGGGGAAGTGAGAGTCGGGGATCAGTCCTGCAAGCTACGGAGTCACTACAGGGAGAGGTCTCATCACTAGAAATAGCCGAAGAACCTGCAGCCTCAACCA 
CD38 NM_001775.2 1035-1135 
CCTTGACTCCTTGTGGTTTATGTCATCATACATGACTCAGCATACCTGCTGGTGCAGAGCTGAA
GATTTTGGAGGGTCCTCCACAATAAGGTCAATGCCA 
CD3D NM_000732.4 110-210 TATCTACTGGATGAGTTCCGCTGGGAGATGGAACATAGCACGTTTCTCTCTGGCCTGGTACTGGCTACCCTTCTCTCGCAAGTGAGCCCCTTCAAGATAC 
CD3E NM_000733.2 75-175 AAGTAACAGTCCCATGAAACAAAGATGCAGTCGGGCACTCACTGGAGAGTTCTGGGCCTCTGCCTCTTATCAGTTGGCGTTTGGGGGCAAGATGGTAATG 
CD4 NM_000616.3 835-935 AGACATCGTGGTGCTAGCTTTCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAGTTCTCCTTCCCACTCGCCTTTACAGTTGAA 
CD40LG NM_000074.2 1225-1325 
GCATTTGATTTATCAGTGAAGATGCAGAAGGGAAATGGGGAGCCTCAGCTCACATTCAGTTAT
GGTTGACTCTGGGTTCCTATGGCCTTGTTGGAGGGGG 
CD44 NM_000610.3 2460-2560 
GTGGGCAGAAGAAAAAGCTAGTGATCAACAGTGGCAATGGAGCTGTGGAGGACAGAAAGCCA
AGTGGACTCAACGGAGAGGCCAGCAAGTCTCAGGAAAT 
CD45R-scfv SCFV006.1 222-322 TTCACCCTGAACATCCACCCCGTGGAGGAAGAGGACGCCGCCACCTACTACTGCCAGCACAGCAGAGAGCTGCCCTTCACCTTCGGCTCCGGCACCAAGC 
CD47 NM_001777.3 897-997 GCCATATTGGTTATTCAGGTGATAGCCTATATCCTCGCTGTGGTTGGACTGAGTCTCTGTATTGCGGCGTGTATACCAATGCATGGCCCTCTTCTGATTT 
CD56R-scfv SCFV008.1 197-297 ATTCAGCGGCTCTGGCTCCGGCACCGACTTCACTCTGATGATCTCTCGGGTGGAGGCCGAGGACCTGGGCGTGTACTACTGCTTTCAGGGCAGCCACGTG 
CD58 NM_001779.2 478-578 GTGCTTGAGTCTCTTCCATCTCCCACACTAACTTGTGCATTGACTAATGGAAGCATTGAAGTCCAATGCATGATACCAGAGCATTACAACAGCCATCGAG 
CD63 NM_001780.4 350-450 GTCATCATCGCAGTGGGTGTCTTCCTCTTCCTGGTGGCTTTTGTGGGCTGCTGCGGGGCCTGCAAGGAGAACTATTGTCTTATGATCACGTTTGCCATCT 
CD69 NM_001781.1 460-560 AGGACATGAACTTTCTAAAACGATACGCAGGTAGAGAGGAACACTGGGTTGGACTGAAAAAGGAACCTGGTCACCCATGGAAGTGGTCAAATGGCAAAGA 
CD7 NM_006137.6 440-540 CCTACACCTGCCAGGCCATCACGGAGGTCAATGTCTACGGCTCCGGCACCCTGGTCCTGGTGACAGAGGAACAGTCCCAAGGATGGCACAGATGCTCGGA 
CD80 NM_005191.3 1288-1388 
AAAGATCTGAAGGTCCCACCTCCATTTGCAATTGACCTCTTCTGGGAACTTCCTCAGATGGACA
AGATTACCCCACCTTGCCCTTTACGTATCTGCTCTT 
CD86 NM_006889.3 146-246 TATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGGTGCTGCTCCTCTGAAGATTCAAGCTTATTTCAATGAGACTGCAGACCTGCCA 
CD8A NM_001768.5 1320-1420 
GCTCAGGGCTCTTTCCTCCACACCATTCAGGTCTTTCTTTCCGAGGCCCCTGTCTCAGGGTGA
GGTGCTTGAGTCTCCAACGGCAAGGGAACAAGTACTT 
CDH1 NM_004360.2 1230-1330 
CGATAATCCTCCGATCTTCAATCCCACCACGTACAAGGGTCAGGTGCCTGAGAACGAGGCTAA
CGTCGTAATCACCACACTGAAAGTGACTGATGCTGAT 
CDK2 NM_001798.2 220-320 TCGCTGGCGCTTCATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAAGCCAGAAACAAGTTGACGGGAGAGGTG 
CDK4 NM_000075.2 1055-1155 
ACTTTTAACCCACACAAGCGAATCTCTGCCTTTCGAGCTCTGCAGCACTCTTATCTACATAAGG
ATGAAGGTAATCCGGAGTGAGCAATGGAGTGGCTGC 
CDKN1A NM_000389.2 1975-2075 
CATGTGTCCTGGTTCCCGTTTCTCCACCTAGACTGTAAACCTCTCGAGGGCAGGGACCACACC
CTGTACTGTTCTGTGTCTTTCACAGCTCCTCCCACAA 
CDKN1B NM_004064.2 365-465 GCTTCCGAGAGGGGTTCGGGCCGCGTAGGGGCGCTTTGTTTTGTTCGGTTTTGTTTTTTTGAGAGTGCGAGAGAGGCGGTCGTGCAGACCCGGGAGAAAG 
CDKN2A NM_000077.3 975-1075 AAGCGCACATTCATGTGGGCATTTCTTGCGAGCCTCGCAGCCTCCGGAAGCTGTCGACTTCATGACAAGCATTTTGTGAACTAGGGAAGCTCAGGGGGGT 
CDKN2C NM_001262.2 1295-1395 
ATAATGTAAACGTCAATGCACAAAATGGATTTGGAAGGACTGCGCTGCAGGTTATGAAACTTG
GAAATCCCGAGATTGCCAGGAGACTGCTACTTAGAGG 
CEBPA NM_004364.2 1320-1420 
GAGCTGGGAGCCCGGCAACTCTAGTATTTAGGATAACCTTGTGCCTTGGAAATGCAAACTCAC
CGCTCCAATGCCTACTGAGTAGGGGGAGCAAATCGTG 
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CFLAR NM_003879.3 445-545 CAAGACCCTTGTGAGCTTCCCTAGTCTAAGAGTAGGATGTCTGCTGAAGTCATCCATCAGGTTGAAGAAGCACTTGATACAGATGAGAAGGAGATGCTGC 
CFLAR NM_001127183.1 653-753 TAGAGTGCTGATGGCAGAGATTGGTGAGGATTTGGATAAATCTGATGTGTCCTCATTAATTTTCCTCATGAAGGATTACATGGGCCGAGGCAAGATAAGC 
CHPT1 NM_020244.2 1303-1403 
GATATGGTGATATACTTTAGTGCTTTGTGCCTGCAAATTTCAAGACACCTTCATCTAAATATATT
CAAGACTGCATGTCATCAAGCACCTGAACAGGTTC 
CIITA NM_000246.3 470-570 GCCTGAGCAAGGACATTTTCAAGCACATAGGACCAGATGAAGTGATCGGTGAGAGTATGGAGATGCCAGCAGAAGTTGGGCAGAAAAGTCAGAAAAGACC 
CITED2 NM_006079.3 965-1065 AGGAGCTGCCCGAACTCTGGCTGGGGCAAAACGAGTTTGATTTTATGACGGACTTCGTGTGCAAACAGCAGCCCAGCAGAGTGAGCTGTTGACTCGATCG 
CLIC1 NM_001288.4 310-410 GTGATGGGGCCAAGATTGGGAACTGCCCATTCTCCCAGAGACTGTTCATGGTACTGTGGCTCAAGGGAGTCACCTTCAATGTTACCACCGTTGACACCAA 
CLNK NM_052964.2 1108-1208 
GAAGGAGAACAAGGATGGTAGTTTCTTGGTCCGAGATTGTTCCACAAAATCCAAGGAAGAGCC
CTATGTTTTGGCTGTGTTTTATGAGAACAAAGTCTAC 
c-MET-scfv SCFV004.1 138-238 CTGATCTACGCCGCCAGCAGCCTGAAGAGCGGCGTGCCCAGCCGGTTTAGCGGCTCTGGCTCTGGCGCCGACTTCACCCTGACCATCAGCAGCCTGCAGC 
CREB1 NM_004379.3 4855-4955 
TTTGATGGTAGGTCAGCAGCAGTGCTAGTCTCTGAAAGCACAATACCAGTCAGGCAGCCTATC
CCATCAGATGTCATCTGGCTGAAGTTTATCTCTGTCT 
CREM NM_001881.2 260-360 CTCCACCTCCTCGCGTCCGTAATCAGTGACGAGGTCCGCTACGTAAATCCCTTTGCGGCGGACAAATGACCATGGAAACAGTTGAATCCCAGCATGATGG 
CRIP1 NM_001311.4 269-369 CAACCACCCCTGCTACGCAGCCATGTTTGGGCCTAAAGGCTTTGGGCGGGGCGGAGCCGAGAGCCACACTTTCAAGTAAACCAGGTGGTGGAGACCCCAT 
CRLF2 NM_022148.2 1420-1520 
CAAGGCAGCACGTCCAAAATGCTGTAAAACCATCTTCCCACTCTGTGAGTCCCCAGTTCCGTC
CATGTACCTGTTCCATAGCATTGGATTCTCGGAGGAT 
CSAD NM_015989.4 205-305 TCAAATTCTTCTGCCTAGCCTTAGCCATTAGAGAGAGGTCCTGCTAAAGATGGACTGCAAATGCGCTTGATGGAAGGAGATGTCAATTCCACTGAAGTCC 
CSF2 NM_000758.2 475-575 AGATGAGGCTGGCCAAGCCGGGGAGCTGCTCTCTCATGAAACAAGAGCTAGAAACTCAGGATGGTCATCTTGGAGGGACCAAGGGGTGGGCCACAGCCAT 
CSNK2A1 NM_177559.2 1930-2030 
CCATTCCCACCATTGTTCCTCCACCGTCCCACACTTTAGGGGGTTGGTATCTCGTGCTCTTCTC
CAGAGATTACAAAAATGTAGCTTCTCAGGGGAGGCA 
CTGF NM_001901.2 1100-1200 
ACCACCCTGCCGGTGGAGTTCAAGTGCCCTGACGGCGAGGTCATGAAGAAGAACATGATGTT
CATCAAGACCTGTGCCTGCCATTACAACTGTCCCGGAG 
CTLA4 NM_005214.3 405-505 AGTCTGTGCGGCAACCTACATGATGGGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCACGGGCACCTCCAGTGGAAATCAAGTGAACCTCACTATC 
CTNNA1 NM_001903.2 75-175 TCGCCCAGCTAGCCGCAGAAATGACTGCTGTCCATGCAGGCAACATAAACTTCAAGTGGGATCCTAAAAGTCTAGAGATCAGGACTCTGGCAGTTGAGAG 
CTNNB1 NM_001098210.1 1815-1915 
TCTTGCCCTTTGTCCCGCAAATCATGCACCTTTGCGTGAGCAGGGTGCCATTCCACGACTAGT
TCAGTTGCTTGTTCGTGCACATCAGGATACCCAGCGC 
CTNNBL1 NM_030877.3 855-955 TGATGCCAACAAACTGTATTGCAGTGAAGTGCTGGCCATATTGCTCCAGGACAATGATGAAAACAGGGAATTGCTTGGGGAGCTGGATGGAATCGATGTG 
CTSC NM_001114173.1 260-360 TGCTCGGTTATGGGACCACAAGAAAAAAAAGTAGTGGTGTACCTTCAGAAGCTGGATACAGCATATGATGACCTTGGCAATTCTGGCCATTTCACCATCA 
CTSD NM_001909.3 1495-1595 
GAAGCCGGCGGCCCAAGCCCGACTTGCTGTTTTGTTCTGTGGTTTTCCCCTCCCTGGGTTCAG
AAATGCTGCCTGCCTGTCTGTCTCTCCATCTGTTTGG 
CX3CL1 NM_002996.3 140-240 AGCACCACGGTGTGACGAAATGCAACATCACGTGCAGCAAGATGACATCAAAGATACCTGTAGCTTTGCTCATCCACTATCAACAGAACCAGGCATCATG 
CX3CR1 NM_001337.3 1040-1140 
GGGCGCTCAGTCCACGTTGATTTCTCCTCATCTGAATCACAAAGGAGCAGGCATGGAAGTGTT
CTGAGCAGCAATTTTACTTACCACACGAGTGATGGAG 
CXCL10 NM_001565.1 40-140 GCAGAGGAACCTCCAGTCTCAGCACCATGAATCAAACTGCGATTCTGATTTGCTGCCTTATCTTTCTGACTCTAAGTGGCATTCAAGGAGTACCTCTCTC 
CXCL12 NM_199168.2 505-605 GGGCCTGAGGTTTGCCAGCATTTAGACCCTGCATTTATAGCATACGGTATGATATTGCAGCTTATATTCATCCATGCCCTGTACCTGTGCACGTTGGAAC 
CXCL9 NM_002416.1 1975-2075 
CACCATCTCCCATGAAGAAAGGGAACGGTGAAGTACTAAGCGCTAGAGGAAGCAGCCAAGTC
GGTTAGTGGAAGCATGATTGGTGCCCAGTTAGCCTCTG 
CXCR1 NM_000634.2 1950-2050 
GCAGCCACCAGTCCATTGGGCAGGCAGATGTTCCTAATAAAGCTTCTGTTCCGTGCTTGTCCC
TGTGGAAGTATCTTGGTTGTGACAGAGTCAAGGGTGT 
CXCR3 NM_001504.1 80-180 GTGAGTGACCACCAAGTGCTAAATGACGCCGAGGTTGCCGCCCTCCTGGAGAACTTCAGCTCTTCCTATGACTATGGAGAAAACGAGAGTGACTCGTGCT 
CXCR4 NM_001008540.1 135-235 GTCACTATGGGAAAAGATGGGGAGGAGAGTTGTAGGATTCTACATTAATTCTCTTGTGCCCTTAGCCCACTACTTCAGAATTTCCTGAAGAAAGCAAGCC 
DAPL1 NM_001017920.2 190-290 CGAGAAAACAAGTGCCATTGCAAATGTTGCCAAAATACAGACACTGGATGCCCTGAATGACGCACTGGAGAAGCTCAACTATAAATTTCCAGCAACAGTG 
DEC1 NM_017418.2 190-290 AGGCCTTACTTTCCAGATCCAGATCCTTGTGCATACAACTGACTTGTGTGGGTGAGGCTTGCAGAAAAAATCAGCTAGAACAGCCTTGGGGGTAGTGGCA 
DECTIN-1R SCFV010.1 270-370 CTGAAGATCGACAGCAGCAACGAGCTGGGCTTCATCGTGAAGCAGGTGTCCAGCCAGCCCGACAACTCCTTCTGGATCGGCCTGAGCAGGCCCCAGACCG 
DGKA NM_001345.4 1375-1475 
TTCCTAACACCCACCCACTTCTCGTCTTTGTCAATCCTAAGAGTGGCGGGAAGCAGGGGCAAA
GGGTGCTCTGGAAGTTCCAGTATATATTAAACCCTCG 
DOCK5 NM_024940.6 630-730 TGCGAGATGACAATGGGAACATCCTAGACCCTGACGAAACCAGCACCATTGCCCTCTTCAAGGCCCATGAGGTGGCCTCCAAAAGGATTGAGGAAAAGAT 
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DOK2 NM_003974.2 650-750 GCCAGGGACCCAGCTGTACGACTGGCCCTACAGGTTTCTGCGGCGCTTTGGGCGGGACAAGGTAACCTTTTCCTTTGAGGCAGGCCGTCGCTGCGTCTCT 
DPP4 NM_001935.3 2700-2800 
CAGCAGTCAGCTCAGATCTCCAAAGCCCTGGTCGATGTTGGAGTGGATTTCCAGGCAATGTG
GTATACTGATGAAGACCATGGAATAGCTAGCAGCACAG 
DUSP16 NM_030640.2 615-715 ATGGGTTTAACTCTCCTTTTGCCAGTCACCACCAGCCTGACCTCATACACTTTTAGTACAATGGAGTGGCTGAGCCTTTGAGCACACCACCATTACATCA 
EGFR-scfv_    
(NIMO CAR) SCFV015.1 7-107 
AGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGCGACAGAGTGACCATCACCTG
CCGGTCCAGCCAGAACATCGTGCACAGCAACGGCAACAC 
EGLN1 NM_022051.1 3975-4075 
AGCAGCATGGACGACCTGATACGCCACTGTAACGGGAAGCTGGGCAGCTACAAAATCAATGG
CCGGACGAAAGCCATGGT 
EGLN3 NM_022073.3 800-900 AAGCTACATGGTGGGATCCTGCGGATATTTCCAGAGGGGAAATCATTCATAGCAGATGTGGAGCCCATTTTTGACAGACTCCTGTTCTTCTGGTCAGATC 
EIF1 NM_005801.3 869-969 CCTGAACAGTCCTCGGTGAATCTGAGAGGAGAGGATGGGGTAAGGCAGAAGCACCAGCTGTACTACTAGAAGGGAGCTTTTGGTGGTAGATCCCCTGGTG 
ELF4 NM_001421.3 335-435 AGCTCTGGAGGGCTCTGATAATCCCGTTGTCAGCTCTCTGAAAAGACAGCATGGCTATTACCCTACAGCCCAGTGACCTGATCTTTGAGTTCGCAAGCAA 
ELOF1 NM_032377.3 125-225 AGACCCAGTTCACCTGCCCCTTCTGCAACCACGAGAAATCCTGTGATGTGAAAATGGACCGTGCCCGCAACACCGGAGTCATCTCTTGTACCGTGTGCCT 
ENTPD1 NM_001776.4 225-325 TTCGAGTAACTTTAGGAAAATGAGCTGCTGGACTCCTCAGTCAATCTGTCCTTTCTAGTCAATGAAAAAGACAGGGTTTGAGGTTCCTTCCGAAACGGGG 
EOMES NM_005442.2 1670-1770 
ATCCCATGCCCTGGGGTATTACCCAGACCCAACCTTTCCTGCAATGGCAGGGTGGGGAGGTC
GAGGTTCTTACCAGAGGAAGATGGCAGCTGGACTACCA 
EPHA2 NM_004431.2 1525-1625 
GAGCCGAGTGTGGAAGTACGAGGTCACTTACCGCAAGAAGGGAGACTCCAACAGCTACAATG
TGCGCCGCACCGAGGGTTTCTCCGTGACCCTGGACGAC 
EPHA4 NM_004438.3 20-120 GCAGCGTTGGCACCGGCGAACCATGGCTGGGATTTTCTATTTCGCCCTATTTTCGTGTCTCTTCGGGATTTGCGACGCTGTCACAGGTTCCAGGGTATAC 
EPHB2 NM_017449.2 785-885 CAAAGCAGGCTTCGAGGCCGTTGAGAATGGCACCGTCTGCCGAGGTTGTCCATCTGGGACTTTCAAGGCCAACCAAGGGGATGAGGCCTGTACCCACTGT 
ETV6 NM_001987.4 3840-3940 
GTATGAATATGAAATCAGAGACCAGGGCATGATGTTGCTAGGATTAGAGCCTCTCAGTCTGGC
CTCTTCACCCAAGTGCAAGAACTCAGTCTCTTACTGT 
FADD NM_003824.2 1560-1660 
TGAGACTGCTAAGTAGGGGCAGTGATGGTTGCCAGGACGAATTGAGATAATATCTGTGAGGT
GCTGATGAGTGATTGACACACAGCACTCTCTAAATCTT 
FAM129A NM_052966.2 3526-3626 
TGCCCAATAGATTCAAGAGAAGCTAAGCGGAAATGGAGGGTGGAAGGTGTGATCTGTGGGAC
TGTCTGGGCCTGTTACTCATCCTGCTATCAATTTCTTA 
FANCC NM_000136.2 2130-2230 
GACTCAGTCAGACATGTTCACTAATGACTCAAGTGAGCCTTCGGTACTCCTGGTGCCCGCCCG
GCCAGACCGTCAGCTTGATAATTACTAAAGCAAAGGC 
FAS NM_000043.3 90-190 CACCGGGGCTTTTCGTGAGCTCGTCTCTGATCTCGCGCAAGAGTGACACACAGGTGTTCAAAGACGCTTCTGGGGAGTGAGGGAAGCGGTTTACGAGTGA 
FASLG NM_000639.1 625-725 TCCATGCCTCTGGAATGGGAAGACACCTATGGAATTGTCCTGCTTTCTGGAGTGAAGTATAAGAAGGGTGGCCTTGTGATCAATGAAACTGGGCTGTACT 
FCGR3B NM_000570.3 73-173 CCTATTCCTGTTCTATGGTGGGGCTCCATTGCGAGACTTCAGATTGAGAAATCAGATGAAGTTTCAAGAAAAGGAAACTGGCAGGTGACAGAGATGGGTG 
FGL2 NM_006682.2 250-350 CAATTCAGCAGGATCGAGGAGGTGTTCAAAGAAGTCCAAAACCTCAAGGAAATCGTAAATAGTCTAAAGAAATCTTGCCAAGACTGCAAGCTGCAGGCTG 
FLT1 NM_002019.2 5615-5715 
TTCAACTGCTTTGAAACTTGCCTGGGGTCTGAGCATGATGGGAATAGGGAGACAGGGTAGGA
AAGGGCGCCTACTCTTCAGGGTCTAAAGATCAAGTGGG 
FLT3LG NM_001459.2 927-1027 CCTCCCCAGAATGGAGGCAACGCCAGAATCCAGCACCGGCCCCATTTACCCAACTCTGTACAAAGCCCTTGTCCCCATGAAATTGTATATAAATCATCCT 
FOS NM_005252.2 1475-1575 
ACTCAAGTCCTTACCTCTTCCGGAGATGTAGCAAAACGCATGGAGTGTGTATTGTTCCCAGTG
ACACTTCAGAGAGCTGGTAGTTAGTAGCATGTTGAGC 
FOXO1 NM_002015.3 1526-1626 
TCTCATCACCAACATCATTAACTGTTTCGACCCAGTCCTCACCTGGCACCATGATGCAGCAGA
CGCCGTGCTACTCGTTTGCGCCACCAAACACCAGTTT 
FOXO3 NM_001455.2 1860-1960 
CCGGAACGTGATGCTTCGCAATGATCCGATGATGTCCTTTGCTGCCCAGCCTAACCAGGGAA
GTTTGGTCAATCAGAACTTGCTCCACCACCAGCACCAA 
FOXP1 NM_032682.5 6758-6858 
CCTGAAAATCAGATTTACAATGCTGAAGGCATTTCTTGGGCCCAGTGTAGCTCACGCAATCTCT
GCTACCCATAAGCCTTGATGAAGATGATACAGTCCG 
FOXP3 NM_014009.3 1230-1330 
GGGCCATCCTGGAGGCTCCAGAGAAGCAGCGGACACTCAATGAGATCTACCACTGGTTCACA
CGCATGTTTGCCTTCTTCAGAAACCATCCTGCCACCTG 
FYN NM_002037.3 765-865 GTCTTTGGAGGTGTGAACTCTTCGTCTCATACGGGGACCTTGCGTACGAGAGGAGGAACAGGAGTGACACTCTTTGTGGCCCTTTATGACTATGAAGCAC 
FZD1 NM_003505.1 2430-2530 
GTGCCAATCCTGACATCTCGAGGTTTCCTCACTAGACAACTCTCTTTCGCAGGCTCCTTTGAAC
AACTCAGCTCCTGCAAAAGCTTCCGTCCCTGAGGCA 
G6PD NM_000402.2 1155-1255 
ACAACATCGCCTGCGTTATCCTCACCTTCAAGGAGCCCTTTGGCACTGAGGGTCGCGGGGGC
TATTTCGATGAATTTGGGATCATCCGGGACGTGATGCA 
GABPA NM_002040.3 1160-1260 
GACCAAGTCCTGCATTGGGTGGTTTGGGTAATGAAGGAATTCAGCATGACCGATATAGACCTC
ACCACACTCAACATTTCGGGGAGAGAATTATGTAGTC 
GADD45A NM_001924.2 865-965 GTTACTCCCTACACTGATGCAAGGATTACAGAAACTGATGCCAAGGGGCTGAGTGAGTTCAACTACATGTTCTGGGGGCCCGGAGATAGATGACTTTGCA 
GADD45B NM_015675.2 365-465 TGTGGACCCAGACAGCGTGGTCCTCTGCCTCTTGGCCATTGACGAGGAGGAGGAGGATGACATCGCCCTGCAAATCCACTTCACGCTCATCCAGTCCTTC 
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GAL3ST4 NM_024637.4 1140-1240 
CGAGCCCAAACCCTCAATCCCAATGCCCTCATCCATCCTGTTTCCACTGTTACTGATCATCGCA
GCCAGATATCAAGCCCTGCCTCTTTCGATTTGGGGT 
GAS2 NM_005256.3 915-1015 GATCTCCCGTGTGGATGGCAAAACATCCCCTATCCAAAGCAAATCTCCAACTCTAAAGGACATGAATCCAGATAACTACTTGGTGGTCTCTGCCAGTTAT 
GATA2 NM_032638.3 1495-1595 
GAAGAAGGAAGGGATCCAGACTCGGAACCGGAAGATGTCCAACAAGTCCAAGAAGAGCAAGA
AAGGGGCGGAGTGCTTCGAGGAGCTGTCAAAGTGCATG 
GATA3 NM_001002295.1 2835-2935 
AAGAGTCCGGCGGCATCTGTCTTGTCCCTATTCCTGCAGCCTGTGCTGAGGGTAGCAGTGTAT
GAGCTACCAGCGTGCATGTCAGCGACCCTGGCCCGAC 
gBAD-1R-scfv SCFV001.1 1-101 AGACAGACACCCTGCTCCTCTGGGTGTCCGGCACCTGTGGCGACATCGTGATGAGCAGAAGCCCCAGCAGCCTGGCCGTGTCCGTGGGCGAGAAAGTGAC 
GEMIN2 NM_001009182.1 537-637 ACAAGCAACAGTAACTAGTGTCTTGGAATATCTGAGTAATTGGTTTGGAGAAAGAGACTTTACTCCAGAATTGGGAAGATGGCTTTATGCTTTATTGGCT 
GFI1 NM_005263.2 2235-2335 
TCATCACTGGAGGTAAAAGCACAAGCAATGCCTGTGGACAAGATGTCATTCATTCACTCAGCA
AATGTTCATGGATCACCGGCTACCAAGGTACCAGGCA 
GLIPR1 NM_006851.2 255-355 CTGCGTTCGAATCCATAACAAGTTCCGATCAGAGGTGAAACCAACAGCCAGTGATATGCTATACATGACTTGGGACCCAGCACTAGCCCAAATTGCAAAA 
GLO1 NM_006708.1 1240-1340 
GGAAATGATATGGTACCCAGACACTGGGCTAGGCTGCAACTTTATCTCATTTAATACTCCCAGC
TGTCATGTGAGAAAGAAAGCAGGCTAGGCATGTGAA 
GNLY NM_006433.2 305-405 CAGGAGCTGGGCCGTGACTACAGGACCTGTCTGACGATAGTCCAAAAACTGAAGAAGATGGTGGATAAGCCCACCCAGAGAAGTGTTTCCAATGCTGCGA 
GSK3B NM_002093.2 925-1025 ACTGATTATACCTCTAGTATAGATGTATGGTCTGCTGGCTGTGTGTTGGCTGAGCTGTTACTAGGACAACCAATATTTCCAGGGGATAGTGGTGTGGATC 
GZMA NM_006144.2 155-255 AGACCCTACATGGTCCTACTTAGTCTTGACAGAAAAACCATCTGTGCTGGGGCTTTGATTGCAAAAGACTGGGTGTTGACTGCAGCTCACTGTAACTTGA 
GZMB NM_004131.3 540-640 ACACTACAAGAGGTGAAGATGACAGTGCAGGAAGATCGAAAGTGCGAATCTGACTTACGCCATTATTACGACAGTACCATTGAGTTGTGCGTGGGGGACC 
GZMH NM_033423.3 705-805 AAAAAAGGGACACCTCCAGGAGTCTACATCAAGGTCTCACACTTCCTGCCCTGGATAAAGAGAACAATGAAGCGCCTCTAACAGCAGGCATGAGACTAAC 
HCST NM_001007469.1 132-232 ATCCTCTTCCTGCTTTTGCTCCCAGTGGCTGCAGCTCAGACGACTCCAGGAGAGAGATCATCACTCCCTGCCTTTTACCCTGGCACTTCAGGCTCTTGTT 
HDAC1 NM_004964.2 785-885 CAAGCCGGTCATGTCCAAAGTAATGGAGATGTTCCAGCCTAGTGCGGTGGTCTTACAGTGTGGCTCAGACTCCCTATCTGGGGATCGGTTAGGTTGCTTC 
HDAC2 NM_001527.1 930-1030 AAGCCTATTATCTCAAAGGTGATGGAGATGTATCAACCTAGTGCTGTGGTATTACAGTGTGGTGCAGACTCATTATCTGGTGATAGACTGGGTTGTTTCA 
HER2-scfv SCFV014.1 64-164 CCTGCAGCGCCAGCAGCAGCGTGTCCTACATGCACTGGTATCAGCAGAAGTCCGGCACTAGCCCCAAGCGGTGGATCTACGACACCTACAAGCTCGCCAG 
HERV-K          
6H5-scfv SCFV012.1 137-237 
CGGCGGCACCAGCTACAACCAGAAGTTCAAGGACAAGGCCATCCTGACCGTGGACAAGAGCA
GCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGC 
HLA-A NM_002116.5 1000-1100 
GGAAGAGCTCAGATAGAAAAGGAGGGAGTTACACTCAGGCTGCAAGCAGTGACAGTGCCCAG
GGCTCTGATGTGTCCCTCACAGCTTGTAAAGTGTGAGA 
HMGB2 NM_001130688.1 125-225 CTGTCAACATGGGTAAAGGAGACCCCAACAAGCCGCGGGGCAAAATGTCCTCGTACGCCTTCTTCGTGCAGACCTGCCGGGAAGAGCACAAGAAGAAACA 
HOPX NM_001145460.1 1117-1217 
AACAATAGGAAGCTATGTGTATCTTCTGTGTAAAGCAGTGGCTTCACTGGAAAAATGGTGTGG
CTAGCATTTCCCTTTGAGTCATGATGACAGATGGTGT 
HOXA10 NM_018951.3 1503-1603 
TTCTATAGAGATAGATATTGTCCTAAGTGTCAAGTCCTGACTGGGCTGGGTTTGCTGTCTTGGG
GTCCCACTGCTCGAAATGGCCCCTGTCTTCGGCCGA 
HOXA9 NM_152739.3 1015-1115 
GGCTCTAAACCTCAGGCCACATCTTTTCCAAGGCAAACCCTGTTCAGGCTGGCTCGTAGGCCT
GCCGCTTTGATGGAGGAGGTATTGTAAGCTTTCCATT 
HOXB3 NM_002146.4 60-160 TGTCCGTTTAAATGCTGCTGGGAGACTCGTAAAAAAATCATCGTGGACCTGGAGGATGAGAGGGGCGAGCTTTATTTCGGTCGGATTGCGGTGTGGTGGT 
HOXB4 NM_024015.4 1340-1440 
CCTTTCTTTGTCCCCCACTCCCGATACCCAGCGAAAGCACCCTCTGACTGCCAGATAGTGCAG
TGTTTTGGTCACGGTAACACACACACACTCTCCCTCA 
HPRT1 NM_000194.1 240-340 TGTGATGAAGGAGATGGGAGGCCATCACATTGTAGCCCTCTGTGTGCTCAAGGGGGGCTATAAATTCTTTGCTGACCTGCTGGATTACATCAAAGCACTG 
HRH1 NM_000861.2 3055-3155 
GTGGCAGCTCAAAATGATATGTTTGAGTAGACGAACAGCTGACATGGAGTTCCCGTGCACCTA
CGGAAGGGGACGCTTTGAAGGAACCAAGTGCATTTTT 
HRH2 NM_022304.1 600-700 GCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCGTGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGT 
Human CD19R-
scfv SCFV009.1 215-315 
CTTCACCATCAGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCAGCAGTACCAGA
GCCTGCCCTACACCTTCGGCCAGGGCACCAAGCTGCAG 
ICOS NM_012092.2 640-740 AACTCTGGCACCCAGGCATGAAGCACGTTGGCCAGTTTTCCTCAACTTGAAGTGCAAGATTCTCTTATTTCCGGGACCACGGAGAGTCTGACTTAACTAC 
ICOSLG NM_015259.4 1190-1290 
CTGCTGGCGTTGGCTGTGATCCTGGAATGAGGCCCTTTCAAAAGCGTCATCCACACCAAAGG
CAAATGTCCCCAAGTGAGTGGGCTCCCCGCTGTCACTG 
ID2 NM_002166.4 505-605 CGGATATCAGCATCCTGTCCTTGCAGGCTTCTGAATTCCCTTCTGAGTTAATGTCAAATGACAGCAAAGCACTGTGTGGCTGAATAAGCGGTGTTCATGA 
ID3 NM_002167.3 195-295 AGGAAGCCTGTTTGCAATTTAAGCGGGCTGTGAACGCCCAGGGCCGGCGGGGGCAGGGCCGAGGCGGGCCATTTTGAATAAAGAGGCGTGCCTTCCAGGC 
IDO1 NM_002164.3 50-150 CTATTATAAGATGCTCTGAAAACTCTTCAGACACTGAGGGGCACCAGAGGAGCAGACTACAAGAATGGCACACGCTATGGAAAACTCCTGGACAATCAGT 
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IFNA1 NM_024013.1 585-685 ATCCCTCTCTTTATCAACAAACTTGCAAGAAAGATTAAGGAGGAAGGAATAACATCTGGTCCAACATGAAAACAATTCTTATTGACTCATACACCAGGTC 
IFNG NM_000619.2 970-1070 ATACTATCCAGTTACTGCCGGTTTGAAAATATGCCTGCAATCTGAGCCAGTGCTTTAATGGCATGTCAGACAGAACTTGAATGTGTCAGGTGACCCTGAT 
IFNGR1 NM_000416.1 1140-1240 
CCCGGGCAGCCATCTGACTCCAATAGAGAGAGAGAGTTCTTCACCTTTAAGTAGTAACCAGTC
TGAACCTGGCAGCATCGCTTTAAACTCGTATCACTCC 
IGF1R NM_000875.2 455-555 TCGGGGGGCCATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATCCTGGATGCGGTGTCCAATAACTACATTGTG 
IKZF1 NM_006060.3 4485-4585 
CCGCTGTGTACTACTGTGTGCCTAGATTCCATGCACTCTCGTTGTGTTTGAAGTAAATATTGGA
GACCGGAGGGTAACAGGTTGGCCTGTTGATTACAGC 
IKZF2 NM_001079526.1 945-1045 CCATGTACCTCCTATGGAAGATTGTAAGGAACAAGAGCCTATTATGGACAACAATATTTCTCTGGTGCCTTTTGAGAGACCTGCTGTCATAGAGAAGCTC 
IL10 NM_000572.2 230-330 AAGGATCAGCTGGACAACTTGTTGTTAAAGGAGTCCTTGCTGGAGGACTTTAAGGGTTACCTGGGTTGCCAAGCCTTGTCTGAGATGATCCAGTTTTACC 
IL10RA NM_001558.2 150-250 TGCCCAGCCCTCCGTCTGTGTGGTTTGAAGCAGAATTTTTCCACCACATCCTCCACTGGACACCCATCCCAAATCAGTCTGAAAGTACCTGCTATGAAGT 
IL12A NM_000882.2 775-875 CTTTCTAGATCAAAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAAATCCTCCCTTGAAGAACCG 
IL12B NM_002187.2 1435-1535 
GCAAGGCTGCAAGTACATCAGTTTTATGACAATCAGGAAGAATGCAGTGTTCTGATACCAGTG
CCATCATACACTTGTGATGGATGGGAACGCAAGAGAT 
IL12RB1 NM_005535.1 1292-1392 
AGGAAAAGTGTTACTACATTACCATCTTTGCCTCTGCGCACCCCGAGAAGCTCACCTTGTGGT
CTACGGTCCTGTCCACCTACCACTTTGGGGGCAATGC 
IL12RB2 NM_001559.2 1315-1415 
CCTCCGTGGGACATTAGAATCAAATTTCAAAAGGCTTCTGTGAGCAGATGTACCCTTTATTGGA
GAGATGAGGGACTGGTACTGCTTAATCGACTCAGAT 
IL13 NM_002188.2 516-616 TTTCTTTCTGATGTCAAAAATGTCTTGGGTAGGCGGGAAGGAGGGTTAGGGAGGGGTAAAATTCCTTAGCTTAGACCTCAGCCTGTGCTGCCCGTCTTCA 
IL15 NM_172174.1 1685-1785 
AGGGTGATAGTCAAATTATGTATTGGTGGGGCTGGGTACCAATGCTGCAGGTCAACAGCTATG
CTGGTAGGCTCCTGCCAGTGTGGAACCACTGACTACT 
IL15RA NM_002189.2 39-139 CGCTCGCCCGGGGAGTCCAGCGGTGTCCTGTGGAGCTGCCGCCATGGCCCCGCGGCGGGCGCGCGGCTGCCGGACCCTCGGTCTCCCGGCGCTGCTACTG 
IL17A NM_002190.2 240-340 TACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATATCCCTCTGTGATCTGGGAGGCAAAGTGCCGCCACTTGGGCT 
IL17F NM_052872.3 210-310 GCCCGCCTGTGCCAGGAGGTAGTATGAAGCTTGACATTGGCATCATCAATGAAAACCAGCGCGTTTCCATGTCACGTAACATCGAGAGCCGCTCCACCTC 
IL17RA NM_014339.4 3020-3120 
CTACTATGTGGCGGGCATTTGGGATACCAAGATAAATTGCATGCGGCATGGCCCCAGCCATGA
AGGAACTTAACCGCTAGTGCCGAGGACACGTTAAACG 
IL18 NM_001562.2 48-148 GACAGTCAGCAAGGAATTGTCTCCCAGTGCATTTTGCCCTCCTGGCTGCCAACTCTGGCTGCTAAAGCGGCTGCCACCTGCTGCAGTCTACACAGCTTCG 
IL18R1 NM_003855.2 2025-2125 
GAATGAGGGGATTTTAAGTGTCTGAAGAGGCATTTTCTAGGGACCAGTGGGTGACTGAGTAAC
TGAAATGCTGCTTTCACTCCCTAACACCATGGATCTG 
IL18RAP NM_003853.2 2412-2512 
GCTTGATGGACAATGGAGTGGGATTGAGACTGTGGTTTAGAGCCTTTGATTTCCTGGACTGGA
CTGACGGCGAGTGAATTCTCTAGACCTTGGGTACTTT 
IL1A NM_000575.3 1085-1185 
ACTCCATGAAGGCTGCATGGATCAATCTGTGTCTCTGAGTATCTCTGAAACCTCTAAAACATCC
AAGCTTACCTTCAAGGAGAGCATGGTGGTAGTAGCA 
IL1B NM_000576.2 840-940 GGGACCAAAGGCGGCCAGGATATAACTGACTTCACCATGCAATTTGTGTCTTCCTAAAGAGAGCTGTACCCAGAGAGTCCTGTGCTGAATGTGGACTCAA 
IL2 NM_000586.2 300-400 AGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACAAACAGTGCACCTACTTCAAGTTCTACAAAGAAAACACAGCTACAACTGGAGC 
IL21R NM_021798.2 2080-2180 
CGTGTTTGTGGTCAACAGATGACAACAGCCGTCCTCCCTCCTAGGGTCTTGTGTTGCAAGTTG
GTCCACAGCATCTCCGGGGCTTTGTGGGATCAGGGCA 
IL22 NM_020525.4 319-419 CTATCTGATGAAGCAGGTGCTGAACTTCACCCTTGAAGAAGTGCTGTTCCCTCAATCTGATAGGTTCCAGCCTTATATGCAGGAGGTGGTGCCCTTCCTG 
IL23A NM_016584.2 411-511 CAGGGACAACAGTCAGTTCTGCTTGCAAAGGATCCACCAGGGTCTGATTTTTTATGAGAAGCTGCTAGGATCGGATATTTTCACAGGGGAGCCTTCTCTG 
IL23R NM_144701.2 710-810 AACTGCAAATTCACCTGGATGATATAGTGATACCTTCTGCAGCCGTCATTTCCAGGGCTGAGACTATAAATGCTACAGTGCCCAAGACCATAATTTATTG 
IL27 NM_145659.3 143-243 CAGGAGCTGCGGAGGGAGTTCACAGTCAGCCTGCATCTCGCCAGGAAGCTGCTCTCCGAGGTTCGGGGCCAGGCCCACCGCTTTGCGGAATCTCACCTGC 
IL2RA NM_000417.1 1000-1100 
CTTGGTAAGAAGCCGGGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAATCAAAGGTGCT
AAATGGTCGCCCAGGAGACATCCGTTGTGCTTGCCTGC 
IL2RB NM_000878.2 1980-2080 
GTCCTGCTGCCCGAGCCAGGAACTGTGTGTGTTGCAGGGGGGCAGTAACTCCCCAACTCCCT
CGTTAATCACAGGATCCCACGAATTTAGGCTCAGAAGC 
IL2RG NM_000206.1 595-695 CCACAGCTGGACTGAACAATCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACGTTTCGTGTTCGGAGCCGCTTT 
IL4 NM_000589.2 625-725 GACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCACAAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGG 
IL4R NM_000418.2 705-805 ATCATCTCACCTATGCAGTCAACATTTGGAGTGAAAACGACCCGGCAGATTTCAGAATCTATAACGTGACCTACCTAGAACCCTCCCTCCGCATCGCAGC 
IL5 NM_000879.2 105-205 CCACAGAAATTCCCACAAGTGCATTGGTGAAAGAGACCTTGGCACTGCTTTCTACTCATCGAACTCTGCTGATAGCCAATGAGACTCTGAGGATTCCTGT 
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IL6 NM_000600.1 220-320 TGACAAACAAATTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAAGAGTAACATGTGTGAAAGCAGCAAAGAGGCACTGGCA 
IL6R NM_000565.2 993-1093 CTTTCTACATAGTGTCCATGTGCGTCGCCAGTAGTGTCGGGAGCAAGTTCAGCAAAACTCAAACCTTTCAGGGTTGTGGAATCTTGCAGCCTGATCCGCC 
IL7R NM_002185.2 1610-1710 
TTGCTTTGACCACTCTTCCTGAGTTCAGTGGCACTCAACATGAGTCAAGAGCATCCTGCTTCTA
CCATGTGGATTTGGTCACAAGGTTTAAGGTGACCCA 
IL9 NM_000590.1 300-400 AAGTACTAAAGAACAACAAGTGTCCATATTTTTCCTGTGAACAGCCATGCAACCAAACCACGGCAGGCAACGCGCTGACATTTCTGAAGAGTCTTCTGGA 
IRF1 NM_002198.1 510-610 CTGTGCGAGTGTACCGGATGCTTCCACCTCTCACCAAGAACCAGAGAAAAGAAAGAAAGTCGAAGTCCAGCCGAGATGCTAAGAGCAAGGCCAAGAGGAA 
IRF2 NM_002199.2 1375-1475 
CAGTACCTGGAGCTTCTCTTTAACTCAGGACTCCAGCCCATTGGTAGACGTGTGTTTCTAGAG
CCTGCTGGATCTCCCAGGGCTACTCACTCAAGTTCAA 
IRF4 NM_002460.1 325-425 GGGCACTGTTTAAAGGAAAGTTCCGAGAAGGCATCGACAAGCCGGACCCTCCCACCTGGAAGACGCGCCTGCGGTGCGCTTTGAACAAGAGCAATGACTT 
ITCH NM_031483.4 155-255 ACTGTGAGAACTTCAGGTTTTCCAACCTATTGGTGGTATGTCTGACAGTGGATCACAACTTGGTTCAATGGGTAGCCTCACCATGAAATCACAGCTTCAG 
ITGA1 NM_181501.1 1875-1975 
AAGTGGCAAGACTATAAGGAAAGAGTATGCACAACGTATTCCATCAGGTGGGGATGGTAAGAC
ACTGAAATTTTTTGGCCAGTCTATCCACGGAGAAATG 
ITGA4 NM_000885.4 975-1075 GCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCCGGGGCGATTTACAGATGCAGGATCGGAAAGAATCCCGGCCAGACGTGCGAACAGCTC 
ITGA5 NM_002205.2 925-1025 AGAAGACTTTGTTGCTGGTGTGCCCAAAGGGAACCTCACTTACGGCTATGTCACCATCCTTAATGGCTCAGACATTCGATCCCTCTACAACTTCTCAGGG 
ITGAL NM_002209.2 3905-4005 
GTGAGGGCTTGTCATTACCAGACGGTTCACCAGCCTCTCTTGGTTTCCTTCCTTGGAAGAGAA
TGTCTGATCTAAATGTGGAGAAACTGTAGTCTCAGGA 
ITGAM NM_000632.3 515-615 GCCCTCCGAGGGTGTCCTCAAGAGGATAGTGACATTGCCTTCTTGATTGATGGCTCTGGTAGCATCATCCCACATGACTTTCGGCGGATGAAGGAGTTTG 
ITGAX NM_000887.3 700-800 CCCCTCAGCCTGTTGGCTTCTGTTCACCAGCTGCAAGGGTTTACATACACGGCCACCGCCATCCAAAATGTCGTGCACCGATTGTTCCATGCCTCATATG 
ITGB1 NM_033666.2 2000-2100 
TTTTAACATTACCAAGGTAGAAAGTCGGGACAAATTACCCCAGCCGGTCCAACCTGATCCTGT
GTCCCATTGTAAGGAGAAGGATGTTGACGACTGTTGG 
ITGB7 NM_000889.1 1278-1378 
CAACGTGGTACAGCTCATCATGGATGCTTATAATAGCCTGTCTTCCACCGTGACCCTTGAACA
CTCTTCACTCCCTCCTGGGGTCCACATTTCTTACGAA 
ITK NM_005546.3 3430-3530 
GCCAGTAAAGAAGTCAGTATAGAACCACTAGCGAATAGTGTTGCTCTGGCACAGACCACTGTG
GTTGATGGCATGGCCCTCCAACTTGGAATAGGATTTT 
JAK1 NM_002227.1 285-385 GAGAACACCAAGCTCTGGTATGCTCCAAATCGCACCATCACCGTTGATGACAAGATGTCCCTCCGGCTCCACTACCGGATGAGGTTCTATTTCACCAATT 
JAK2 NM_004972.2 455-555 CTCCTCCCGCGACGGCAAATGTTCTGAAAAAGACTCTGCATGGGAATGGCCTGCCTTACGATGACAGAAATGGAGGGAACATCCACCTCTTCTATATATC 
JAK3 NM_000215.2 1715-1815 
GTGCTGCTGAAGGTCATGGATGCCAAGCACAAGAACTGCATGGAGTCATTCCTGGAAGCAGC
GAGCTTGATGAGCCAAGTGTCGTACCGGCATCTCGTGC 
JUN NM_002228.3 140-240 ACACAGCCAGCCAGCCAGGTCGGCAGTATAGTCCGAACTGCAAATCTTATTTTCTTTTCACCTTCTCTCTAACTGCCCAGAGCTAGCGCCTGTGGCTCCC 
JUNB NM_002229.2 1155-1255 
GCGCGCCTGGAGGACAAGGTGAAGACGCTCAAGGCCGAGAACGCGGGGCTGTCGAGTACCG
CCGGCCTCCTCCGGGAGCAGGTGGCCCAGCTCAAACAGA 
KIR2DL1 NM_014218.2 881-981 GCAGGAAACAGAACAGCGAATAGCGAGGACTCTGATGAACAAGACCCTCAGGAGGTGACATACACACAGTTGAATCACTGCGTTTTCACACAGAGAAAAA 
KIR2DL2 NM_014219.2 814-914 TCTCCTTCATCGCTGGTGCTCCAACAAAAAAAATGCTGCGGTAATGGACCAAGAGTCTGCAGGGAACAGAACAGCGAATAGCGAGGACTCTGATGAACAA 
KIR2DL3 NM_015868.2 741-841 CTCCGAAACCGGTAACCCCAGACACCTGCATGTTCTGATTGGGACCTCAGTGGTCATCATCCTCTTCATCCTCCTCCTCTTCTTTCTCCTTCATCGCTGG 
KIR2DL4 NM_002255.5 15-115 GCGTCCTGGCAGCAGAAGCTGCACCATGTCCATGTCACCCACGGTCATCATCCTGGCATGTCTTGGGTTCTTCTTGGACCAGAGTGTGTGGGCACACGTG 
KIR2DL5A NM_020535.3 1451-1551 
GACACGTGCTGTTCCACCTTCCCTCATGCTGTTTCACCTTTCCTCAGACTATTTTCCAGCCTTC
TGTCAGTCAGCAGTGAAACTTATAAAATTTTTTGTG 
KIR2DS1 NM_014512.1 698-798 CTTCACCCACTGAACCAAGCTCCGAAACCGGTAACCCCAGACACCTACATGTTCTGATTGGGACCTCAGTGGTCAAAATCCCTTTCACCATCCTCCTCTT 
KIR2DS2 NM_012312.2 856-956 CAAGAGCCTGCAGGGAACAGAACAGTGAACAGCGAGGATTCTGATGAACAAGACCATCAGGAGGTGTCATACGCATAATTGGATCACTGTGTTTTCACAC 
KIR2DS3 NM_012313.1 693-793 GGCCTTCACCCACTGAACCAAGCTCCAAAACCGGTAACCCCAGACACCTACACGTTCTGATTGGGACCTCAGTGGTCAAACTCCCTTTCACCATCCTCCT 
KIR2DS4 NM_012314.3 1427-1527 
ACATACAAGAGGCTGCCTCTTAACACAGCACTTAGACACGTGCTGTTCCACCTCCCTTCAGAC
TATCTTTCAGCCTTCTGCCAGCAGTAAAACTTATAAA 
KIR2DS5 NM_014513.2 204-304 CTTCCTTCTGCACAGAGAGGGGACGTTTAACCACACTTTGCGCCTCATTGGAGAGCACATTGATGGGGTCTCCAAGGGCAACTTCTCCATCGGTCGCATG 
KIR3DL1 NM_013289.2 1054-1154 
CCAAATCTGGTAACCCCAGACACCTGCACATTCTGATTGGGACCTCAGTGGTCATCATCCTCT
TCATCCTCCTCCTCTTCTTTCTCCTTCATCTCTGGTG 
KIR3DL2 NM_006737.2 884-984 TGCCACCCACGGAGGGACCTACAGATGCTTCGGCTCTTTCCGTGCCCTGCCCTGCGTGTGGTCAAACTCAAGTGACCCACTGCTTGTTTCTGTCACAGGA 
KIR3DL3 NM_153443.3 508-608 CCTTGCGCCTCGTTGGACAGCTCCACGATGCGGGTTCCCAGGTCAACTATTCCATGGGTCCCATGACACCTGCCCTTGCAGGGACCTACAGATGCTTTGG 
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KIR3DS1 NM_001083539.1 1000-1100 
CTCCAAATCTGGTAACCTCAGACACCTGCACATTCTGATTGGGACCTCAGTGGTCAAAATCCC
TTTCACCATCCTCCTCTTCTTTCTCCTTCATCGCTGG 
KIT NM_000222.1 5-105 CATCGCAGCTACCGCGATGAGAGGCGCTCGCGGCGCCTGGGATTTTCTCTGCGTTCTGCTCCTACTGCTTCGCGTCCAGACAGGCTCTTCTCAACCATCT 
KLF10 NM_005655.1 570-670 GCTCAGGCAACAAGTGTGATTCGTCATACAGCTGATGCCCAGCTATGTAACCACCAGACCTGCCCAATGAAAGCAGCCAGCATCCTCAACTATCAGAACA 
KLF2 NM_016270.2 1015-1115 
GGAAGTTTGCGCGCTCAGACGAGCTCACGCGCCACTACCGAAAGCACACGGGCCACCGGCC
ATTCCAGTGCCATCTGTGCGATCGTGCCTTCTCGCGCTC 
KLF4 NM_004235.4 1980-2080 
CGAGCATTTTCCAGGTCGGACCACCTCGCCTTACACATGAAGAGGCATTTTTAAATCCCAGAC
AGTGGATATGACCCACACTGCCAGAAGAGAATTCAGT 
KLF6 NM_001008490.1 1165-1265 
GGGATGCGTGTTCCAGCCAAAGCATGCCGTTCTGCACCCTACCCAGTTGCCTCCAGGGCCTC
TCCTTGGAAGGTCTTTTGAGGGCTAAAAAGGTCCTGTA 
KLF7 NM_001270943.1 1546-1646 
GTACTATTGAGATCTTTCGCGTCGATCCCAACGGCCTTAGCGGCGGCAGACTGGAATAACACC
TTACACCTTTCTGGCCTGCATTTCTGTAGACTTCACT 
KLRAP1 NR_028045.1 414-514 CCTTCAGAGTCACAGAATAGATTAAGGCCTGATGATACTCAAAGGCCTGGGAAAACTGATGACAAAGAATTTTCAGTGCCCTGGCACCTCATTGCAGTGA 
KLRB1 NM_002258.2 85-185 TGAGTTAAACTTACCCACAGACTCAGGCCCAGAAAGTTCTTCACCTTCATCTCTTCCTCGGGATGTCTGTCAGGGTTCACCTTGGCATCAATTTGCCCTG 
KLRC1 NM_002259.3 335-435 ACCTATCACTGCAAAGATTTACCATCAGCTCCAGAGAAGCTCATTGTTGGGATCCTGGGAATTATCTGTCTTATCTTAATGGCCTCTGTGGTAACGATAG 
KLRC2 NM_002260.3 942-1042 TATGTGAGTCAGCTTATAGGAAGTACCAAGAACAGTCAAACCCATGGAGACAGAAAGTAGAATAGTGGTTGCCAATGTCTCAGGGAGGTTGAAATAGGAG 
KLRC3 NM_002261.2 760-860 ACTCCTGAGCTCAAGAAATCAACACATCTTGGCCTCCCAAGTTGCTGGGATTACTGACACAAGCCACCGCCCCTGAGTGCTCATGTACCATTTAGCTTGT 
KLRC4 NM_013431.2 29-129 TTATATTGGTCAACAGCAAAATGAACATTACTACTCAGCCTCCAACACATGCAGTTTGCCTATACCAGGGATCCTGTCAAAATATACACCACTTATAGCT 
KLRD1 NM_002262.3 542-642 AGCCTGCTTCAGCTTCAAAACACAGATGAACTGGATTTTATGAGCTCCAGTCAACAATTTTACTGGATTGGACTCTCTTACAGTGAGGAGCACACCGCCT 
KLRF1 NM_016523.1 275-375 AAAAAGGAAGTTGTTCAAATGCCACTCAGTATGAGGACACTGGAGATCTAAAAGTGAATAATGGCACAAGAAGAAATATAAGTAATAAGGACCTTTGTGC 
KLRG1 NM_005810.3 45-145 TGCCTACGGCAACCCAAGCCCAGAATGACTATGGACCACAGCAAAAATCTTCCTCTTCCAGGCCTTCTTGTTCTTGCCTTGTGGCAATAGCTTTGGGGCT 
KLRK1 NM_007360.1 760-860 GGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTC 
LAG3 NM_002286.5 1735-1835 
CTTTTGGTGACTGGAGCCTTTGGCTTTCACCTTTGGAGAAGACAGTGGCGACCAAGACGATTT
TCTGCCTTAGAGCAAGGGATTCACCCTCCGCAGGCTC 
LAIR1 NM_002287.3 1195-1295 
GCACCTGAGGGTAGAAAGTCACTCTAGGAAAAGCCTGAAGCAGCCATTTGGAAGGCTTCCTG
TTGGATTCCTCTTCATCTAGAAAGCCAGCCAGGCAGCT 
LAT NM_001014987.1 1290-1390 
TGTGTAATAGAATAAAGGCCTGCGTGTGTCTGTGTTGAGCGTGCGTCTGTGTGTGCCTGTGTG
CGAGTCTGAGTCAGAGATTTGGAGATGTCTCTGTGTG 
LAT2 NM_014146.3 1863-1963 
TGCAGAGCTGATTAAACAGTGTTGTGACTGTCTCATGGGAAGAGCTGGGGCCCAGAGGGACC
TTGAGTCAGAAATGTTGCCAGAAAAAGTATCTCCTCCA 
LCK NM_005356.2 1260-1360 
ATTAAGTGGACAGCGCCAGAAGCCATTAACTACGGGACATTCACCATCAAGTCAGATGTGTGG
TCTTTTGGGATCCTGCTGACGGAAATTGTCACCCACG 
LDHA NM_005566.1 985-1085 CAGAATGGAATCTCAGACCTTGTGAAGGTGACTCTGACTTCTGAGGAAGAGGCCCGTTTGAAGAAGAGTGCAGATACACTTTGGGGGATCCAAAAGGAGC 
LEF1 NM_016269.3 1165-1265 
CCGTCACACATCCCATCAGATGTCAACTCCAAACAAGGCATGTCCAGACATCCTCCAGCTCCT
GATATCCCTACTTTTTATCCCTTGTCTCCGGGTGGTG 
LGALS1 NM_002305.3 60-160 GGTGCGCCTGCCCGGGAACATCCTCCTGGACTCAATCATGGCTTGTGGTCTGGTCGCCAGCAACCTGAATCTCAAACCTGGAGAGTGCCTTCGAGTGCGA 
LGALS3 NM_002306.2 120-220 CAGCCGTCCGGAGCCAGCCAACGAGCGGAAAATGGCAGACAATTTTTCGCTCCATGATGCGTTATCTGGGTCTGGAAACCCAAACCCTCAAGGATGGCCT 
LIFR NM_002310.3 2995-3095 
CCTATTGTCCACCCATCATTGAGGAAGAAATACCAAACCCAGCCGCAGATGAAGCTGGAGGGA
CTGCACAGGTTATTTACATTGATGTTCAGTCGATGTA 
LILRB1 NM_001081637.1 2332-2432 
AGCTGAGAAAACTAAGTCAGAAAGTGCATTAAACTGAATCACAATGTAAATATTACACATCAAG
CGATGAAACTGGAAAACTACAAGCCACGAATGAATG 
LOC282997 NR_026932.1 665-765 TGATCACATTCTACCTGGCATTATTTCATCTGAGTCCCTGTCCTAGCCCTTCTGCCCATTAGACTGTAACCTTGTTTAGGGAAAGACCTGTGTCTTACTC 
LRP5 NM_002335.1 2515-2615 
TGGACACCAACATGATCGAGTCGTCCAACATGCTGGGTCAGGAGCGGGTCGTGATTGCCGAC
GATCTCCCGCACCCGTTCGGTCTGACGCAGTACAGCGA 
LRP6 NM_002336.1 2185-2285 
CTTAGATTATCCAGAAGGCATGGCAGTAGACTGGCTTGGGAAGAACTTGTACTGGGCAGACAC
AGGAACGAATCGAATTGAGGTGTCAAAGTTGGATGGG 
LRRC32 NM_005512.2 3470-3570 
CACCCTGGTGTGGGTTCTCCTGTTCTCTCTGTGCTCTTGCATTCTCTCATTCCCTTTTCCTCTAT
TGAGCAGAGCCTGGAGTTTGAGACTATGGAATCCA 
LTA NM_000595.2 885-985 CTGATCAAGTCACCGGAGCTTTCAAAGAAGGAATTCTAGGCATCCCAGGGGACCACACCTCCCTGAACCATCCCTGATGTCTGTCTGGCTGAGGATTTCA 
LTBR NM_002342.1 1435-1535 
CTAACAGGGGCCCAAGGAACCAATTTATCACCCATGACTGACGGAGTCTGAGAAAAGGCAGA
AGAAGGGGGGCACAAGGGCACTTTCTCCCTTGAGGCTG 
LYN NM_002350.1 1285-1385 
TCCTGAAGAGCGATGAAGGTGGCAAAGTGCTGCTTCCAAAGCTCATTGACTTTTCTGCTCAGA
TTGCAGAGGGAATGGCATACATCGAGCGGAAGAACTA 
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MAD1L1 NM_003550.2 306-406 GAAGACCTGGGGGAAAACACCATGGTTTTATCCACCCTGAGATCTTTGAACAACTTCATCTCTCAGCGTGTGGAGGGAGGCTCTGGACTGGATATTTCTA 
MAP2K1 NM_002755.2 970-1070 ACGGAATGGACAGCCGACCTCCCATGGCAATTTTTGAGTTGTTGGATTACATAGTCAACGAGCCTCCTCCAAAACTGCCCAGTGGAGTGTTCAGTCTGGA 
MAPK14 NM_001315.1 450-550 TGGGCTCTGGCGCCTATGGCTCTGTGTGTGCTGCTTTTGACACAAAAACGGGGTTACGTGTGGCAGTGAAGAAGCTCTCCAGACCATTTCAGTCCATCAT 
MAPK3 NM_002746.2 580-680 AACGTGCTCCACCGAGATCTAAAGCCCTCCAACCTGCTCATCAACACCACCTGCGACCTTAAGATTTGTGATTTCGGCCTGGCCCGGATTGCCGATCCTG 
MAPK8 NM_139049.1 945-1045 TCTCTGTAGATGAAGCTCTCCAACACCCGTACATCAATGTCTGGTATGATCCTTCTGAAGCAGAAGCTCCACCACCAAAGATCCCTGACAAGCAGTTAGA 
MBD2 NM_003927.3 2015-2115 
ATTTACATTCAACTCTGATCCCTGGGCCTTAGGTTTGACATGGAGGTGGAGGAAGATAGCGCA
TATATTTGCAGTATGAACTATTGCCTCTGGACGTTGT 
MCL1 NM_021960.3 1260-1360 
GCTGTAACTTCCTAGAGTTGCACCCTAGCAACCTAGCCAGAAAAGCAAGTGGCAAGAGGATTA
TGGCTAACAAGAATAAATACATGGGAAGAGTGCTCCC 
MIF NM_002415.1 319-419 TCCTACAGCAAGCTGCTGTGCGGCCTGCTGGCCGAGCGCCTGCGCATCAGCCCGGACAGGGTCTACATCAACTATTACGACATGAACGCGGCCAATGTGG 
MMP14 NM_004995.2 1470-1570 
GACAAGATTGATGCTGCTCTCTTCTGGATGCCCAATGGAAAGACCTACTTCTTCCGTGGAAAC
AAGTACTACCGTTTCAACGAAGAGCTCAGGGCAGTGG 
MPL NM_005373.2 895-995 CAGTGGCACTTGGACTGCAATGCTTTACCTTGGACCTGAAGAATGTTACCTGTCAATGGCAGCAACAGGACCATGCTAGCTCCCAAGGCTTCTTCTACCA 
MTOR NM_004958.2 5095-5195 
TTAGTGTTGCTCCTGGGAGTTGATCCGTCTCGGCAACTTGACCATCCTCTGCCAACAGTTCAC
CCTCAGGTGACCTATGCCTACATGAAAAACATGTGGA 
MXD1 NM_002357.2 880-980 GAGAATAAAGCTGCAGGACAGTCACAAGGCGTGTCTTGGTCTCTAAGAGAGTGGGCACTGCGGCTGTCTCCTTGAAGGTTCTCCCTGTTGGTTCTGATTA 
MYB NM_005375.2 3145-3245 
AACTGTTGCATGGATCCTGTGTTTGCAACTGGGGAGACAGAAACTGTGGTTGATAGCCAGTCA
CTGCCTTAAGAACATTTGATGCAAGATGGCCAGCACT 
MYC NM_002467.3 1610-1710 
TCGGACACCGAGGAGAATGTCAAGAGGCGAACACACAACGTCTTGGAGCGCCAGAGGAGGA
ACGAGCTAAAACGGAGCTTTTTTGCCCTGCGTGACCAGA 
MYO6 NM_004999.3 6655-6755 
AAGTTGGGGAGATGGCACCTTCTCAGAGGATTGTGAAAATATGAGGAAGAAACAAAACAGTGC
ATGTAGGAGCACAGGGCCACACAAAGGCATTCTATTG 
NANOG NM_024865.2 1100-1200 
CTACTCCATGAACATGCAACCTGAAGACGTGTGAAGATGAGTGAAACTGATATTACTCAATTTC
AGTCTGGACACTGGCTGAATCCTTCCTCTCCCCTCC 
NBEA NM_015678.3 8645-8745 
CTGAGAGCCCTTGAAGGACCAGAAAACTGCTTATTCCCACGCTTGATATCTGTCTCCAGCGAA
GGCCACTGTATCATATACTATGAACGAGGGCGATTCA 
NCAM1 NM_000615.5 1620-1720 
GGTATTTGCCTATCCCAGTGCCACGATCTCATGGTTTCGGGATGGCCAGCTGCTGCCAAGCTC
CAATTACAGCAATATCAAGATCTACAACACCCCCTCT 
NCL NM_005381.2 1492-1592 
GAACAGAGATCGATGGGCGATCTATTTCCCTGTACTATACTGGAGAGAAAGGTCAAAATCAAG
ACTATAGAGGTGGAAAGAATAGCACTTGGAGTGGTGA 
NCR1 NM_001145457.1 145-245 TTTCATGGTTCCAAAGGAAAAGCAAGTGACCATCTGTTGCCAGGGAAATTATGGGGCTGTTGAATACCAGCTGCACTTTGAAGGAAGCCTTTTTGCCGTG 
NCR2 NM_004828.3 798-898 CTTCAACAGGTCACGGACCTTCCCTGGACCTCAGTTTCCTCACCTGTAGAGAGAGAAATATTATATCACACTGTTGCAAGGACTAAGATAAGCGATGATG 
NCR3 NM_147130.1 50-150 GCATCTGTCCTCTCTCCTCAGGGAGGCAAGCATTTGATGCTCGAGGTCCCTGGCAGTTGTGGTCCTTGGCAAGTGATGTGTGAGTCCCGTGTGTCATAGG 
NCRNA00185 NR_001544.2 143-243 GAGGCTGTCTGCCAACATCTTTCATCACTCTGCCTGCAACTATGAAAAATTTAGTTCTAAAAAATGCAACCTTGCTAAATTGAGTACTAATAGGATTGGT 
NEIL1 NM_024608.2 1675-1775 
TTAGCAGGAGGCTCTCCTTGCTTGCACTCACCCTTTCTTATTGTCTTGCCCTGCATCTGGGGG
TCTGAATTTTTGGGAGCAGGCAATATCTGAAGGTGCA 
NEIL2 NM_145043.2 2570-2670 
GCCCGGTGGTGTGTAGAGAAAAGCTGCTTGTTTACTCCTTAAGTCAATGTATTGGTGACTGTT
GATTTGTTGAACAATTCAGGAATCAAGGGCTGTGGAG 
NFAT5 NM_173214.1 3290-3390 
CCCTGACAACTATTCAAACCCAGGACATCTCACAGCCTGGTACTTTTCCAGCAGTTTCTGCTTC
TAGTCAGCTGCCCAACAGCGATGCACTATTGCAGCA 
NFATC1 NM_172390.1 2510-2610 
CCAGTACCAGCGTTTCACCTACCTTCCCGCCAACGGTAACGCCATCTTTCTAACCGTAAGCCG
TGAACATGAGCGCGTGGGGTGCTTTTTCTAAAGACGC 
NFATC2 NM_012340.3 1815-1915 
GACGGACATTGGAAGAAAGAACACGCGGGTGAGACTGGTTTTCCGAGTTCACATCCCAGAGT
CCAGTGGCAGAATCGTCTCTTTACAGACTGCATCTAAC 
NFATC3 NM_004555.2 2190-2290 
GTCCTTGAAGTTCCTCCATATCATAACCCAGCAGTTACAGCTGCAGTGCAGGTGCACTTTTATC
TTTGCAATGGCAAGAGGAAAAAAAGCCAGTCTCAAC 
NFKB1 NM_001165412.1 2305-2405 
CTTGGGTAACTCTGTTTTGCACCTAGCTGCCAAAGAAGGACATGATAAAGTTCTCAGTATCTTA
CTCAAGCACAAAAAGGCAGCACTACTTCTTGACCAC 
NOS2 NM_000625.4 605-705 TTGCCTGGGGTCCATTATGACTCCCAAAAGTTTGACCAGAGGACCCAGGGACAAGCCTACCCCTCCAGATGAGCTTCTACCTCAAGCTATCGAATTTGTC 
NOTCH1 NM_017617.3 735-835 CTGCCAGGCTTCACCGGCCAGAACTGTGAGGAAAATATCGACGATTGTCCAGGAAACAACTGCAAGAACGGGGGTGCCTGTGTGGACGGCGTGAACACCT 
NR3C1 NM_001018077.1 1665-1765 
GCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAACTCGAATGAGGACTG
CAAGCCTCTCATTTTACCGGACACTAAACCCAAAATT 
NR4A1 NM_002135.3 155-255 CGGCCGGGTAGGGTGCAGCCTGAGGCTTGTTCAGCAGAACAGGTGCAAGCCACATTGTTGCCAAGACCTGCCTGAAGCCGGATTCTCCCCACTGCCTCCT 
NREP NM_001142474.1 990-1090 AAACTCATTGTTTCCTTGTGGTAAGTGACCGAGATGCTGCCACAGGACCTGAGACACTGATGAATGGTGCTATTTTGGACTTTCAACATGCTCCTTGGCG 
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NRIP1 NM_003489.2 335-435 TGACTCATGGAGAAGAGCTTGGCTCTGATGTGCACCAGGATTCTATTGTTTTAACTTACCTAGAAGGATTACTAATGCATCAGGCAGCAGGGGGATCAGG 
NRP1 NM_003873.5 370-470 GCCTCGCTGCTTTCTTTTCTCCAAGACGGGCTGAGGATTGTACAGCTCTAGGCGGAGTTGGGGCTCTTCGGATCGCTTAGATTCTCCTCTTTGCTGCATT 
NT5E NM_002526.2 1214-1314 
ATTCGGGTTTTGAAATGGATAAACTCATCGCTCAGAAAGTGAGGGGTGTGGACGTCGTGGTG
GGAGGACACTCCAACACATTTCTTTACACAGGCAATCC 
OAZ1 NM_004152.2 313-413 GGTGGGCGAGGGAATAGTCAGAGGGATCACAATCTTTCAGCTAACTTATTCTACTCCGATGATCGGCTGAATGTAACAGAGGAACTAACGTCCAACGACA 
OPTN NM_001008211.1 625-725 TGAAGCTAAATAATCAAGCCATGAAAGGGAGATTTGAGGAGCTTTCGGCCTGGACAGAGAAACAGAAGGAAGAACGCCAGTTTTTTGAGATACAGAGCAA 
P2RX7 NM_002562.4 340-440 AGTTGGTGCACAGTGTCTTTGACACCGCAGACTACACCTTCCCTTTGCAGGGGAACTCTTTCTTCGTGATGACAAACTTTCTCAAAACAGAAGGCCAAGA 
PAX5 NM_016734.1 2288-2388 
CTCCAAGAGGAGCACACTTTGGGGAGATGTCCTGGTTTCCTGCCTCCATTTCTCTGGGACCGA
TGCAGTATCAGCAGCTCTTTTCCAGATCAAAGAACTC 
PDCD1 NM_005018.1 175-275 CTTCTTCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGC 
PDCD1LG2 NM_025239.3 235-335 TGTGGAGCTGTGGCAAGTCCTCATATCAAATACAGAACATGATCTTCCTCCTGCTAATGTTGAGCCTGGAATTGCAGCTTCACCAGATAGCAGCTTTATT 
PDE3A NM_000921.3 3010-3110 
CTGGCCAACCTTCAGGAATCCTTCATCTCTCACATTGTGGGGCCTCTGTGCAACTCCTATGATT
CAGCAGGACTAATGCCTGGAAAATGGGTGGAAGACA 
PDE4A NM_001111307.1 3855-3955 
AATAATGGTGTATACCCTCATTCTCATTCCTGGGCAGCCCTTCCTTCCACCCTGGCACCAAAAT
AATTTCTCCTCCATCCGTACCTTGCCTAGCCTCTCC 
PDE7A NM_002604.2 2210-2310 
GTAGCTCAACAAGGAATAGAGGGAGGAGTGTAATTTTGGTAGCTGGTGTTGAATAGGGCCTTT
GAGAATCAGACTGAACACAGTGAAATATGTGCCCAAA 
PDK1 NM_002610.3 1170-1270 
TGGATTGCCCATATCACGTCTTTACGCACAATACTTCCAAGGAGACCTGAAGCTGTATTCCCTA
GAGGGTTACGGGACAGATGCAGTTATCTACATTAAG 
PDXK NM_003681.3 580-680 TCCCGGAGGACCTCCTTCCCGTCTACAAAGAAAAAGTGGTGCCGCTTGCAGACATTATCACGCCCAACCAGTTTGAGGCCGAGTTACTGAGTGGCCGGAA 
PECAM1 NM_000442.3 1365-1465 
ATCTGCACTGCAGGTATTGACAAAGTGGTCAAGAAAAGCAACACAGTCCAGATAGTCGTATGT
GAAATGCTCTCCCAGCCCAGGATTTCTTATGATGCCC 
PHACTR2 NM_001100164.1 8350-8450 
GGCAGAATGCCACTCTACCCTCAGGTCAATTTTATGGTATATGAAAATGCCAGTAATATTTGTG
CCACTTGCCAACTCGGGGGAGGAGGGGCTTTTCCCT 
PHC1 NM_004426.2 2905-3005 
ATACAGCTCCACCTACACCGGAATTACATGGCATCAACCCTGTGTTCCTGTCCAGTAATCCCA
GCCGTTGGAGTGTAGAGGAGGTGTACGAGTTTATTGC 
POLR1B NM_019014.3 3320-3420 
GGAGAACTCGGCCTTAGAATACTTTGGTGAGATGTTAAAGGCTGCTGGCTACAATTTCTATGG
CACCGAGAGGTTATATAGTGGCATCAGTGGGCTAGAA 
POLR2A NM_000937.2 3775-3875 
TTCCAAGAAGCCAAAGACTCCTTCGCTTACTGTCTTCCTGTTGGGCCAGTCCGCTCGAGATGC
TGAGAGAGCCAAGGATATTCTGTGCCGTCTGGAGCAT 
POP5 NM_015918.3 560-660 GCTTCAGGCCCACTTGTTGAACAGAACAATCTGGGTAGCAACAGCATCTTCCACAGTTTTCCAAACTGGATAGCTGCCAACCAGCAGACATTACCCACTT 
POU5F1 NM_002701.4 1225-1325 
AAGTTCTTCATTCACTAAGGAAGGAATTGGGAACACAAAGGGTGGGGGCAGGGGAGTTTGGG
GCAACTGGTTGGAGGGAAGGTGAAGTTCAATGATGCTC 
PPARA NM_001001928.2 5220-5320 
GGGTGTGTTTGCTATACGAACATAATGGACGTGAAGTGGGGCAGAAACCCAGAACTCAGCATT
CAAGGATGCCCAGGAGAGCTGTCCCTGTTTTAAAGAG 
PPP2R1A NM_014225.3 1440-1540 
AACTTAACTCCTTGTGCATGGCCTGGCTTGTGGATCATGTATATGCCATCCGCGAGGCAGCCA
CCAGCAACCTGAAGAAGCTAGTGGAAAAGTTTGGGAA 
PRDM1 NM_182907.1 310-410 CATCCCTGCCAACCAGGAACTTCTTGTGTGGTATTGTCGGGACTTTGCAGAAAGGCTTCACTACCCTTATCCCGGAGAGCTGACAATGATGAATCTCACA 
PRF1 NM_005041.3 2120-2220 
ACTGTTTTTCAGGGAGGTGGCTGGGTTTACACGCTAATCCCGATTCACCCTGTCCAAACTGCC
TAAGCCCTCCGCCATTCTCAAGCCCTGCAGTCACAGC 
PRKAA2 NM_006252.2 975-1075 ATAGTGGTGACCCTCAAGACCAGCTTGCAGTGGCTTATCATCTTATCATTGACAATCGGAGAATAATGAACCAAGCCAGTGAGTTCTACCTCGCCTCTAG 
PRKCQ NM_006257.2 1325-1425 
GATGGACGATGATGTTGAGTGCACGATGGTAGAGAAGAGAGTTCTTTCCTTGGCCTGGGAGC
ATCCGTTTCTGACGCACATGTTTTGTACATTCCAGACC 
PROM1 NM_006017.1 925-1025 AGCCTGCGGTCATCTCTCAATGACCCTCTGTGCTTGGTGCATCCATCAAGTGAAACCTGCAACAGCATCAGATTGTCTCTAAGCCAGCTGAATAGCAACC 
PTGER2 NM_000956.2 1410-1510 
GTCAGAAGGAGCTACAAAACCTACCCTCAGTGAGCATGGTACTTGGCCTTTGGAGGAACAATC
GGCTGCATTGAAGATCCAGCTGCCTATTGATTTAAGC 
PTK2 NM_005607.3 1005-1105 
GGTTCAAGCTGGATTATTTCAGTGGAACTGGCAATCGGCCCAGAAGAAGGAATCAGTTACCTA
ACGGACAAGGGCTGCAATCCCACACATCTTGCTGACT 
PTPN11 NM_002834.3 4650-4750 
TAGTCCCTAGGTTGCTACGGCTTATCATGTGCTTGGTAAAAGGTGATCGCAGGTTCTCAGACG
AGTTTACTTTACATGAGATGGAATCAGGCAGAGAGGC 
PTPN4 NM_002830.2 705-805 TCGAGGCTTTTTTTCTCCAGCCGAGAGGACGCGGCTGTGATATACGAAGACTTTGTGTGGACAGTAATGACCTCACGTTTCCGATTGCCTGCTGGCAGAA 
PTPN6 NM_002831.5 1734-1834 
TGGTGCAGACGGAGGCGCAGTACAAGTTCATCTACGTGGCCATCGCCCAGTTCATTGAAACC
ACTAAGAAGAAGCTGGAGGTCCTGCAGTCGCAGAAGGG 
PTPRK NM_001135648.1 4315-4415 
GTGATCAACCGGATTTTTAGGATATGCAATCTAACAAGACCACAGGAAGGTTATCTGATGGTG
CAACAGTTTCAGTACCTAGGATGGGCTTCTCATCGAG 
RAB31 NM_006868.3 3800-3900 
TTTTGTAAAGAGCTTCCATCTGGGCTGGACCCAGTTCTTGCACATACAAGACACCGCTGCAGT
CAGCTAGGACCTTTCCGCCATGTATTCTATTCTGTAG 
121 
 
RAC1 NM_198829.1 1250-1350 
AAAGACCTTCGTCTTTGAGAAGACGGTAGCTTCTGCAGTTAGGAGGTGCAGACACTTGCTCTC
CTATGTAGTTCTCAGATGCGTAAAGCAGAACAGCCTC 
RAC2 NM_002872.3 1069-1169 
GCTGCCACAACTTGTGTACCTTCAGGGATGGGGCTCTTACTCCCTCCTGAGGCCAGCTGCTCT
AATATCGATGGTCCTGCTTGCCAGAGAGTTCCTCTAC 
RAF1 NM_002880.2 1990-2090 
CCTATGGCATCGTATTGTATGAACTGATGACGGGGGAGCTTCCTTATTCTCACATCAACAACC
GAGATCAGATCATCTTCATGGTGGGCCGAGGATATGC 
RAP1GAP2 NM_015085.4 4140-4240 
CCCACGGCTGGAAAGAGGCCTGTACGTTCTGGACGCGTTTTGTTGGCTGGGCTTCTGGAGGC
ACTGGCAAGGTCAAACTGCATTTCTTTAAGAACAGTTG 
RARA NM_000964.2 115-215 AGCCACCTAGCTGGGGCCCATCTAGGAGTGGCATCTTTTTTGGTGCCCTGAAGGCCAGCTCTGGACCTTCCCAGGAAAAGTGCCAGCTCACAGAACTGCT 
RBPMS NM_001008710.1 842-942 AAACAGCCTGTAGGTTTTGTCAGTTTTGACAGTCGCTCAGAAGCAGAGGCTGCAAAGAATGCTTTGAATGGCATCCGCTTCGATCCTGAAATTCCGCAAA 
RHOA NM_001664.2 1230-1330 
GGTACTCTGGTGAGTCACCACTTCAGGGCTTTACTCCGTAACAGATTTTGTTGGCATAGCTCT
GGGGTGGGCAGTTTTTTGAAAATGGGCTCAACCAGAA 
RNF125 NM_017831.3 790-890 GCAAGGTGTGTATGTCCCTTTTGTCAGAGGGAACTGTATGAAGACAGCTTGCTGGATCATTGTATTACTCATCACAGATCGGAACGGAGGCCTGTGTTCT 
RORA NM_134261.2 1715-1815 
AAAATTAACCGAGACACTTTATATGGCCCTGCACAGACCTGGAGCGCCACACACTGCACATCT
TTTGGTGATCGGGGTCAGGCAAAGGAGGGGAAACAAT 
RORC NM_001001523.1 1350-1450 
CTCATCAATGCCCATCGGCCAGGGCTCCAAGAGAAAAGGAAAGTAGAACAGCTGCAGTACAAT
CTGGAGCTGGCCTTTCATCATCATCTCTGCAAGACTC 
RPL27 NM_000988.3 23-123 GGGCCGGGTGGTTGCTGCCGAAATGGGCAAGTTCATGAAACCTGGGAAGGTGGTGCTTGTCCTGGCTGGACGCTACTCCGGACGCAAAGCTGTCATCGTG 
RPS13 NM_001017.2 331-431 GCATCTTGAGAGGAACAGAAAGGATAAGGATGCTAAATTCCGTCTGATTCTAATAGAGAGCCGGATTCACCGTTTGGCTCGATATTATAAGACCAAGCGA 
RUNX1 NM_001754.4 635-735 CAGCCATGAAGAACCAGGTTGCAAGATTTAATGACCTCAGGTTTGTCGGTCGAAGTGGAAGAGGGAAAAGCTTCACTCTGACCATCACTGTCTTCACAAA 
RUNX2 NM_004348.3 1850-1950 
GAAGCCACAGCAGTTCCCCAACTGTTTTGAATTCTAGTGGCAGAATGGATGAATCTGTTTGGC
GACCATATTGAAATTCCTCAGCAGTGGCCCAGTGGTA 
RUNX3 NM_004350.1 2085-2185 
GTGGTCTCATAATTCCATTTGTGGAGAGAACAGGAGGGCCAGATAGATAGGTCCTAGCAGAAG
GCATTGAGGTGAGGGATCATTTTGGGTCAGACATCAA 
S100A4 NM_002961.2 263-363 CAGGGACAACGAGGTGGACTTCCAAGAGTACTGTGTCTTCCTGTCCTGCATCGCCATGATGTGTAACGAATTCTTTGAAGGCTTCCCAGATAAGCAGCCC 
S100A6 NM_014624.3 539-639 TTCCTGGGGGCCTTGGCTTTGATCTACAATGAAGCCCTCAAGGGCTGAAAATAAATAGGGAAGATGGAGACACCCTCTGGGGGTCCTCTCTGAGTCAAAT 
SATB1 NM_001131010.1 1335-1435 
TTCCGAAATCTACCAGTGGGTACGCGATGAACTGAAACGAGCAGGAATCTCCCAGGCGGTATT
TGCACGTGTGGCTTTTAACAGAACTCAGGGCTTGCTT 
SCML1 NM_001037540.1 925-1025 GCAACGTATGGTTCTTCTTCAGGGCTCTGCCTTGGCAACCCTCGGGCTGACAGCATCCACAACACTTACTCAACTGACCATGCTTCTGCAGCACCACCTT 
SCML2 NM_006089.2 360-460 ATTGGAAGCCCGTGACCCTCGCAATGCCACTTCAGTATGTATTGCTACGGTTATTGGAATTACTGGGGCCAGGTTACGGTTACGACTGGATGGTAGTGAC 
SEL1L NM_005065.4 980-1080 GGGCAATCTAATAGCCCACATGGTTTTGGGTTACAGATACTGGGCTGGCATCGGCGTCCTCCAGAGTTGTGAATCTGCCCTGACTCACTATCGTCTTGTT 
SELL NM_000655.3 110-210 CTCCCTTTGGGCAAGGACCTGAGACCCTTGTGCTAAGTCAAGAGGCTCAATGGGCTGCAGAAGAACTAGAGAAGGACCAAGCAAAGCCATGATATTTCCA 
SELPLG NM_003006.3 2297-2397 
CATGGGCTGTTAGGTTGACTTCAGTTTTGCCTCTTGGACAACAGGGGGTCTTGTACATCCTTG
GGTGACCAGGAAAAGTTCAGGCTATGGGGGGCCAAAG 
SERPINE2 NM_006216.2 240-340 CGCTGCCTTCCATCTGCTCCCACTTCAATCCTCTGTCTCTCGAGGAACTAGGCTCCAACACGGGGATCCAGGTTTTCAATCAGATTGTGAAGTCGAGGCC 
SH2B3 NM_005475.2 4285-4385 
CCTCCAGCCAGAAGTTAAACATCTGGGATATGACGTCTTCATGCCAGGGGCACTCATTTCTTA
GCAGCCTCTCTACATACATCTCTCAGGTGGTGCCAAG 
SH2D2A NM_001161443.1 341-441 TGCTGGAGCCCAAGCCTCAGGGGTGCTACTTGGTGCGGTTCAGCGAGAGCGCGGTGACCTTCGTGCTGACTTACAGGAGCCGGACTTGCTGCCGCCACTT 
SIT1 NM_014450.2 720-820 GCCCCAGCCCCCCGTAGCAGGGGCATGACTGTTTCCCAACCAGCACCCAAAGACGGGCGCCATTGCCAAGTCACAGGATGTGATCTACCCCGGACTTCCT 
SKAP1 NM_003726.3 1360-1460 
AAGTGGGAAGAGGCACGTTCATCAAACCTGTTACTAAACCAGCCTAGTCATAGCTCATCCCCA
TCTCTAAATGTGTCCACACAACCACATCTGCCTTTTC 
SKAP2 NM_003930.3 3374-3474 
TTTTACAGTTAATCCAGGAGAGGGAGTCCTTTGCCAACTGATGACCAACAGTTCCAAGCCAGA
TAGTCTCGTGAACAGTGACAATACAGAAATAAGGTGT 
SLA2 NM_032214.2 1640-1740 
AAAGGAAAGCTGAGATGATGTCTTACCGTAGCAGCAGATCTTGGATGGTCCAGGCTCTATGTG
ACCTCCAGAGCAAAGAGAAAGACTTCGGACAGTCTAG 
SLAMF1 NM_003037.2 580-680 GTGTCTCTTGATCCATCCGAAGCAGGCCCTCCACGTTATCTAGGAGATCGCTACAAGTTTTATCTGGAGAATCTCACCCTGGGGATACGGGAAAGCAGGA 
SLAMF7 NM_021181.3 215-315 GGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGATGGAGGCTACTCCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCA 
SLC2A1 NM_006516.2 2500-2600 
AGGCTCCATTAGGATTTGCCCCTTCCCATCTCTTCCTACCCAACCACTCAAATTAATCTTTCTTT
ACCTGAGACCAGTTGGGAGCACTGGAGTGCAGGGA 
SMAD3 NM_005902.3 4220-4320 
TTAAAGGACAGTTGAAAAGGGCAAGAGGAAACCAGGGCAGTTCTAGAGGAGTGCTGGTGACT
GGATAGCAGTTTTAAGTGGCGTTCACCTAGTCAACACG 
SMAD4 NM_005359.3 1370-1470 
AGGTTGCACATAGGCAAAGGTGTGCAGTTGGAATGTAAAGGTGAAGGTGATGTTTGGGTCAG
GTGCCTTAGTGACCACGCGGTCTTTGTACAGAGTTACT 
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SNAI1 NM_005985.2 63-163 GACCACTATGCCGCGCTCTTTCCTCGTCAGGAAGCCCTCCGACCCCAATCGGAAGCCTAACTACAGCGAGCTGCAGGACTCTAATCCAGAGTTTACCTTC 
SOCS1 NM_003745.1 1025-1125 
TTAACTGTATCTGGAGCCAGGACCTGAACTCGCACCTCCTACCTCTTCATGTTTACATATACCC
AGTATCTTTGCACAAACCAGGGGTTGGGGGAGGGTC 
SOCS3 NM_003955.3 1870-1970 
GGAGGATGGAGGAGACGGGACATCTTTCACCTCAGGCTCCTGGTAGAGAAGACAGGGGATTC
TACTCTGTGCCTCCTGACTATGTCTGGCTAAGAGATTC 
SOD1 NM_000454.4 35-135 GCCTATAAAGTAGTCGCGGAGACGGGGTGCTGGTTTGCGTCGTAGTCTCCTGCAGCGTCTGGGGTTTCCGTTGCAGTCCTCGGAACCAGGACCTCGGCGT 
SOX13 NM_005686.2 3039-3139 
ATTTATTGAGTGCCCACTACGTGCCAGGCACTGTTGCTGAGTTCCTGTGGGTGTGTCTCTCGA
TGCCACTCCTGCTTCTCTGGGGGCCTCTTTCTGTGCT 
SOX2 NM_003106.2 151-251 CTTAAGCCTTTCCAAAAAATAATAATAACAATCATCGGCGGCGGCAGGATCGGCCAGAGGAGGAGGGAAGCGCTTTTTTTGATCCTGATTCCAGTTTGCC 
SOX4 NM_003107.2 3040-3140 
GTTCACGGTCAAACTGAAATGGATTTGCACGTTGGGGAGCTGGCGGCGGCGGCTGCTGGGC
CTCCGCCTTCTTTTCTACGTGAAATCAGTGAGGTGAGAC 
SOX5 NM_152989.2 1885-1985 
TAGCCATGCAATGATGGATTTCAATCTGAGTGGAGATTCTGATGGAAGTGCTGGAGTCTCAGA
GTCAAGAATTTATAGGGAATCCCGAGGGCGTGGTAGC 
SPI1 NM_003120.1 730-830 CTCCGCAGCGGCGACATGAAGGACAGCATCTGGTGGGTGGACAAGGACAAGGGCACCTTCCAGTTCTCGTCCAAGCACAAGGAGGCGCTGGCGCACCGCT 
SPN NM_001030288.1 2798-2898 
AAGCCAGGCTTCATGGAAAGATCGTATGTGTGACCCAAATATGAGTTCTTCAGCTCAGCCATG
GTAATCCCTTCCTTGAAGTCTCCATTTCTGCAGTACA 
SPRY2 NM_005842.2 85-185 AAAGAGGAAATACTCCGCGTGCGCTTGTAGAAGGGGAGTCGTCTCCAGCTCCGAACCCCGGAGTGTTCATCAGCGGGGAATCTGGCTCCGAATTCTCTTT 
STAT1 NM_007315.2 205-305 TTTGCTGTATGCCATCCTCGAGAGCTGTCTAGGTTAACGTTCGCACTCTGTGTATATAACCTCGACAGTCTTGGCACCTAACGTGCTGTGCGTAGCTGCT 
STAT3 NM_139276.2 4535-4635 
AGACTTGGGCTTACCATTGGGTTTAAATCATAGGGACCTAGGGCGAGGGTTCAGGGCTTCTCT
GGAGCAGATATTGTCAAGTTCATGGCCTTAGGTAGCA 
STAT4 NM_003151.2 789-889 AGACAATGGATCAGAGTGACAAGAATAGTGCCATGGTGAATCAGGAAGTTTTGACACTGCAGGAAATGCTTAACAGCCTCGATTTCAAGAGAAAGGAGGC 
STAT5A NM_003152.2 3460-3560 
GAGACAGAGAGAGAGAAAGAGAGAGTGTGTGGGTCTATGTAAATGCATCTGTCCTCATGTGTT
GATGTAACCGATTCATCTCTCAGAAGGGAGGCTGGGG 
STAT5B NM_012448.3 200-300 AAGGAGAAGCCCTTCATCAGATGCAAGCGTTATATGGCCAGCATTTTCCCATTGAGGTGCGGCATTATTTATCCCAGTGGATTGAAAGCCAAGCATGGGA 
STAT6 NM_003153.3 2030-2130 
AGAACATCCAGCCATTCTCTGCCAAAGACCTGTCCATTCGCTCACTGGGGGACCGAATCCGG
GATCTTGCTCAGCTCAAAAATCTCTATCCCAAGAAGCC 
STMN1 NM_203401.1 287-387 CGTGGGTGGCGGCAGGACTTTCCTTATCCCAGTTGATTGTGCAGAATACACTGCCTGTCGCTTGTCTTCTATTCACCATGGCTTCTTCTGATATCCAGGT 
SYK NM_003177.3 1685-1785 
CGGACTCTCCAAAGCACTGCGTGCTGATGAAAACTACTACAAGGCCCAGACCCATGGAAAGT
GGCCTGTCAAGTGGTACGCTCCGGAATGCATCAACTAC 
TAL1 NM_003189.2 4635-4735 
ACAGCATCTGTAGTCAGCCGACAACTATTTCGGCCTTTTGGGGGTGGGTCTGGCCGTACTTGT
GATTTCGATGGTACGTGACCCTCTGCTGAAGACTTGC 
TBP NM_003194.3 25-125 CGCCGGCTGTTTAACTTCGCTTCCGCTGGCCCATAGTGATCTTTGCAGTGACCCAGCAGCATCACTGTTTCTTGGCGTGTGAAGATAACCCAAGGAATTG 
TBX21 NM_013351.1 890-990 ACACAGGAGCGCACTGGATGCGCCAGGAAGTTTCATTTGGGAAACTAAAGCTCACAAACAACAAGGGGGCGTCCAACAATGTGACCCAGATGATTGTGCT 
TBXA2R NM_001060.3 385-485 CACACGCGCTCCTCCTTCCTCACCTTCCTCTGCGGCCTCGTCCTCACCGACTTCCTGGGGCTGCTGGTGACCGGTACCATCGTGGTGTCCCAGCACGCCG 
TCF12 NM_207037.1 1105-1205 
CACATGACCGCTTGAGTTATCCTCCACACTCAGTTTCACCAACAGACATAAACACGAGTCTTCC
ACCAATGTCCAGCTTTCATCGCGGCAGTACCAGCAG 
TCF3 NM_003200.2 4325-4425 
ATACGTGTCAACACAGCTGGCTGGATGATTGGGACTTTAAAACGACCCTCTTTCAGGTGGATT
CAGAGACCTGTCCTGTATATAACAGCACTGTAGCAAT 
TCF7 NM_003202.2 2420-2520 
ATTCCATTTCCAGTTCATCTATGGCAGTCCAGCCAGCTCCTGGGCAGCTTGAGAGGGCAAACC
CAAAACCTCATGACAGCCAGAGCCTGTCTTTCAGCAT 
TDGF1 NM_003212.2 1567-1667 
AAGGAAAGAAAACATCTTTAAGGGGAGGAACCAGAGTGCTGAAGGAATGGAAGTCCATCTGC
GTGTGTGCAGGGAGACTGGGTAGGAAAGAGGAAGCAAA 
TDO2 NM_005651.1 0-100 AAGGTCAATGATAGCATCTGCCTAGAGTCAAACCTCCGTGCTTCTCAGACAGTGCCTTTTCACCATGAGTGGGTGCCCATTTTTAGGAAACAACTTTGGA 
TEK NM_000459.2 615-715 CGAGTTCGAGGAGAGGCAATCAGGATACGAACCATGAAGATGCGTCAACAAGCTTCCTTCCTACCAGCTACTTTAACTATGACTGTGGACAAGGGAGATA 
TERF1 NM_003218.3 1037-1137 
CTGAAAGCAGAATACCTGTTTCAAAGAGTCAGCCGGTAACTCCTGAAAAACATCGAGCTAGAA
AAAGACAGGCATGGCTTTGGGAAGAAGACAAGAATTT 
TERT NM_198253.1 2570-2670 
GGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTTGGGGTCTTGCGGCTGAAGTGTCA
CAGCCTGTTTCTGGATTTGCAGGTGAACAGCCTCCAGA 
TF NM_001063.2 640-740 CTGCTCCACCCTTAACCAATACTTCGGCTACTCGGGAGCCTTCAAGTGTCTGAAGGATGGTGCTGGGGATGTGGCCTTTGTCAAGCACTCGACTATATTT 
TFRC NM_003234.1 1220-1320 
CAGTTTCCACCATCTCGGTCATCAGGATTGCCTAATATACCTGTCCAGACAATCTCCAGAGCTG
CTGCAGAAAAGCTGTTTGGGAATATGGAAGGAGACT 
TGFA NM_003236.2 780-880 TGCCACAGACCTTCCTACTTGGCCTGTAATCACCTGTGCAGCCTTTTGTGGGCCTTCAAAACTCTGTCAAGAACTCCGTCTGCTTGGGGTTATTCAGTGT 
TGFB1 NM_000660.3 1260-1360 
TATATGTTCTTCAACACATCAGAGCTCCGAGAAGCGGTACCTGAACCCGTGTTGCTCTCCCGG
GCAGAGCTGCGTCTGCTGAGGCTCAAGTTAAAAGTGG 
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TGFB2 NM_003238.2 1125-1225 
AAGCCAGAGTGCCTGAACAACGGATTGAGCTATATCAGATTCTCAAGTCCAAAGATTTAACATC
TCCAACCCAGCGCTACATCGACAGCAAAGTTGTGAA 
TGFBR1 NM_004612.2 4280-4380 
GGGGAAATACGACTTAGTGAGGCATAGACATCCCTGGTCCATCCTTTCTGTCTCCAGCTGTTT
CTTGGAACCTGCTCTCCTGCTTGCTGGTCCCTGACGC 
Thymidine 
Kinase SCFV007.1 100-200 
TCTACGTACCCGAGCCGATGACTTACTGGCAGGTGCTGGGGGCTTCCGAGACAATCGCGAAC
ATCTACACCACACAACACCGCCTCGACCAGGGTGAGAT 
TIE1 NM_005424.2 2610-2710 
CATCGGGGAGGGGAACTTCGGCCAGGTCATCCGGGCCATGATCAAGAAGGACGGGCTGAAG
ATGAACGCAGCCATCAAAATGCTGAAAGAGTATGCCTCT 
TLR2 NM_003264.3 180-280 CTGCTTTCAACTGGTAGTTGTGGGTTGAAGCACTGGACAATGCCACATACTTTGTGGATGGTGTGGGTCTTGGGGGTCATCATCAGCCTCTCCAAGGAAG 
TLR8 NM_138636.3 2795-2895 
GACAAAAACGTTCTCCTTTGTCTAGAGGAGAGGGATTGGGATCCGGGATTGGCCATCATCGAC
AACCTCATGCAGAGCATCAACCAAAGCAAGAAAACAG 
TNF NM_000594.2 1010-1110 
AGCAACAAGACCACCACTTCGAAACCTGGGATTCAGGAATGTGTGGCCTGCACAGTGAAGTG
CTGGCAACCACTAAGAATTCAAACTGGGGCCTCCAGAA 
TNFRSF14 NM_003820.2 916-1016 CTCAGGGAGCCTCGTCATCGTCATTGTTTGCTCCACAGTTGGCCTAATCATATGTGTGAAAAGAAGAAAGCCAAGGGGTGATGTAGTCAAGGTGATCGTC 
TNFRSF18 NM_004195.2 445-545 AGGGGAAATTCAGTTTTGGCTTCCAGTGTATCGACTGTGCCTCGGGGACCTTCTCCGGGGGCCACGAAGGCCACTGCAAACCTTGGACAGACTGCACCCA 
TNFRSF1B NM_001066.2 835-935 CCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTTCCAGTTGGACTGATTGTGGGTGTGACAGCCTTGGGTCTACTAATAATAGGAGTGGTGAACTGTGTC 
TNFRSF4 NM_003327.2 200-300 CCGTGCGGGCCGGGCTTCTACAACGACGTGGTCAGCTCCAAGCCGTGCAAGCCCTGCACGTGGTGTAACCTCAGAAGTGGGAGTGAGCGGAAGCAGCTGT 
TNFRSF9 NM_001561.4 255-355 AGATTTGCAGTCCCTGTCCTCCAAATAGTTTCTCCAGCGCAGGTGGACAAAGGACCTGTGACATATGCAGGCAGTGTAAAGGTGTTTTCAGGACCAGGAA 
TNFSF10 NM_003810.2 115-215 GGGGGGACCCAGCCTGGGACAGACCTGCGTGCTGATCGTGATCTTCACAGTGCTCCTGCAGTCTCTCTGTGTGGCTGTAACTTACGTGTACTTTACCAAC 
TNFSF11 NM_003701.2 490-590 TACCTGATTCATGTAGGAGAATTAAACAGGCCTTTCAAGGAGCTGTGCAAAAGGAATTACAACATATCGTTGGATCACAGCACATCAGAGCAGAGAAAGC 
TNFSF14 NM_003807.2 270-370 ATTTTCAGAAGCCTCTGGAAAGTCGTGCACAGCCCAGGAGTGTTGAGCAATTTCGGTTTCCTCTGAGGTTGAAGGACCCAGGCGTGTCAGCCCTGCTCCA 
TOX NM_014729.2 3950-4050 
AATGAGCAGCTTTGACTTTGACAGGCGGTTTGTGCAGGAAAGCACAGTGCCGTGTTGTTTACA
GCTTTTCTAGAGCAGCTGTGCGACCAGGGTAGAGAGT 
TP53 NM_000546.2 1330-1430 
GGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATA
AAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGAC 
TRAF1 NM_005658.3 3735-3835 
CGAGTGATGGGTCTAGGCCCTGAAACTGATGTCCTAGCAATAACCTCTTGATCCCTACTCACC
GAGTGTTGAGCCCAAGGGGGGATTTGTAGAACAAGCC 
TRAF2 NM_021138.3 1325-1425 
GTGGCCCTTCAACCAGAAGGTGACCTTAATGCTGCTCGACCAGAATAACCGGGAGCACGTGA
TTGACGCCTTCAGGCCCGACGTGACTTCATCCTCTTTT 
TRAF3 NM_145725.1 1795-1895 
ATATGATGCCCTGCTTCCTTGGCCGTTTAAGCAGAAAGTGACACTCATGCTGATGGATCAGGG
GTCCTCTCGACGTCATTTGGGAGATGCATTCAAGCCC 
TSC22D3 NM_198057.2 1400-1500 
TTAAGCAGAGGCAACCTCTCTCTTCTCCTCTGTTTCGTGAAGGCAGGGGACACAGATGGGAGA
GATTGAGCCAAGTCAGCCTTCTGTTGGTTAATATGGT 
TSLP NM_033035.3 395-495 CCGTCTCTTGTAGCAATCGGCCACATTGCCTTACTGAAATCCAGAGCCTAACCTTCAATCCCACCGCCGGCTGCGCGTCGCTCGCCAAAGAAATGTTCGC 
TXK NM_003328.1 800-900 ATGACTCGTCTCCGATATCCAGTTGGGCTGATGGGCAGTTGTTTACCAGCCACAGCTGGGTTTAGCTACGAAAAGTGGGAGATAGATCCATCTGAGTTGG 
TYK2 NM_003331.3 485-585 TCATCGCTGACAGCTGAGGAAGTCTGCATCCACATTGCACATAAAGTTGGTATCACTCCTCCTTGCTTCAATCTCTTTGCCCTCTTCGATGCTCAGGCCC 
TYROBP NM_003332.2 457-557 CTGCACCTCATTCCAACTCCTACCGCGATACAGACCCACAGAGTGCCATCCCTGAGAGACCAGACCGCTCCCCAATACTCTCCTAAAATAAACATGAAGC 
UBASH3A NM_001001895.1 1970-2070 
GAGATGCTGCTGTTTCCAGAGGCGTCTTAGTCTCACCCAATGTGATTTGTAGAAGCACGAGAC
GCACTTTTATATCCCGGAATATTTCCCTCCGGCTTTC 
VAX2 NM_012476.2 871-971 CAGCGCCAGCAGCTGCAAGAAAGCTAACACTTAAGACTCCCACCCTGTGACACTGAGTCCCGAGCACAGCACCTTCCCAGTCTCCTGTGCCCCAGCGGAC 
VEGFA NM_001025366.1 1325-1425 
GAGTCCAACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAG
ATGAGCTTCCTACAGCACAACAAATGTGAATGCAGAC 
WEE1 NM_003390.2 5-105 TGCGTTTGAGTTTGCCGCGAGCCGGGCCAATCGGTTTTGCCAACGCATGCCCACGTGCTGGCGAACAAATGTAAACACGGAGATCGTGTGCCGGGCACTT 
XBP1 NM_005080.2 440-540 GGAGTTAAGACAGCGCTTGGGGATGGATGCCCTGGTTGCTGAAGAGGAGGCGGAAGCCAAGGGGAATGAAGTGAGGCCAGTGGCCGGGTCTGCTGAGTCC 
XBP1 NM_001079539.1 935-1035 ATTCATTGTCTCAGTGAAGGAAGAACCTGTAGAAGATGACCTCGTTCCGGAGCTGGGTATCTCAAATCTGCTTTCATCCAGCCACTGCCCAAAGCCATCT 
YY1AP1 NM_139118.2 755-855 ATGGGAGCTATGCAGCTGATTGAAGACTTCAGCACACATGTCAGCATTGACTGCAGCCCTCATAAAACTGTCAAGAAGACTGCCAATGAATTTCCCTGTT 
ZAP70 NM_001079.3 1175-1275 
GGAGCTCAAGGACAAGAAGCTCTTCCTGAAGCGCGATAACCTCCTCATAGCTGACATTGAACT
TGGCTGCGGCAACTTTGGCTCAGTGCGCCAGGGCGTG 
ZBTB16 NM_006006.4 1585-1685 
TCCTGGATAGTTTGCGGCTGAGAATGCACTTACTGGCTCATTCAGCGGGTGCCAAAGCCTTTG
TCTGTGATCAGTGCGGTGCACAGTTTTCGAAGGAGGA 
ZC2HC1A NM_016010.2 665-765 ACGATTACCGCAGCCAAGTGGCGCTGGCAAAACTGTTGTAGGTGTTCCTTCAGGTAAAGTGTCTTCAAGTAGCAGCTCTTTGGGAAACAAACTTCAGACC 
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ZEB2 NM_014795.2 20-120 TCCCAGAGAGAAACTTGGCGATCACGTTTTCACATGATGCTCACGCTCAGGGCGCTTCAATTATCCCTCCCCACAAAGATAGGTGGCGCGTGTTTCAGGG 
ZNF516 NM_014643.2 4830-4930 
GGTGGGGGACGGCTTCATATACCTCTTCCTCAGTAATGCAAATGCGAGTTTTTGTGGTGGGGG
TTAAGGCCCATAACAAAGGATCTTAAACCATGCAGTG 
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Appendix B.  Fold change in mRNA abundance of mIL15-CAR T cells relative to CAR 
T cells  
GENE logFC PValue FDR 
IL7RA -2.4 1.9E-05 6.7E-03 
NRP1 -2.7 1.6E-04 2.9E-02 
DAP12 1.9 3.1E-04 3.7E-02 
CD4 -1.9 5.5E-04 4.9E-02 
TNFRSF4 -1.7 2.5E-03 1.5E-01 
TIE1 -1.9 2.6E-03 1.5E-01 
HRH2 1.6 4.6E-03 2.2E-01 
CPT1 -1.6 5.0E-03 2.2E-01 
PDCD1 -1.6 8.6E-03 3.4E-01 
ICOSLG -1.3 1.3E-02 4.2E-01 
CMRF35H -1.7 1.4E-02 4.2E-01 
CCR4 -1.4 1.4E-02 4.2E-01 
RORC 1.4 2.5E-02 6.4E-01 
GILZ -1.1 2.6E-02 6.4E-01 
CD86 -1.3 2.7E-02 6.4E-01 
TSLPR -1.5 3.1E-02 6.8E-01 
BCL6 -1.1 3.8E-02 7.9E-01 
PAX5 1.1 4.2E-02 8.3E-01 
IL23R 1.1 4.8E-02 8.9E-01 
KIR2DS2 1.1 5.2E-02 9.2E-01 
CD40LG -1.1 6.3E-02 1.0E+00 
IKZF2 -1.0 7.6E-02 1.0E+00 
BCL2 0.8 9.2E-02 1.0E+00 
SOX5 1.3 1.1E-01 1.0E+00 
SOX13 -0.9 1.4E-01 1.0E+00 
BNIP3 -0.8 1.5E-01 1.0E+00 
GZMH 0.7 1.5E-01 1.0E+00 
CD11B -0.8 1.6E-01 1.0E+00 
LEF1 0.9 1.6E-01 1.0E+00 
SMAD3 -0.7 1.6E-01 1.0E+00 
FLT1 0.7 1.6E-01 1.0E+00 
KLRB1 -0.7 1.7E-01 1.0E+00 
CCL5 -0.6 1.7E-01 1.0E+00 
C5ORF13 -0.8 1.8E-01 1.0E+00 
KLF2 -0.6 2.0E-01 1.0E+00 
CD276 -0.9 2.0E-01 1.0E+00 
LRP5 0.7 2.0E-01 1.0E+00 
P2RX7 -0.7 2.1E-01 1.0E+00 
NCAM1 0.6 2.1E-01 1.0E+00 
ATF3 0.8 2.2E-01 1.0E+00 
ANXA1 -0.7 2.2E-01 1.0E+00 
EOMES -0.8 2.3E-01 1.0E+00 
NFATC1 -0.6 2.3E-01 1.0E+00 
MMP14 -0.8 2.5E-01 1.0E+00 
PHACTR2 -0.7 2.6E-01 1.0E+00 
GATA3 -0.7 2.6E-01 1.0E+00 
CD44 -0.6 2.6E-01 1.0E+00 
AIM2 -0.6 2.7E-01 1.0E+00 
AGER -0.6 2.7E-01 1.0E+00 
TGFBR1 0.6 2.8E-01 1.0E+00 
CSF2 -0.7 2.9E-01 1.0E+00 
CD80 -0.6 3.0E-01 1.0E+00 
IL10 0.4 3.2E-01 1.0E+00 
FGL2 -0.6 3.3E-01 1.0E+00 
MYC -0.5 3.4E-01 1.0E+00 
PHC1 -0.6 3.5E-01 1.0E+00 
LOC282997 -0.5 3.5E-01 1.0E+00 
ITGA5 -0.6 3.6E-01 1.0E+00 
SIP1 -0.5 3.7E-01 1.0E+00 
ITGA1 -0.5 3.7E-01 1.0E+00 
KIR3DL2 -0.8 3.7E-01 1.0E+00 
TBXA2R 0.6 3.8E-01 1.0E+00 
CCR7 -0.5 3.9E-01 1.0E+00 
RNF125 -0.5 3.9E-01 1.0E+00 
ITGA4 -0.4 4.1E-01 1.0E+00 
IL17RA 0.4 4.1E-01 1.0E+00 
NOTCH1 0.4 4.1E-01 1.0E+00 
CD28 -0.4 4.2E-01 1.0E+00 
BIM -0.5 4.2E-01 1.0E+00 
STMN1 -0.4 4.3E-01 1.0E+00 
LYN 0.4 4.3E-01 1.0E+00 
KIR2DS1 0.4 4.3E-01 1.0E+00 
NKp30 0.4 4.4E-01 1.0E+00 
TNFRSF18 -0.5 4.4E-01 1.0E+00 
RUNX1 0.4 4.4E-01 1.0E+00 
SH2D2A 0.4 4.5E-01 1.0E+00 
PDK1 -0.4 4.5E-01 1.0E+00 
SELL -0.4 4.6E-01 1.0E+00 
POU5F1 -0.5 4.7E-01 1.0E+00 
EGLN1 -0.4 4.7E-01 1.0E+00 
TRAF1 -0.4 4.7E-01 1.0E+00 
SOCS1 0.4 4.7E-01 1.0E+00 
KIR2DL1 -0.7 4.8E-01 1.0E+00 
IL23p19 0.4 4.8E-01 1.0E+00 
LNK 0.3 4.9E-01 1.0E+00 
SKAP1 -0.4 4.9E-01 1.0E+00 
BIRC2 -0.3 4.9E-01 1.0E+00 
STAT1 -0.2 5.0E-01 1.0E+00 
LAIR1 -0.3 5.0E-01 1.0E+00 
TNFRSF9 -0.5 5.0E-01 1.0E+00 
MYB -0.4 5.0E-01 1.0E+00 
CDK4 0.4 5.0E-01 1.0E+00 
XBP1 0.4 5.0E-01 1.0E+00 
TFRC -0.4 5.0E-01 1.0E+00 
SLA2 0.4 5.1E-01 1.0E+00 
CD69 0.3 5.1E-01 1.0E+00 
FAS -0.4 5.1E-01 1.0E+00 
CCL3 0.2 5.1E-01 1.0E+00 
EGLN3 -0.3 5.1E-01 1.0E+00 
TNF 0.2 5.2E-01 1.0E+00 
IGF1R -0.3 5.2E-01 1.0E+00 
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BACH2 0.3 5.2E-01 1.0E+00 
CD94 -0.4 5.2E-01 1.0E+00 
BCL2L1 0.3 5.2E-01 1.0E+00 
TXK 0.3 5.2E-01 1.0E+00 
IL10RA -0.3 5.3E-01 1.0E+00 
RARA -0.4 5.3E-01 1.0E+00 
XBP1 0.3 5.3E-01 1.0E+00 
IL12RB2 0.4 5.3E-01 1.0E+00 
DPP4 0.3 5.3E-01 1.0E+00 
RUNX3 0.4 5.4E-01 1.0E+00 
HVEM -0.3 5.4E-01 1.0E+00 
FLT3LG -0.3 5.4E-01 1.0E+00 
ITGAL -0.3 5.5E-01 1.0E+00 
EPHA4 -0.3 5.5E-01 1.0E+00 
IL2RA -0.4 5.5E-01 1.0E+00 
PTGER2 -0.3 5.6E-01 1.0E+00 
ID2 0.3 5.6E-01 1.0E+00 
DNAM1 -0.2 5.7E-01 1.0E+00 
CD7 0.3 5.7E-01 1.0E+00 
SLAMF1 -0.4 5.7E-01 1.0E+00 
BCLXL 0.2 5.9E-01 1.0E+00 
SATB1 0.3 5.9E-01 1.0E+00 
TP53 0.2 5.9E-01 1.0E+00 
MAD1L1 0.3 6.0E-01 1.0E+00 
FOS 0.3 6.0E-01 1.0E+00 
NKG2D -0.3 6.0E-01 1.0E+00 
CDK2 0.2 6.0E-01 1.0E+00 
GZMB 0.2 6.0E-01 1.0E+00 
IFNGR1 0.4 6.0E-01 1.0E+00 
CTNNA1 0.2 6.1E-01 1.0E+00 
ICOS -0.2 6.2E-01 1.0E+00 
SNAI1 -0.3 6.2E-01 1.0E+00 
KIR2DL3 0.2 6.2E-01 1.0E+00 
LAG3 0.2 6.2E-01 1.0E+00 
HES1 -0.3 6.2E-01 1.0E+00 
CD85 -0.3 6.3E-01 1.0E+00 
PRF1 0.2 6.4E-01 1.0E+00 
CDH1 -0.3 6.5E-01 1.0E+00 
VEGFA -0.2 6.5E-01 1.0E+00 
mTOR 0.3 6.6E-01 1.0E+00 
AKT1 0.2 6.6E-01 1.0E+00 
CD38 -0.2 6.6E-01 1.0E+00 
TRAF3 0.3 6.6E-01 1.0E+00 
GLIPR1 -0.2 6.6E-01 1.0E+00 
Dock5 0.2 6.6E-01 1.0E+00 
BCL2L11 -0.3 6.6E-01 1.0E+00 
LAT2 -0.3 6.6E-01 1.0E+00 
ANXA2P2 0.2 6.7E-01 1.0E+00 
p38 0.3 6.7E-01 1.0E+00 
ETV6 -0.2 6.7E-01 1.0E+00 
ATM 0.3 6.7E-01 1.0E+00 
KIR3DL3 0.3 6.8E-01 1.0E+00 
CBLB -0.3 6.8E-01 1.0E+00 
IL15RA -0.2 6.9E-01 1.0E+00 
CATHEPSINC 0.2 6.9E-01 1.0E+00 
MAPK8 -0.2 6.9E-01 1.0E+00 
FYN -0.2 6.9E-01 1.0E+00 
ITGB1 -0.3 6.9E-01 1.0E+00 
RUNX2 -0.2 7.0E-01 1.0E+00 
CCR1 0.1 7.0E-01 1.0E+00 
PTPN4 -0.2 7.0E-01 1.0E+00 
FASLG 0.2 7.0E-01 1.0E+00 
CD19Rscfv -0.3 7.0E-01 1.0E+00 
PDE4 -0.2 7.1E-01 1.0E+00 
STAT5A -0.2 7.1E-01 1.0E+00 
SHP2 0.2 7.1E-01 1.0E+00 
E2A -0.2 7.2E-01 1.0E+00 
CREM 0.2 7.2E-01 1.0E+00 
LTA -0.3 7.3E-01 1.0E+00 
FOXO3 -0.2 7.3E-01 1.0E+00 
CASP1 0.2 7.3E-01 1.0E+00 
SHP1 0.2 7.3E-01 1.0E+00 
BATF 0.2 7.4E-01 1.0E+00 
MAD -0.1 7.4E-01 1.0E+00 
SOCS3 -0.2 7.4E-01 1.0E+00 
NKG2F -0.3 7.4E-01 1.0E+00 
IRF4 -0.2 7.4E-01 1.0E+00 
RAC2 0.2 7.4E-01 1.0E+00 
NFATC2 0.2 7.5E-01 1.0E+00 
STAT6 -0.2 7.5E-01 1.0E+00 
GNLY 0.2 7.5E-01 1.0E+00 
CCL4 0.0 7.5E-01 1.0E+00 
CD11C -0.2 7.5E-01 1.0E+00 
CSAD -0.2 7.5E-01 1.0E+00 
ABCB1 -0.2 7.6E-01 1.0E+00 
CD8A 0.2 7.6E-01 1.0E+00 
BMI1 -0.1 7.6E-01 1.0E+00 
RAC1 0.2 7.6E-01 1.0E+00 
LAT -0.1 7.6E-01 1.0E+00 
PNK -0.2 7.6E-01 1.0E+00 
AP1 0.2 7.6E-01 1.0E+00 
STAT5B -0.2 7.6E-01 1.0E+00 
CD19RCD28CAR -0.3 7.7E-01 1.0E+00 
CITED2 0.2 7.7E-01 1.0E+00 
DGKA -0.2 7.7E-01 1.0E+00 
CD274 -0.2 7.7E-01 1.0E+00 
YAP -0.1 7.7E-01 1.0E+00 
IL2RG -0.2 7.7E-01 1.0E+00 
POP5 0.2 7.7E-01 1.0E+00 
TRF 0.2 7.7E-01 1.0E+00 
SLC2A1 -0.2 7.8E-01 1.0E+00 
NFATC3 -0.2 7.8E-01 1.0E+00 
CFLIP -0.1 7.9E-01 1.0E+00 
SERPINE2 -0.3 7.9E-01 1.0E+00 
PDCD1LG2 -0.1 8.0E-01 1.0E+00 
CTLA4 -0.2 8.0E-01 1.0E+00 
SLAMF7 0.1 8.0E-01 1.0E+00 
HOPX 0.1 8.1E-01 1.0E+00 
TERT 0.2 8.1E-01 1.0E+00 
NFAT5 -0.1 8.1E-01 1.0E+00 
SCAP2 0.1 8.1E-01 1.0E+00 
TNFRSF1B -0.1 8.1E-01 1.0E+00 
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FANCC 0.1 8.1E-01 1.0E+00 
JUNB 0.1 8.1E-01 1.0E+00 
NT5E -0.1 8.1E-01 1.0E+00 
LGALS1 -0.2 8.1E-01 1.0E+00 
ITK 0.1 8.1E-01 1.0E+00 
BAX 0.2 8.1E-01 1.0E+00 
CCR6 -0.1 8.2E-01 1.0E+00 
APAF1 -0.2 8.2E-01 1.0E+00 
BTLA 0.2 8.2E-01 1.0E+00 
GADD45alpha 0.1 8.2E-01 1.0E+00 
B2M -0.1 8.2E-01 1.0E+00 
LDHA -0.2 8.2E-01 1.0E+00 
CD43 -0.1 8.2E-01 1.0E+00 
KLRC1 0.0 8.3E-01 1.0E+00 
STS2 -0.2 8.3E-01 1.0E+00 
HOXB3 -0.2 8.3E-01 1.0E+00 
IL15 0.2 8.3E-01 1.0E+00 
RAP46 -0.1 8.3E-01 1.0E+00 
CDKN2C 0.1 8.3E-01 1.0E+00 
MCL1 -0.1 8.4E-01 1.0E+00 
CAT -0.1 8.4E-01 1.0E+00 
HPRT1 0.1 8.4E-01 1.0E+00 
IKZF1 0.1 8.4E-01 1.0E+00 
JAK2 -0.1 8.4E-01 1.0E+00 
NEIL2 -0.2 8.4E-01 1.0E+00 
NFkB -0.1 8.5E-01 1.0E+00 
CXCR4 0.1 8.5E-01 1.0E+00 
KLF10 0.2 8.5E-01 1.0E+00 
DUSP16 -0.1 8.5E-01 1.0E+00 
MAP2K1 -0.1 8.6E-01 1.0E+00 
IL21R 0.1 8.6E-01 1.0E+00 
RAF1 0.1 8.6E-01 1.0E+00 
FOXO1 0.1 8.6E-01 1.0E+00 
MIF -0.1 8.6E-01 1.0E+00 
FADD 0.1 8.6E-01 1.0E+00 
GADD45beta 0.2 8.6E-01 1.0E+00 
FOXP1 0.1 8.7E-01 1.0E+00 
HLAA -0.1 8.7E-01 1.0E+00 
NR3C1 -0.1 8.7E-01 1.0E+00 
PRKCQ 0.1 8.8E-01 1.0E+00 
TCF12 0.1 8.8E-01 1.0E+00 
NR4A1 -0.1 8.8E-01 1.0E+00 
BCL10 -0.1 8.8E-01 1.0E+00 
ITGB7 0.0 8.8E-01 1.0E+00 
MAPK14 0.1 8.8E-01 1.0E+00 
HDAC2 0.1 8.8E-01 1.0E+00 
CD244 0.0 8.9E-01 1.0E+00 
IL18R1 0.1 8.9E-01 1.0E+00 
S100A4 0.1 8.9E-01 1.0E+00 
HOXB4 -0.1 8.9E-01 1.0E+00 
CSNK2A1 0.1 8.9E-01 1.0E+00 
BCL11B 0.0 9.0E-01 1.0E+00 
CTNNBL1 0.1 9.0E-01 1.0E+00 
NCL 0.1 9.0E-01 1.0E+00 
ELF1 0.1 9.0E-01 1.0E+00 
MBD2 0.1 9.0E-01 1.0E+00 
DAP10 -0.1 9.0E-01 1.0E+00 
ELF4 0.1 9.0E-01 1.0E+00 
GSK3B -0.1 9.1E-01 1.0E+00 
IRF1 0.0 9.1E-01 1.0E+00 
CDKN1A -0.1 9.1E-01 1.0E+00 
CREB1 0.0 9.1E-01 1.0E+00 
TDO2 0.1 9.1E-01 1.0E+00 
STAT3 -0.1 9.1E-01 1.0E+00 
AHNAK 0.1 9.1E-01 1.0E+00 
CD63 0.0 9.1E-01 1.0E+00 
LCK 0.0 9.1E-01 1.0E+00 
KLF6 0.1 9.2E-01 1.0E+00 
IL2RB 0.0 9.2E-01 1.0E+00 
NKp46 0.0 9.2E-01 1.0E+00 
EIF1 0.1 9.2E-01 1.0E+00 
TRAF2 0.1 9.2E-01 1.0E+00 
DOK2 0.1 9.2E-01 1.0E+00 
ADAM19 -0.1 9.2E-01 1.0E+00 
GFI1 0.0 9.2E-01 1.0E+00 
NKG2E -0.1 9.3E-01 1.0E+00 
AIF1 0.0 9.3E-01 1.0E+00 
HMGB2 0.0 9.3E-01 1.0E+00 
HDAC1 0.1 9.3E-01 1.0E+00 
CTNNB1 0.0 9.3E-01 1.0E+00 
TYK2 0.1 9.3E-01 1.0E+00 
IAP 0.1 9.3E-01 1.0E+00 
C80RF70 0.2 9.3E-01 1.0E+00 
PPARA 0.0 9.3E-01 1.0E+00 
PRDM1 0.0 9.4E-01 1.0E+00 
ITCH 0.0 9.4E-01 1.0E+00 
CLA 0.0 9.4E-01 1.0E+00 
LGALS3 0.1 9.4E-01 1.0E+00 
CATHEPSIND 0.0 9.4E-01 1.0E+00 
IL18RAP 0.0 9.4E-01 1.0E+00 
IL4R 0.0 9.5E-01 1.0E+00 
TNFSF10 0.0 9.5E-01 1.0E+00 
CD58 0.0 9.5E-01 1.0E+00 
BID 0.1 9.5E-01 1.0E+00 
JAK1 0.0 9.5E-01 1.0E+00 
CD247 0.0 9.5E-01 1.0E+00 
SOD1 0.0 9.6E-01 1.0E+00 
CIITA 0.1 9.6E-01 1.0E+00 
CRIP1 0.1 9.6E-01 1.0E+00 
BetaArrestin 0.1 9.6E-01 1.0E+00 
NEIL1 -0.1 9.6E-01 1.0E+00 
SMAD4 0.0 9.6E-01 1.0E+00 
SELL 0.0 9.6E-01 1.0E+00 
C11ORF17 0.0 9.6E-01 1.0E+00 
TNFSF14 0.0 9.6E-01 1.0E+00 
RHOA 0.0 9.6E-01 1.0E+00 
CCR5 -0.1 9.6E-01 1.0E+00 
NKG2C -0.1 9.7E-01 1.0E+00 
S100A6 0.0 9.7E-01 1.0E+00 
SIT1 0.0 9.7E-01 1.0E+00 
KIR2DL4 -0.1 9.7E-01 1.0E+00 
CD3E 0.0 9.7E-01 1.0E+00 
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GZMA 0.0 9.7E-01 1.0E+00 
TBX21 0.0 9.7E-01 1.0E+00 
GLO1 0.1 9.7E-01 1.0E+00 
IFNG -0.1 9.7E-01 1.0E+00 
IL12RB1 0.0 9.7E-01 1.0E+00 
CCNB1 -0.1 9.7E-01 1.0E+00 
IRF2 0.0 9.7E-01 1.0E+00 
PDE7 0.0 9.7E-01 1.0E+00 
TNFRSF7 0.0 9.8E-01 1.0E+00 
CLIC1 0.0 9.8E-01 1.0E+00 
JAK3 0.0 9.8E-01 1.0E+00 
OPTN 0.0 9.8E-01 1.0E+00 
MAPK3 0.0 9.8E-01 1.0E+00 
RORA 0.1 9.8E-01 1.0E+00 
KLF7 0.0 9.9E-01 1.0E+00 
CDKN1B 0.0 9.9E-01 1.0E+00 
PPP2R1A 0.0 9.9E-01 1.0E+00 
ATP2B4 0.0 9.9E-01 1.0E+00 
CD2 0.0 9.9E-01 1.0E+00 
CXCR3 0.0 9.9E-01 1.0E+00 
C10RF24 0.0 9.9E-01 1.0E+00 
TGFB1 0.0 9.9E-01 1.0E+00 
STAT4 0.0 1.0E+00 1.0E+00 
ZAP70 0.0 1.0E+00 1.0E+00 
CD3D 0.0 1.0E+00 1.0E+00 
GABPa 0.0 1.0E+00 1.0E+00 
CCR10 -0.1 1.0E+00 1.0E+00 
PECAM1 -0.1 1.0E+00 1.0E+00 
SOX4 0.1 1.0E+00 1.0E+00 
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